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An average human cell accumulates tens of thousands of DNA lesions per day. Therefore, 
DNA repair pathways are set up to continuously proofread the DNA and correct DNA 
lesions, thus ensuring accurate expression and propagation of genetic material. Nucleotide 
excision DNA repair (NER) is a major DNA repair pathway which removes UV-induced 
lesions and bulky DNA modifications. Defects in NER promote cancer development and 
cause human diseases, such as Xeroderma pigmentosum (XP), Cockayne syndrome and 
trichothiodystrophy. During NER, lesions are cut out of the DNA as part of a short 
oligonucleotide and the resulting gap is filled by DNA synthesis using the nondamaged DNA 
strand as a template. The NER machinery assembles around the heterodecameric 
transcription factor IIH (TFIIH), comprised of the core module and the kinase module. The 
TFIIH core module utilizes the ATP-consuming subunits XPB and XPD to open the DNA 
repair bubble, scan for the lesion and coordinate the excision of the damaged DNA. 
However, due to the complete lack of structural information on NER assembly intermediates 
and difficulties in preparing the NER complexes for in vitro analysis, the molecular 
mechanism of NER is still not well understood.  
Here we prepare human TFIIH and other NER factors involved in DNA excision. 
We reconstitute several steps of the NER pathway and analyze the trapped intermediates 
with biochemical assays, cross-linking mass-spectrometry and electron microscopy (EM). 
We systematically dissect the regulation of the TFIIH ATPases XPB and XPD and show 
that the additional NER factors XPA and XPG stimulate the enzymatic activities of the 
ATPases. We report the core TFIIH-XPA-DNA structure at 3.6Å resolution, which 
represents the lesion scanning NER intermediate, and we map the position of XPG within 
the complex by chemical crosslinking. The structure expands the previous model for the 
TFIIH core and explains many disease mutations. The structure further elucidates the 
topology of NER factors around the 5’ edge of the repair bubble: XPB binds the DNA 
duplex, XPD binds the 3’ single strand extension and XPA wraps around the duplex single-
strand junction and bridges the ATPases. XPA and XPB form a DNA duplex tunnel which 
anchors the NER machinery to the DNA. Our biochemical analysis and comparison to 
previous structures reveal how XPA and XPG activate TFIIH for repair. The TFIIH kinase 
module inhibits NER by repressing the XPD helicase activity. XPA stabilizes a completely 
novel TFIIH conformation in which the ATPases are dramatically reoriented, which 
displaces the TFIIH kinase module and removes the “plug” element from the DNA-binding 
pore in XPD. This allows XPD to move by ~80Å, engage the DNA and rapidly scan for the 
lesion. XPG facilitates lesion scanning by directly stimulating XPD migration on DNA and 
by sequestering the kinase module binding site on XPD. The results presented here greatly 
extend our understanding of human NER and provide the basis for future structure-function 
analysis of this repair pathway, also in the context of transcription. 





1.1 Overview of DNA repair 
 
DNA integrity is constantly threatened by exogeneous and endogenous sources of DNA 
damage resulting in tens of thousands of DNA injuries per human cell per day1. DNA 
damage encompasses a variety of covalent modifications in DNA bases and non-covalent 
alterations in DNA, such as base-pairing mismatches, bubbles and loops2. These unfavorable 
changes in the DNA interfere with a correct interpretation and propagation of the genetic 
material, which often leads to disease development3-5. To counteract the high load of DNA 
damage, cells are equipped with different DNA repair systems, each directed towards a 
different subset of DNA lesions. Thus, DNA repair can be sub-classified into several 
pathways: direct DNA repair, DNA mismatch repair, base excision repair, nucleotide 
excision repair and double-strand break repair2. 
Direct DNA repair is a simple and error-free repair pathway in which a DNA lesion 
is directly restored to the original DNA sequence6. However, the repair pathway focuses on 
a narrow set of DNA lesions which include the UV-light induced photolesions, O- and N-
alkylated DNA6. Photolyase and O6-alkylguanine DNA alkyltransferase are the best studied 
enzymes involved in direct DNA repair. Photolyase splits the UV-induced pyrimidine 
dimers in an electron-transfer reaction driven by blue light7. Placental mammals lack the 
enzyme even though it is wide-spread in all kingdoms of life2. O6-alkylguanine DNA 
alkyltransferase recognizes a highly mutagenic O6-methyl guanine8 and transfers the O6-
methyl group to its active site cysteine9. The reaction is suicidal because the modified 
cysteine cannot be regenerated to participate in further rounds of catalysis9. 
 DNA mismatch repair (MMR) removes single-nucleotide mismatches and DNA 
loops created by errors in DNA replication10,11. Thus, the MMR machinery must be able to 
differentiate between the parental DNA strand and the newly replicated DNA strand which 
contains the incorrect DNA sequence. In bacteria this differentiation is enabled by DNA 
modifications, as the parental DNA strand is methylated and the newly synthesized DNA is 
unmethylated12. During bacterial MMR MutS recognizes the mismatches in DNA13 with the 
help of MutL14, followed by the recruitment of the MutH endonuclease15. MutH binds the 
hemi-methylated DNA duplex and cleaves the unmethylated DNA strand to initiate the 
degradation of a newly synthesized DNA strand in the 5’ or 3’ direction depending on the 
position of the cleavage site10,11.  The resulting gap in the DNA is filled by a high-fidelity 
DNA polymerase and sealed by a DNA ligase. The overall mechanism is highly conserved 
from bacteria to humans10,11. However, it is still unclear how the eukaryotic MMR 
discriminates between the parental and daughter DNA strands. 
  
 




Base excision repair (BER) targets small modifications of DNA bases such as 
deamination, oxidation and methylation16. The repair reaction is mediated by glycosylases 
which can identify a damaged DNA base within the overwhelming amount of undamaged 
substrate and cleave off the modified base leaving an abasic site (AP-site)2. In mammals, 11 
different glycosylases were identified thus far, each recognizing a subset of similar lesions17. 
Uracil-DNA glycosylases, a well-studied group of glycosylases, are used to remove a highly 
mutagenic uracil generated by cytosine deamination18. The AP-site is further processed by 
an AP-endonuclease which cleaves the sugar-phosphate DNA backbone, a DNA-
polymerase which removes the abasic sugar and fills in the single nucleotide gap and a DNA 
ligase which seals the nick in the DNA16.  
Nucleotide excision repair (NER) is the main repair pathway for the removal of bulky 
DNA modifications caused by irradiation, exogenous and endogenous mutagens, and 
chemotherapeutics19,20.  NER can remove the biggest variety of chemically and structurally 
unrelated DNA lesions21-24, because the NER machinery recognizes the lesion-induced 
distortion in the DNA secondary structure, rather than the lesion itself24-26. NER is a complex 
biochemical process which utilizes four different factors in bacteria (UvrA-UvrD)27 and six 
factors in humans (XPA-XPG) to perform a controlled sequence of several enzymatic 
steps19,20. After the recognition of a DNA lesion, the DNA is unwound around the lesion site 
and the damaged DNA strand is incised on both sides of the lesion, resulting in the release 
of a lesion-containing oligonucleotide from the DNA19,20. The resulting gap is filled by a 
DNA polymerase using the healthy DNA strand as a template for reparatory DNA 
synthesis19,20.  
Double-strand break (DSB) repair is required when both DNA strands are broken, 
mostly due to reactive oxygen species and ionizing radiation28-30. DSBs also underlie some 
biochemical processes in the cell, such as V(D)J recombination in the immune system 
maturation, replication fork collapses and topoisomerase failures28-30. There are two main 
strategies for repairing DSBs: the non-homologous end joining (NHEJ) and the homologous 
recombination (HR)28-30. NHEJ facilitates a direct ligation of the two DNA ends31,32. Since 
NHEJ is template-independent, this solution is error-prone and it often leads to deletions, 
insertions or even chromosomal rearrangements. In contrast, HR is a template-dependent 
and mostly error-free way to repair DSBs33,34. A free DNA end is first resected to produce a 
single-stranded overhang, which invades a homologues DNA and uses it as a template for 
repair33,34. Thus, this repair strategy is only feasible in G and S2 phases of the cell cycle 
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1.2 Nucleotide excision DNA repair (NER) 
 
NER was discovered in 1964 when several groups observed that DNA lesion-containing 
oligonucleotides are cut out of the DNA and the resulting gaps in the DNA are filled in by 
the reparatory DNA synthesis35-38. The inability to perform such a DNA correction was 
linked to the development of the genetic disease Xeroderma pigmentosum (XP)3,39, 
characterized by a high incidence of skin cancer40. Genetic complementation studies on 
patient cell lines revealed that the underlying core DNA repair machinery is comprised of 7 
main factors named XPA, XPB, XPC, XPD, XPE, XPF and XPG41,42. A major milestone in 
NER research was the reconstitution of the NER reaction in vitro with purified 
components43-45 which defined a minimal set of factors required for a complete NER (listed 
in Table1), as well as the main sequence of events accompanying the repair process (Fig. 1). 
Two different strategies are employed for the initial lesion recognition which divides NER 
into 2 sub-pathways: in global-genome NER (GGR) the XPC-Rad23b complex recognizes 
the lesion induced distortions in DNA structure and in transcription-coupled NER (TCR) the 
lesion arrested RNA-polymerase II (RNAP) elicits the repair19,20 (Fig. 1).  
 
                       
 
Figure 1 | The main steps of nucleotide excision DNA repair (NER). 
XPC-Rad23B recognizes the helix-distorting lesions24,46-48 and the elongating RNA-polymerase II recognizes 
the transcription blocking lesions49-51 (lesions are indicated by the purple square). After the lesion recognition, 
the two sub-pathways converge into a conserved series of reactions which include the DNA unwinding, DNA 
incisions around the lesion site and the removal of the damaged DNA single-strand19,20. The resulting gap in 
DNA is filled by DNA synthesis templated by the undamaged DNA strand (the newly synthesized DNA is 
shown in green)19,20. 
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1.2.1 Global-genome nucleotide excision repair (GGR) 
 
Efficient substrate for GGR contains the two following structural features: the disruption of 
base pairing and the presence of a bulky DNA modification24,52,53 (Fig. 2). Disruption of 
base pairing is recognized by the main GGR lesion sensor XPC24,46-48 assisted by Rad23B54 
and centrin255.  XPC does not interact with DNA lesions directly26, which explains how XPC 
initiates repair on a diverse set of structurally unrelated DNA lesions. Thus, the physical 
presence of a bulky DNA modification in the distorted DNA recognized by XPC must be 
additionally verified by a downstream GGR component which is known as bipartite lesion 
recognition56. UV-induced cyclobutane pyrimidine dimers (CPDs) are efficiently repaired 
by GGR but are poor substrates for XPC because these lesions do not significantly melt the 
DNA24. However, an additional DNA lesion sensor comprised of DDB1 and DDB2 (XPE) 
binds CPDs with a very high affinity, bends the DNA and facilitates the recruitment of XPC 
to the lesion site57-60.  
Following the recognition of damaged DNA, XPC recruits transcription factor IIH 
(TFIIH) to the lesion site61-63 (Fig. 2). TFIIH is a heterodecameric complex comprised of 
two modules, the core and the kinase module64. The TFIIH core contains two SF2-type DNA 
helicases XPB and XPD which are essential for repair64. TFIIH recruitment allows XPB to 
engage the DNA and to open the DNA around the lesion, thereby creating a DNA repair 
bubble65-68. XPB was shown to have a 3’-5’ helicase67 and a 5’-3’ translocase activity69, 
however, it is still unclear how these activities are employed for the initial repair bubble 
opening. It was also reported that only the ATPase, and not the helicase activity of XPB is 
required for DNA melting68. This suggested that the ATP-hydrolysis by XPB is not used for 
DNA unwinding but rather to fuel the large scale conformational changes in XPB which can 
lead to twisting of DNA and DNA melting66. The yeast XPB homologue, Ssl2, in the context 
of TFIIH acts as a DNA translocase, rather than a helicase69. Thus, XPB may open the repair 
bubble in analogy to its role in promotor opening during transcription initiation69,70. The 
repair bubble opening creates a binding substrate for the XPD helicase that unwinds DNA 
in 5’-3’ direction71-73. XPD most likely verifies the presence of a lesion because the 
movement of XPD on DNA is arrested by lesions23,73-75. In addition, XPC orients TFIIH 
during the initial stages of NER so that XPD specifically scans the damaged DNA strand56,73. 
It is still uncertain how XPD recognizes DNA lesions. The structure of the archaeal XPD 
homologue has revealed a narrow pore formed by the accessory domains inserted into the 
helicase lobe of XPD76,77. The dimensions of the pore would allow the passage of single 
stranded DNA, but would restrict the passage of a DNA duplex. The DNA trajectory was 
proposed to lead towards the pore, which could be used to sift the DNA single strand for 
bulky modifications66,78. In addition, XPD contains a redox reactive iron-sulfur (FeS) cluster 
situated next to the narrow pore66,78. The FeS cluster is also present in other DNA repair 
proteins, such as the E.coli endonuclease III and the mismatch specific adenine glycosylase 
MutY, where the cluster is involved in DNA lesion processing79. Moreover, the FeS cluster 
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can participate in an electron exchange between the protein and the bound DNA which could 
be used for lesion scanning in a process called a DNA-mediated charge transfer79. A similar 
mechanism was also shown for the archaeal XPD in vitro74, suggesting a role for the FeS 
cluster in lesion detection and verification during NER.  
 
 
Table 1 | List of NER factors and their role in DNA repair.* 





recruits NER factors to the lesion site, stimulates 
XPD helicase activity 
XPB** Rad25 
3’-5’ helicase, 5’-3’ translocase, opens DNA 
repair bubble, facilitates XPD loading on the 
DNA 
XPD Rad3 5’-3’ helicase, verifies lesions 
p62 Tfb1 
binds XPC during TFIIH recruitment to the 
lesion site 
p52 Tfb2 stimulates XPB 
p44 SSL1 stimulates XPD, ubiquitin ligase 
p34 Tfb4  
TTDA Tfb5 stimulates XPB 
MAT1 Tfb3  
CDK7 Kin28 
kinase activity, required for transcription 
initiation but not for NER 
Cyclin H Ccl1 stimulates Cdk7 
XPG Rad2 endonuclease, cleaves 3’ of the lesion 
XPF-ERCC1 Rad10-Rad1 endonuclease, cleaves 5’ of the lesion 




XPC Rad4 recognizes lesions in GGR 





translocase, recognizes lesion-arrested RNAP, 
stimulates RNAP elongation 
CsA not found part of E3-ubiquitin ligase, ubiquitinates CsB 
UVSSA not found stabilizes CsB during TCR 




PCNA Pcna stimulates processivity of DNA polymerase 
RFC Rfc loads PCNA on the DNA 
DNA Pol !, # Pol2, Pol3 resynthesizes excised DNA 
FEN1 Rad27 exonuclease, degrades damaged DNA 
DNA ligase 1 Cdc9 seals the gap after the reparatory DNA synthesis 
* adapted from80 
** XPB, XPD, p62, p52, p44, p34 and TTDA form the TFIIH core module and MAT1, CDK7 and 
cyclin H form the TFIIH kinase module64. 
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XPA is recruited in the early stages of the repair reaction, most likely following the 
recruitment of TFIIH61,63 (Fig. 2). XPA is a DNA binding protein with a preference for 
kinked DNA duplex structures81 and duplex-single strand DNA junctions82. Even though 
XPA is essential for repair and mutations in XPA cause the most severe cases of Xeroderma 
pigmentosum83, its role in repair is not yet clear. The arrival of XPA to the NER assembly 
was linked to the dissociation of the TFIIH kinase module in vivo84. The kinase module 
inhibits XPD helicase activity72,73 and needs to be removed before the lesion scanning by 
XPD can begin. Moreover, XPA stimulates XPD helicase activity in vitro but the mechanism 
of this stimulation is not known73. Despite its small size, XPA is considered the main 
scaffolding protein during repair83 because it interacts with almost all NER factors, including 
XPC-Rad23b, TFIIH, RPA, XPF-ERCC1, DDB2 and PCNA85-98. The location of XPA 
within the NER assembly is unknown but some model studies suggest it may sit on the 5’ 
edge of the repair bubble99 where it would be ideally positioned to recruit the XPF-ERCC1 
endonuclease95,96. XPA was also proposed to play a role during the initial recognition of 
DNA lesions100.  
The replication protein A (RPA) binds the DNA cooperatively with XPA101,102. RPA 
is a eukaryotic single-stranded DNA binding protein comprised of three subunits, RPA1-
3103. The largest RPA subunit contains three DNA-binding domains, while the other two 
subunits contain only one such domain103. This allows RPA to bind DNA fragments of 
different lengths by successively engaging the DNA-binding domains103,104. The cooperative 
binding of RPA subunits to DNA results in a very high overall affinity for the single-stranded 
DNA (sub-nanomolar range)100. During NER, RPA most likely engages the nondamaged 
DNA strand because the damaged DNA strand needs to be scanned by XPD56. By coating 
the nondamaged DNA strand, RPA might stabilize the open DNA bubble and also protect 
the solvent-exposed DNA strand from the DNA damage19. Interestingly, when all RPA 
subunits are bound to DNA, RPA covers 30 nucleotides of DNA which corresponds to the 
size of the excised DNA fragment during NER103. RPA binds the DNA in a defined polarity 
and it was suggested that RPA helps to position the endonucleases on the opposite sites of 
the DNA repair bubble for the dual-incision reaction105 (Fig. 2). 
XPG and XPF-ERCC1 are structure-specific endonucleases which cleave the DNA 
around the lesion site106 (Fig. 2). XPG belongs to the FEN1 family of endonucleases and 
cleaves the duplex-single strand junctions and other DNA substrates containing a 5’ DNA 
overhang107,108. The XPF-ERCC1 endonuclease is comprised of two polypeptides which 
together form a unique active site109. XPF-ERCC1, like XPG, recognizes and cleaves the 
duplex single-strand DNA junctions110. However, XPF-ERCC1 cleaves the DNA substrates 
containing a 3’ overhang110. Thus, both endonucleases bind the duplex-single strand 
junctions which are formed during the repair bubble opening but cleave the DNA with 
different polarities. In vitro repair assays have shown that XPG cleaves the damaged DNA 
5 nucleotides 3’ of the lesion site and the XPF-ERCC1 cleaves the DNA ~25 nucleotides 5’ 
of the lesion site65,110,111 (Fig. 2).  






Figure 2 | Schematic representation of human global-genome nucleotide excision repair (GGR). 
A bulky DNA modification (indicated by the gray star) induces local DNA melting which is recognized by the 
main lesion sensor XPC-Rad23b24,46-48. XPC recruits TFIIH to the lesion site61-63. This allows the XPB subunit 
of the TFIIH complex to bind the DNA duplex and to open the DNA repair bubble65-68. XPA and RPA 
cooperatively join the NER assembly101,102. XPA facilitates the removal of the TFIIH kinase module because 
the kinase module inhibits the repair84. RPA may coat the undamaged DNA strand and stabilizes the open 
DNA conformation. XPD engages the damaged DNA single-strand and starts to unwind the DNA in 5’-3’ 
direction (towards the lesion) 71-73. XPG and XPF-ERCC1 endonucleases bind the 3’ and the 5’ edge of the 
bubble, respectively, where they cleave the DNA after the presence of the lesion was verified106. Lesions are 
most likely verified by XPD because the helicase activity of XPD is inhibited by lesions23,73-75. The cleaved 
lesion-containing oligonucleotide is released from the NER complex and the components of the reparatory 
DNA synthesis are recruited19,20. DNA polymerase synthesizes a new DNA strand by using the nondamaged 
DNA strand as a template19,20. The final nick in DNA is sealed by a DNA ligase19,20.  
 
                                                                                                  INTRODUCTION 
 
 9 
Despite having the opposite cleavage polarities, the two endonucleases have to be properly 
positioned around the repair bubble by interactions with other NER factors105. XPG is 
constitutively associated with TFIIH in vivo112. XPG is thus recruited early during NER and 
also has a non-catalytic role in facilitating the DNA repair bubble opening61,113. In contrast, 
XPF-ERCC1 is the last core NER factor recruited to the lesion site, which is mediated by 
the interaction between XPA and ERCC195,96. XPF-ERCC1 makes the first incision in the 
DNA, creating a free 3’ DNA end which can be used by a DNA-polymerase to initiate the 
repair DNA synthesis114. XPG likely cleaves the DNA when the reparatory synthesis is in 
progress to ensure that all components required for restoring the DNA duplex are present 
before the DNA fragment is excised115. The DNA gap is filled by a machinery comprised of 
the clamp (PCNA), the clamp loading complex (RFC), DNA polymerase δ and DNA ligase 
144. Depending on the proliferative status of the cell, DNA polymerases ε	and	κ , and 
XRCC1-DNA ligase 3 are also employed116,117. 
 
1.2.2 Transcription-coupled nucleotide excision repair (TCR) 
 
Transcription is an initial stage of gene expression in which the information stored 
in a DNA molecule is copied into a strand of RNA118. This process is mediated by RNA 
polymerases, multiprotein complexes that elongate the RNA molecule by successive 
addition of nucleotides to its 3’ end118. Human cells host several types of RNA 
polymerases119, however, here we focus only on the RNA-polymerase II (RNAP) which can 
participate in DNA repair120. The RNAP transcribes the protein coding genes in three main 
stages: initiation, elongation and termination121. During the initiation, the RNAP is correctly 
positioned at the beginning of a gene and the DNA duplex is opened to expose the DNA 
strand that needs to be transcribed122. The transcribed DNA strand, i.e. the strand copied into 
RNA, is called the template strand (TS), and the complementary DNA strand is called the 
non-template strand (NTS)123 (Fig. 3a). The elongation phase includes the extension of the 
RNA, while the RNAP translocates on the TS in 3’-5’ direction118 (Fig. 3a). Termination is 
the last stage of transcription in which the RNAP dissociates from the DNA template and 
the RNA product is released121. 
Transcription-coupled nucleotide excision repair (TCR) was first discovered in 
human cells where it was observed that UV-induced DNA lesions are preferentially repaired 
in the transcribed strands of active genes124,125 and that the repair requires actively 
transcribing RNAP126. Thus, TCR is initiated by RNAP arrested by transcription-blocking 
lesions49-51. RNAP has a large footprint on the DNA which completely covers the DNA 
lesion51, so the main substrate for the TCR machinery is the lesion arrested RNAP and not 
the lesion itself80. Arrested RNAP is initially recognized by Cockayne syndrome (CS) 
proteins CsA and CsB which are considered to be the main TCR-specific factors127-129. 
Recently, a couple of additional factors, UVSSA and Usp7, were discovered to be essential 
for TCR130-132.  
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 CsB is a member of SF2-familiy of DNA helicases133, however, its helicase or 
translocase activity has up to now not been demonstrated. CsB contains a central ATPase 
domain flanked by long N- and C-terminal regions134. The N-terminal region negatively 
regulates the ATPase function of CsB135 and might be important for the recognition of 
RNAP135. The C-terminal region harbors a ubiquitin binding domain essential for TCR136, 
however, the function of this domain or the ubiquitinated binding partner have not been 
identified. CsB stimulates transcription elongation in vitro137, which helps the RNAP to 
transcribe over small DNA lesions138. Cryo-EM structure of the yeast CsB homologue 
Rad26 bound to the RNAP elongation complex138 shows that Rad26 binds the upstream 
DNA, suggesting that Rad26 facilitates transcription by pushing RNAP forward. However, 
CsB cannot facilitate the RNAP passage over the transcription-blocking lesions137 nor 
dissociate stalled elongation complexes from DNA to remove the RNAP from the lesion 
site50. Since CsB recruits downstream DNA repair factors to the arrested RNAP139, the role 
of CsB in TCR might be to probe the status of elongating RNAP and to initiate repair when 
RNAP forward translocation is blocked by a DNA lesion. CsB is also a member of 
Swi2/Snf2 family of chromatin remodelers and it was shown to remodel chromatin in vitro140 
and in vivo141. In addition, CsB recruits the histone acetyltransferase p300 and the 
nucleosome binding protein HMGN1 to the lesion site139. Thus, CsB might facilitate TCR 
by relaxing the chromatin environment around the lesion arrested RNAP. CsB is also 
important for the transcription restart after UV-irradiation, partially by counteracting the 
function of the transcription repressor ATF3142. The analysis of the CsB interactome by pull-
down and mass-spectrometry143 has revealed that CsB interacts with many components of 
the RNA splicing machinery, suggesting a role for CsB in the RNA metabolism outside 
DNA repair. Interestingly, mutations in CsB cause Cockayne syndrome in humans which is 
characterized by premature aging, mental retardation, dwarfism and other physical 
abnormalities144. These clinical features are more severe compared to diseases caused by 
defects in DNA repair, further emphasizing the important roles for CsB in other cellular 
functions. Overall, despite the large amount of accumulated knowledge on CsB, it is still not 
clear how and if CsB is directly involved in the DNA repair reaction80. It might be that the 
main CsB function in TCR is to stimulate transcription and to prepare the chromatin 
environment surrounding the arrested RNAP for efficient lesion processing by repair 
enzymes.  
CsA is a small seven bladed-WD40 propeller protein that functions as a substrate 
receptor of a DDB1-Cul4-Rbx1 (CRL4) E3-ubiquitin ligase120,145,146. The ubiquitin ligase 
ubiquitinates CsB, thereby facilitating its degradation147, but does not modify the arrested 
RNAP148. Thus, CsA might be required in later stages of TCR to extract CsB from the 
complex with the RNAP and to regulate the TCR progression via post-translational 
modifications. UVSSA is an essential TCR factor130-132 comprised of two domains, the C-
terminal DUF2043 domain and the N-terminal VHS domain131. The VHS domain is 
necessary for the role UVSSA plays in TCR and it was implicated in ubiquitin binding, even 
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though the ubiquitinated binding substrate for UVSSA has not been identified131. UVSSA is 
involved in RNAP ubiquitination by potentially recruiting an E3-ubiquitine ligase to the 
lesion site, however, the ubiquitination does not result in degradation of the RNAP and likely 
has a signaling function131. Co-immunoprecipitation experiments have shown that UVSSA 
interacts with RNAP, CsB, CsA and several TFIIH subunits130-132. The interaction with the 
RNAP might be mediated by CsB and CsA149. Moreover, it was shown by NMR 
spectroscopy that the acidic amino acid stretch in UVSSA binds the PH domain in the p62 
subunit of TFIIH150, which is very similar to the mode of interaction between XPC and 
TFIIH during the initial steps of GGR151. Thus, it was suggested that UVSSA recruits the 
core NER machinery to the lesion-arrested RNAP. Mutations in UVSSA cause the UV-
sensitive syndrome which is accompanied by mild clinical features, mostly limited to the 
UV-hypersensitivity149. Since the sensitivity to UV-irradiation is a typical consequence of a 
defect in DNA repair, UVSSA might exclusively be a DNA repair factor. In addition, 
UVSSA recruits the Usp7 ubiquitin protease to the lesion site130,132. Usp7 is an essential 
TCR factor because the cells lacking Usp7 exhibit a similar TCR defect as the cells lacking 
UVSSA130,132. Usp7 prevents the proteasomal degradation of CsB following DNA 
damage130, most likely by counteracting the CsB ubiquitination by CsA147, which may 
provide a longer time window for the successful completion of TCR.  
 Unlike GGR, TCR has not been successfully reconstituted in vitro with purified 
components and its mechanism is less well understood. After the arrest, the RNAP has to be 
removed to expose the lesion to repair enzymes152. How RNAP is removed remains the 
central open question in TCR but several scenarios can be envisioned (Fig. 3) 152,153: RNAP 
can be dissociated from the DNA, actively pushed or pulled backwards far enough to reveal 
the lesion or degraded by the proteasome152,153. Up to know, a human DNA repair protein 
which could dissociate the lesion-arrested RNAP from the DNA has not been found80. Also, 
a case of active RNAP backtracking in eukaryotes has not been reported yet. The active 
RNAP backtracking would require an ATP-consuming motor protein which can push the 
arrested RNAP backwards – that is, in the direction opposite to the direction of transcription 
(Fig. 3a)154. During the backtracking, the 3’ end of the RNA disengages from the RNAP 
active site and the RNA is threaded through a pore in RNAP which differs from the usual 
RNA trajectory during transcription elongation (Fig. 3e)155. Since the RNA 3’ end is no 
longer accessible to be extended, the RNAP cannot resume transcription. However, a 
specialized transcription elongation factor IIS (TFIIS) can bind the backtracked RNAP and 
induce the intrinsic endonuclease activity of RNAP, which results in the cleavage of RNA156-
159. This creates a new 3’ RNA end and allows the restart of transcription. Thus, the 
backtracking strategy for the removal of RNAP from the lesion site would allow the 
transcription to continue after DNA repair152,153. Finally, the DNA-damage induced 
degradation of the arrested RNAP is considered to be the last resort when the transcription 
arrest persists for a long time160, and the process has been well described in yeast161.  
 





Figure 3 | The fate of lesion arrested RNAP. 
(a) The general architecture of the elongation complex. The transcribing RNAP is shown in gray and RNA in 
yellow. The template (TS) and non-template DNA strands (NTS) are indicated. RNAP translocates on the TS 
in 3’-5’ direction. (b) The elongating RNAP is arrested by a CPD lesion (indicated by the purple square) in the 
TS. The arrested RNAP sequesters the access to the lesion and has to be removed by one of the following 
mechanisms; (c) Accessory factors chaperone transcription past the lesion. If an incorrect nucleotide was paired 
with the damaged DNA base, the RNA transcript will carry a mutation (indicated by the green star). (d) RNAP 
is actively dislodged from the DNA template, but can participate in the next round of transcription. (e) RNAP 
is actively pushed backwards (backtracked) to expose the DNA lesion to repair enzymes. (f) RNAP is marked 
with ubiquitin (indicated by the blue chain) and degraded by the proteasome. Adapted from152. 
 
The RNAP is first marked with K63 polyubiquitin chains by the Rsp5 ubiquitin ligase162 and 
these chains are subsequently hydrolyzed by Ubp2 to produce the monoubiquitinated 
RNAP163.The single ubiquitin can then be extended by the Elc1/Cul3 ubiquitin ligase to form 
the K48 polyubiquitin chains, which targets RNAP for degradation163. In human cells, the 
RNAP ubiquitination following the DNA damage is likely to play out in a similar cascade 
and may involve Nedd4 and the elongin complex148. After the removal of RNAP from the 
lesion site, the canonical DNA excision reaction occurs in the same way as in GGR153.   
The mechanism of RNAP removal from the lesion site has been well characterized 
in bacteria154. The transcription-DNA repair coupling factor Mfd actively dislodges the 
lesion-arrested RNAP from the DNA, and immediately recruits the downstream repair 
machinery to the cleared lesion site164. In addition, the UvrD helicase can pull the arrested 
RNAP backwards to facilitate DNA repair165. It was suggested that the Mfd-mediated 
pathway is preferred during the normal growth conditions when DNA damage is sporadic 
and less frequent154. However, during the excessive DNA damage, bacterial cells upregulate 
the expression of the UvrD helicase which might favor the RNAP backtracking154. Thus, 
bacteria can adapt to different genotoxic conditions by switching between the two alternative 
TCR strategies154.   
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1.3 General transcription factor IIH (TFIIH) is a central NER factor  
 
Since the discovery of transcription factor IIH (TFIIH) nearly three decades ago166, its 
structure, biochemical and cellular functions have been extensively studied64. TFIIH is 
comprised of ten polypeptides divided into two modules, the core and the kinase module 
(Table 1)64. The core is comprised of the DNA helicase XPD73, the DNA 
helicase/translocase XPB67,69,  the ubiquitin ligase p44167 and three non-enzymatic subunits: 
p62, p52 and TTDA (Fig. 4). The heterotrimeric kinase module contains the protein kinase 
CDK7, cyclin H and MAT164. Mutations in various TFIIH subunits were linked to several 
human disorders, including Xeroderma pigmentosum, Cockayne syndrome, 
Trichothiodystrophy and Cerebro-oculo-facio-skeletal syndrome168,169. The range of 
symptoms, from mild UV-sensitivity to neurodegeneration, premature aging and a high risk 
of cancer development emphasizes the important roles TFIIH plays in cellular viability169.  
 TFIIH has a central role in both transcription initiation and DNA repair64 and it has 
also been implicated in the cell-cycle regulation and chromosome segregation170,171. 
Transcription initiation relies on six general transcription factors (GTF) to deliver the RNAP 
to the transcription start site and stimulate the early mRNA synthesis172. One of the GTFs is 
TFIH and its role is to facilitate the DNA melting necessary for the formation of the RNAP 
elongation complex64. This TFIIH function is mediated by the enzymatic activity of the XPB 
subunit64 but the underlying mechanism is not yet well understood. It was proposed that 
XPB acts as a molecular wrench which rotates while gripping the downstream DNA to twist 
and melt the DNA within the RNAP173-175. Another model suggests that XPB utilizes a DNA 
translocase activity to pump the DNA into the RNAP by tracking on the non-template 
promotor strand in the 5’-3’ direction or on the template promotor strand in the 3’-5’ 
direction  (i.e. away from RNAP), which would result in DNA underwinding and promotor 
opening69,70. The TFIIH kinase module also has an important role during the transcription 
initiation176. Initiating RNAP is phosphorylated on the C-terminal domain (CTD) of the 
largest RNAP subunit comprised of 52 heptad repeats (Y1S2P3T4S5P6S7) in humans177. The 
CTD phosphorylation is not important for the RNA synthesis, but rather serves as a 
recruiting platform for the RNA processing machinery, including RNA capping, splicing 
and polyadenylation177. The CKD7 subunit of the TFIIH kinase module phosphorylates 
serine 5 and serine 7178 on the CTD heptad repeats which is needed for mRNA capping179 
and processing spliceosomal small nucleolar RNAs180, respectively.  
 During the DNA repair TFIIH changes its composition and employs different 
enzymatic activities when compared to its role in the transcription initiation64. The kinase 
module is essential for transcription but inhibits DNA repair by suppressing the XPD 
helicase activity and possibly by phosphorylating DNA repair factors72,73. In vivo, the kinase 
module dissociates from the TFIIH core concomitantly to the recruitment of XPA and re-
associates with the core TFIIH after the repair is completed84. Another major difference is 
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the role for the XPD helicase181. During the  transcription initiation, XPD acts as a scaffold 
and stabilizes the interactions between TFIIH and the transcription pre-initiation complex 
(PIC)70. In contrast, the XPD helicase activity is essential for the repair bubble opening and 
the lesion verification during the DNA repair19. Only the XPB ATPase activity is a shared 
requirement for both transcription and DNA repair, and it might be employed for DNA 
melting which underlies both processes64. Cryo-EM structures of TFIIH182 and TFIIH bound 
to the transcription pre-initiation complex (PIC)70 were reported, as discussed in more detail 
below. However, TFIIH has not yet been visualized in the context of DNA repair.  
 
1.4 Structural studies of NER 
 
The core NER machinery is built around the multi-subunit TFIIH complex64, which in 
molecular mass is roughly equal to all of the other NER factors combined. The TFIIH 
architecture was investigated over the past decades with cross-linking mass-spectrometry, 
2D-crystallography and negative stain electron microscopy 64,183-186. The overall shape of the 
core TFIIH resembles a horse shoe with the core TFIIH ATPases located at its open ends. 
The kinase module docks between XPB and XPD but shares a larger interface with XPD. In 
addition, structures of several TFIIH subunits and domains from various organisms were 
solved by X-ray crystallography and NMR, including XPB67, XPD78, TTDA complexed with 
the p52 N-terminus187, p62 PH domain188, p34 vWA domain and p44 RING domain189. 
However, a major breakthrough in the TFIIH structural biology occurred very recently, when 
cryo-EM structures of the human TFIIH182 (Fig. 4) and the yeast TFIIH bound to PIC70 were 
reported at 4.4 Å and ~6 Å resolution, respectively. Combined with the previous structural 
and function studies on TFIIH and homology modelling, the pseudo-atomic structure of the 
almost complete TFIIH core could be assembled70,182. XPB and XPD are joined by a ring 
composed of subunits p52, p44 and p3470. Within the core, p52 interacts with XPB and p44 
interacts with XPD70, which is consistent with the stimulatory effect of p52 and p44 on the 
respective ATPases in vitro68,70. Subunit p62 is not a part of the horse shoe core assembly, 
but wraps around it and acts as a molecular glue which stabilizes TFIIH182. In addition, the 
PH domain of p62 is important for TFIIH recruitment to PIC where it binds the general 
transcription factor IIE (TFIIE)70. The kinase module is poorly resolved in both reported 
structures, likely due to its high flexibility70,182. However, in the human TFIIH structure182, 
a long helix belonging to the MAT 1 subunit of the kinase module bridges the core TFIIH 
ATPases and a MAT1 helical bundle stacks on top of the XPD helicase (Fig. 4).  
  
 




Figure 4 | Cryo-EM structure of human TFIIH. 
Cryo-EM density (left, EMDB:3802)182 and the resulting pseudo-atomic model (center, PDB:5OF4)182 are 
shown. TFIIH subunits are color-coded as indicated (right).  
 
In addition to the structural characterization of TFIIH, the structure of the yeast XPC 
homologue Rad4 in a complex with the lesion containing DNA was reported26. Rad4 is 
comprised of a N-terminal α/β  domain, followed by three consecutive α/β  domains 
containing long β-hairpins (beta-hairpin domains, BHD1-3). Rad 4 extensively interacts 
with 11 base pairs of a DNA duplex 3’ of the lesion-site and with the four base pairs of 
melted DNA surrounding the lesion. BHD2 and BHD3 domains tightly bind the non-
damaged DNA strand and a β-hairpin from BHD3 inserts into the DNA and causes the lesion 
to flip out of the DNA duplex. Thus, Rad4 does not interact with the DNA lesion itself, but 
rather recognizes the DNA elements surrounding the helix-destabilizing DNA lesion26.  
A solution structure of human XPA92 and a crystal structure of a lesion bound yeast 
XPA homologue Rad14100 were also described. XPA is a small protein comprised of a N-
terminal zinc finger and a central DNA-binding domain83. In a structure with damaged 
DNA100, the XPA dimer binds a 13 base pair DNA duplex which is bent by 70° at the lesion 
site, and each XPA copy uses a β-hairpin to stack against the DNA bases at the ends of the 
duplex. Like XPC, XPA does not interact with the DNA lesion directly but the lesion remains 
within the DNA duplex26,100. The structure does not explain the preference of XPA for 
binding Y-shaped DNA junctions82 and it is also hard to conceive how XPA integrates into 
the NER assembly as a dimer, so it is still unclear how relevant this structure is for the role 
XPA plays in the context of NER.  
 Structural insights into TCR are quite limited. The crystal structure of the yeast 
RNAP arrested on a CPD lesion51 represents the initial substrate for TCR. Interestingly, the 
structure is identical to the RNAP elongation complex in the absence of a DNA lesion, 
arguing against an allosteric mechanism for the recruitment of the DNA repair machinery to 
the arrested RNAP51.  
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Recently, a cryo-EM structure of the yeast CsB homologue Rad26 bound to transcribing 
RNAP was solved (Fig. 5)138. The RNAP transcription bubble was artificially extended on 
the upstream end to facilitate the Rad26-RNAP complex formation. Rad26 binds the 
upstream DNA duplex of the elongation complex and uses a structural element in the 
ATPase lobe 2 to wedge between the re-annealing DNA strands138. Interestingly, Rad26 
bends the upstream DNA by 70° 138. The structure suggests that Rad26 stimulates 
transcription by translocating on the template strand in 3’-5’ direction which would push 
RNAP forward138 (Fig. 5). Structures of all the other TCR-specific or core NER factors in 
complex with lesion-arrested RNAP have not yet been solved, probably due to the lack of 
mechanistic knowledge on TCR which would enable identification of relevant and stable 
targets for structural studies.  
 
 
Figure 5 | Cryo-EM structure of Rad26 bound to RNA-polymerase II. 
Cryo-EM density (left, EMDB:8735)138 and the resulting pseudo-atomic model (center, PDB:5VVR)138 are 
shown. Rad26 and the RNA-polymerase II subunits visible in this view are color-coded as indicated (right). 
Rad26 was suggested to translocate on the template strand (TS) in the 3’-5’ direction, which would pull the TS 
out of the RNA-polymerase II (indicated by the arrow) and consequently push the RNA-polymerase II 














                                                                                                  INTRODUCTION 
 
 17 
1.5 Aims and scope of this work  
 
Human NER has been a subject of intense research for over a half of a century. Numerous 
in vivo and in vitro studies have identified factors driving NER and defined the molecular 
framework of this DNA repair pathway. However, the main difficulty in studying the NER 
reaction mechanism is to obtain large amounts of highly purified DNA repair factors, 
especially multi-subunit complexes such as RNA-polymerase II and TFIIH. As a result, we 
are currently lacking thorough biochemical analysis and structures of NER assembly 
intermediates, which hinders our mechanistic understanding of NER. The aim of this work 
was to reconstitute both NER sub-pathways in a highly purified in vitro system and to 
analyze the isolated reaction intermediates biochemically and structurally, using 
spectroscopic and FRET-based enzymatic assays, cross-linking mass-spectrometry and 
cryo-electron microscopy.  
 
Here, we were able to: 
(i) Clone, express and purify all NER factors in milligram amounts and high purity, 
including XPC-Rad23b, RPA, XPA, XPG, XPF-ERCC1, core TFIIH, TFIIH kinase 
module, CsB, CsA-DDB1, UVSSA, Usp7 and TFIIS. Complete heterodecameric TFIIH 
complex was reconstituted from the purified TFIIH core and the kinase module.  
(ii) Reconstitute GGR and TCR initiation. For GGR, XPC-Rad23b was bound to a DNA 
containing a bulky DNA modification, which served as a recruitment platform for 
TFIIH and the core TFIIH-XPA complex. For TCR, we synthesized a DNA scaffold 
containing a site-specific photolesion CPD. Purified pig RNAP was transcribed into a 
photolesion and decorated with TCR factors. Complexes were isolated and analyzed by 
crosslinking mass-spectrometry and negative stain EM. 
(iii) Biochemically characterize the core TFIIH ATPases XPB and XPD and dissect their 
regulation in the context of NER. 
(iv) Solve cryo-EM structure of the core TFIIH-DNA-XPA lesion scanning NER 
intermediate at 3.6 Å resolution. The structure reveals the topology of the NER 
machinery on the DNA, suggests how DNA lesions are recognized by the XPD helicase 
and explains many mutations found in human diseases. The structure also provides 
insights into the role and the positioning of the main NER scaffolding factor XPA. 
(v) Reveal the fate of the lesion-arrested RNAP. RNAP is actively backtracked by a 
machinery comprised of TFIIH core, XPA and XPG. The backtracking is mediated by 
the XPB translocase activity and it is sufficient to fully expose lesions to repair.  
 
Work presented here expands and redefines our understanding of NER and provides the 
basis for unraveling the complete mechanism of this repair pathway. 





2.1 Reconstitution and analysis of GGR initiation 
 
GGR starts with the recognition of damaged DNA by XPC, followed by the XPC-mediated 
recruitment of TFIIH and XPA46,56,73. We reconstituted this step of the NER pathway with 
highly purified human factors and a lesion-containing DNA scaffold. The NER intermediate 
was analyzed by crosslinking mass-spectrometry and negative staining electron microscopy.  
A robust biochemical and structural characterization of human NER was thus far 
hampered because pure TFIIH was not available in large amounts. TFIIH is frequently 
obtained from endogenous sources such as HeLa cells182, which requires large amounts of 
starting material and restricts the manipulation of the TFIIH amino acid sequence. 
Recombinant expression of TFIIH in insect cells was previously reported73, however, the 
final protein yield was limited because many viruses were used to infect insect cells, and 
each virus encoded one or two TFIIH subunits. We used the MacroBac vector series190 to 
combine 6 TFIIH subunits (XPB, p62, p52, p44, p34 and TTDA) into a single vector by 
sequence- and ligation-independent cloning190 (Methods). The XPD subunit was left on a 
separate vector to facilitate mutagenesis of this subunit for later biochemical studies. The 
core TFIIH module was produced by co-infecting insect cells with only two viruses which 
dramatically increased the final protein yield and quality. Several different tagging strategies 
were tested to optimize the core TFIIH purification protocol. We tagged four different 
subunits with an N-terminal 6xHis tag (Table 8) which allowed us to separate the properly 
formed TFIIH core from the excess subunits and subassemblies by a shallow imidazole 
gradient on a nickel column (Fig. 6a). Initial purification attempts always resulted in a sub-
stoichiometric amount of XPD, so we tagged this subunit with a maltose binding protein to 
enrich for the complete TFIIH core assembly by an additional affinity chromatography step 
(Fig. 6b, Methods). 
 
Figure 6 | Purification of the human TFIIH core. 
(a) Elution fractions from the nickel column were analyzed by SDS-PAGE. The full core TFIIH complex eluted 
at higher imidazole concentrations (indicated by the purple frame), while the sub-assemblies eluted at lower 
imidazole concentrations. (b) Purification of core TFIIH before (left) and after (right) an MBP-tag was added 
to the XPD subunit and an amylose affinity step was incorporated into the purification protocol. Gels show the 
fractions from the final purification step (size-exclusion chromatography), analyzed by SDS-PAGE. The 
improved protocol yielded the TFIIH core containing stochiometric amounts of the XPD subunit (indicated by 
the arrow). 




Figure 7 | In vitro reconstitution of the TFIIH complex. 
(left) Chromatograms show analytical size–exclusion elution profiles for the kinase module in black and the 
mixture of the core TFIIH and the kinase module in yellow. (middle) Fractions corresponding to the elution of 
the kinase module were analyzed by SDS-PAGE and Coomassie staining. (right) Fractions corresponding to 
the elution of the kinase module and the core TFIIH were analyzed by SDS-PAGE. Comparison with the kinase 
module only fractions (gray frame) shows a shift of the kinase module to earlier fractions in the presence of 
the TFIIH core, indicating 10 subunit TFIIH complex formation.  
 
 
All tags were cleaved off with tobacco etch virus protease to prevent potential interference 
of tags with the TFIIH enzymatic activities or the reconstitution of NER intermediates. The 
final purification scheme included five different affinity, ion-exchange and size-exclusion 
chromatography steps (Methods) and we could obtain milligram amounts of the TFIIH core 
at near homogeneity. The kinase module which is comprised of subunits MAT1, CDK7 and 
cyclin H64 was purified separately. We could reconstitute the full 10 subunits human TFIIH 
complex from the TFIIH core and the TFIIH kinase module (Fig. 7). XPC is the primary 
lesion sensor in GGR and it is tightly associated with two additional factors, Rad23b and 
centrin 2191,192. In vitro repair assays have shown that only Rad23b is required for efficient 
NER192. Thus, we established the purification protocol for the XPC-Rad23b binary complex 
expressed in insect cells (Fig. 8, Methods). XPA could be purified from both Escherichia 
coli and insect cells, however, we used only the protein obtained from the insect cell 
expression system (Methods).  
XPC recognizes bulky DNA lesions that kink the DNA duplex24,52,53. We designed a 
model DNA scaffold which contains fluorescein and biotin moieties coupled to consecutive 
thymine bases as a bulky lesion mimic (Table 12). To test if the lesion mimic can specifically 
recruit the XPC-Rad23b complex we performed fluorescence anisotropy and measured the 
DNA affinity of XPC-Rad23b for nondamaged and damaged DNA (Fig. 8). We also 
included a control in which a three base pair mismatch was introduced at the site of a DNA 
lesion to check if the impaired DNA base pairing affects XPC binding. We fitted the 
anisotropy data with the single-site binding equation to determine the apparent dissociation 
constant (Kd,app) for different DNA substrates. XPC-Rad23b showed a high affinity for DNA 
duplex (Kd,app=  32.6 ± 3.1 nM) which additionally increased for mismatched DNA (Kd,app 
= 21.8 ± 2.1 nM). However, in the presence of the lesion mimic the affinity increased by two 
orders of magnitude (Kd,app ≈ 0.6 nM). This suggests that fluorescein and biotin efficiently 
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Figure 8 | Binding of XPC-Rad23b to DNA as measured by fluorescence anisotropy. 
(left) Purified XPC-Rad23b complex was resolved by SDS-PAGE and visualized by Coomassie staining. 
(right) Binding of XPC-Rad23b to different DNA scaffolds is shown; fully complementary DNA is in black, 
DNA containing a mismatch bubble in green and DNA containing modified DNA bases that mimic bulky DNA 
lesions in yellow. Error bars represent s.d. from the mean values for 3 experimental replicates. Fluorescein is 
indicated as a yellow star and biotin as a black circle.  
  
 
To investigate the architecture of the NER intermediate which forms after the lesion 
recognition and prior to the repair bubble opening, we assembled the core TFIIH-XPC-
Rad23b-XPA-DNA complex (Fig. 9a) and analyzed the protein interactions by chemical 
crosslinking and mass-spectrometric detection of crosslinking sites (Fig. 9b). The NER 
intermediate was reconstituted by mixing the XPC-Rad23b lesion sensor with the damaged 
DNA, followed by the addition of the core TFIIH and XPA. The resulting complex was 
purified by size-exclusion chromatography (Fig. 9a) and crosslinked with BS3, which 
crosslinks lysine residues within a 30 Å distance. The kinase module was omitted because it 
was shown that the kinase module inhibits DNA repair and dissociates from the TFIIH core 
upon XPA recruitment84.  
The crosslinking network between the core TFIIH subunits is very similar to the BS3 
crosslinking network reported for TFIIH immunopurified from human cells186 which 
validates our crosslinking results and suggests that the core TFIIH subunits are properly 
assembled during the expression in insect cells. The XPC-Rad23b complex does not 
extensively crosslink to TFIIH. The acidic region in the XPC N-terminus mainly crosslinks 
to the pleckstrin homology (PH) domain of the p62 subunit in TFIIH (Fig. 9b). This agrees 
with a coimmunoprecipitation study which showed that the XPC N-terminal region interacts 
with p6262,193. Moreover, an NMR structure of the acidic amino acid stretch in the XPC N-
terminus bound to the PH domain of p62 was previously reported for human and yeast 
proteins151,194.  




Figure 9 | Reconstitution and the crosslinking mass-spectrometry network of the core TFIIH-XPA-XPC-
Rad23b-DNA complex. 
(a) Chromatogram shows the size–exclusion elution profile of the core TFIIH–XPA–XPC-Rad23b–DNA 
complex. We monitored the elution of the fluorescein–containing DNA by absorption at 495 nm (purple). Peak 
fractions were analyzed by SDS–PAGE and Coomassie staining. All protein subunits coeluted in 
stoichiometric amounts in the presence of the lesion–containing DNA scaffold. (b) Crosslinking network of 
the complex. TFIIH subunits are colored as in Fig.4, XPC-Rad23b is shown in blue and XPA in purple. 
Crosslinks between the core TFIIH subunits are shown in gray, between XPC and core TFIIH in blue, and 
between XPA and core TFIIH in purple. Crosslinks with a score above 3 are shown. List of inter-subunit 
crosslinks is provided in the Supplemental Table 1. DRD, damage recognition domain; NTE, N-terminal 
extension; BSD, BTF2-like, synapse-associated and DOS2-like domains; VWFA, von Willebrand factor type 
A domain; UbL, ubiquitin like; UBA, ubiquitin-associated domain; FeS, iron-sulfur domain; Zn, zinc finger; 
DD, dimerization domain; NTD, N-terminal domain 
 
Limited crosslinks between TFIIH and XPC suggest that the interaction is largely mediated 
by DNA. XPA mainly crosslinks to the core TFIIH ATPases. In particular, the N-terminal 
region of XPA crosslinks to XPD and the C-terminal region of XPA crosslinks to XPB. 
Since XPA is a DNA binding protein82,195,196, it may sit on the DNA between the core TFIIH 
ATPases. 
We also analyzed the core TFIIH-XPC-Rad23b-XPA-DNA complex by negative-
stain electron microscopy (EM) (Fig. 10). The complex was purified by sucrose gradient 
ultra-centrifugation in the presence of glutaraldehyde which fixes and stabilizes particles 
during the sample preparation for EM (Fig. 10a)197. The sample was stained with uranyl 
formate (Fig. 10b) and a small data set was acquired. The structure was solved to ~30Å (Fig. 
10c). The structure strongly resembles the previously reported structure of the human TFIIH 
bound to PIC198 (Fig. 10d). After docking the TFIIH structure198 into our negative stain 
envelope, an additional density between the TFIIH ATPases XPB and XPD was observed. 
The additional density might correspond to the XPC-Rad23b lesion sensor. Since XPC-
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Rad23b binds the damaged DNA duplex with a very high affinity48 (Fig. 8) and XPB binds 
the double-stranded DNA in the TFIIH-PIC structure198, it is tempting to speculate that in 
our structure XPC and XPB sit on the DNA (Fig. 10d). This would also be in agreement 
with a model in which XPC first recognizes the lesion, followed by the recruitment of TFIIH 
and the initial DNA melting by XPB199. Moreover, the position of XPD between XPB and 
XPC would be ideally suited for XPD to engage the DNA single-strand after the repair 
bubble opening and to start scanning for the lesion (further discussed in section 3.5 and Fig. 
39). To verify this model, we attempted to solve the high-resolution structure of the complex 
with cryo-EM. However, despite many attempts at sample optimization and different 
strategies used to purify and crosslink the complex, we could never properly align particles 
in 2D or 3D, presumably due to the high flexibility of the complex. 
 
 
            
Figure 10 | Negative stain reconstruction of the core TFIH–XPA–XPC-Rad23b–DNA complex. 
(a) Complex formation on a 10–30% sucrose gradient in the absence (above) or the presence (below) of 
glutaraldehyde. The fraction of the crosslinked sample used for negative staining and electron microscopy is 
indicated by the purple frame. (b) Exemplary micrograph of the sample stained with uranyl formate. (c) 
Negative stain reconstruction of the core TFIIH–XPA–XPC-Rad23b–DNA complex. Two views are shown. 
(d) The cryo-EM density of the core TFIIH bound to PIC (blue dashed line outlines the core TFIIH; EMDB 
8131)198 was fitted into the negative stain reconstruction. The additional density observed in our reconstruction 
is indicated by a yellow dashed line and might correspond to XPC-Rad23b and XPA. Based on the DNA bound 
to the XPB subunit in the TFIIH-PIC structure and a strong affinity of XPC-Rad23b for the DNA duplex, we 
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2.2 Structural basis of TFIIH activation for NER 
 
2.2.1 Biochemical characterization of core TFIIH ATPases 
Systematic biochemical analysis of core TFIIH ATPases XPB and XPD in the context of 
NER is currently lacking due to difficulties in obtaining large amounts of recombinant TFIIH 
and other NER factors. Since we overcame this barrier (Methods), we first measured the 
ability of XPD and XPB to hydrolyze ATP (Fig. 11a).  
 
                
Figure 11 | Biochemical characterization of the core TFIIH ATPases. 
(a) (left) Raw data of the ATPase assay for the TFIIH core. In the assay ADP recycling is coupled to NADH 
oxidation which can be monitored in real time by a decline in absorbance at 340 nm (Methods). The assay was 
performed at different ATP concentrations as indicated next to the plot. (right) The turnover number (kcat) of 
ATP consumption is shown for the core TFIIH (yellow) and the core TFIIH lacking XPD (gray), in absence of 
DNA or in the presence of ssDNA or dsDNA as indicated below the plot. Error bars represent the s.d. of the 
mean values for 2 experimental replicates (b) Polarity of the XPD helicase. DNA unwinding was monitored 
by a FRET-based assay (Methods). Fluorescence traces of the core TFIIH unwinding in the 5’–3’ and the 3’–
5’ direction are shown in yellow and black, respectively. DNA unwinding of the core TFIIH containing the 
XPD K48R mutant is shown in gray. Shown traces are representative of 2 independent experiments. (c) 
Double-stranded DNA translocation by the core TFIIH is mediated by XPB. DNA unwinding and triplex 
disruption were monitored by a FRET-based assay (Methods). Translocase (left) and helicase (right) activities 
of the core TFIIH in the presence (yellow) or absence (gray) of triptolide (100 μM final) are shown. Triptolide 
inhibits XPB200,201 and specifically affects the core TFIIH translocase activity. Bar graphs show the percentage 
of disrupted triplex after 4000 s (left) and the percentage of unwound duplex after 300 s (right) for 2 
independent replicates. Error bars represent s.d. from the mean values. 
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We additionally purified the core TFIIH lacking the XPD subunit, so that the ATP hydrolysis 
by XPB can be measured directly. An NADH-coupled photometric assay202 was used to 
monitor ATP hydrolysis in real time (Fig. 11a). Since XPB and XPD are both DNA motor 
proteins we also tested if the addition of single (ssDNA) or double stranded DNA (dsDNA) 
will stimulate the ATPase rate of core TFIIH. In the absence of nucleic acids both core TFIIH 
ATPases are quite inefficient in hydrolyzing ATP (Fig. 11a), probably to prevent futile ATP 
consumption when their enzymatic function is not required. Upon the addition of excess 
ssDNA or dsDNA the turnover number of ATP consumption for both heptameric and 
hexameric core TFIIH assembly increased ~7 times (Fig. 11a). The stimulation of the TFIIH 
ATPase activity by DNA was also shown before73. However, the contribution of XPB and 
XPD to ATP hydrolysis is dependent on the type of DNA. XPD is more stimulated by 
ssDNA while XPB is more stimulated by dsDNA (Fig. 11a), which reflects the different 
substrate specificities of the two ATPases.  
 To further investigate XPB and XPD, we established fluorescence resonance energy 
transfer (FRET)-based assays to monitor their helicase and dsDNA translocase activities in 
real time. The dsDNA translocase activity (called just translocase activity throughout the 
thesis) of core TFIIH was measured by a triplex disruption assay, as previously 
described69,203. For the helicase activity, we also measured DNA unwinding in 5’-3’ and 3’-
5’ direction. Core TFIIH exhibited a robust 5’-3’ helicase activity (Fig. 11b) which could be 
attributed to XPD as this activity is abolished when XPD is replaced with the XPD point 
mutant which cannot hydrolyze ATP68 (Fig. 11b). This agrees with previous reports which 
described XPD as a 5’-3’ DNA helicase72,73. However, core TFIIH did not show any DNA 
unwinding in 3’-5’ direction (Fig. 11b), the activity which has been demonstrated for 
archaeal XPB67. Core TFIIH also has a translocase activity which can be attributed to XPB 
because this activity is sensitive to the addition of triptolide, a drug that specifically 
inactivates XPB200,201 (Fig. 11c). The translocase activity was also demonstrated for the yeast 
XPB homologue Ssl269. As a control we showed that triptolide does not influence core 
TFIIH helicase activity which depends on XPD (Fig. 11c). A comparison of TFIIH 
enzymatic activities suggests that XPD is the dominant TFIIH motor, since DNA unwinding 
occurs on a shorter time scale and is more efficient compared to DNA translocation (Fig. 
11). In summary, XPD is a 5’-3’ DNA helicase and XPB is a dsDNA translocase. 
 Next we investigated the effect of NER factors on the core TFIIH ATPases. We 
purified XPA, RPA heterotrimeric complex, XPG and XPF-ERCC1 complex in large 
amounts and high purity (Fig. 12a). We first tested the effect of the NER factors on XPD 
helicase activity. XPD helicase activity was stimulated by both XPA and XPG (Fig. 12b). 
Helicase activity was not observed in the presence of RPA complex probably because RPA 
has a very high affinity for ssDNA104,204 and masks the DNA overhang XPD uses to initiate 
DNA unwinding. The XPD helicase activity in the presence of XPG was too fast to be 
captured with a microplate reader which has a dead time of more than 10 s (Fig. 12b, blue 
trace).  
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Figure 12 | Regulation of ATPases in core TFIIH. 
(a) Purified XPA, RPA, XPF-ERCC1 and XPG NER factors were resolved by SDS-PAGE and visualized by 
Coomassie staining. (b) Effect of NER proteins on XPD 5’-3’ helicase activity. Real-time fluorescence 
measurement using a FRET assay as in Fig. 11b is shown. Bars show percentage of unwound product after 
100s. Error bars provide s.d. of the mean of two replicates. (c) (left) Schematic representation of a stopped-
flow apparatus. (right) Stopped-flow measurement of DNA unwinding. TFIIH core (gray) was pre-incubated 
with excess XPA (purple) or XPG (blue) and rapidly mixed with ATP in a stopped-flow apparatus. DNA 
unwinding was monitored by a FRET-based assay as in Fig. 11b. Fluorescence traces represent the average of 
5 measurements. Initial linear parts of the traces were fitted with Prism software to obtain the initial rate of 
DNA unwinding, as indicated below the graph. (d) Effect of NER proteins on XPB translocase activity. Real-
time fluorescence measurement of triplex disruption as in Fig. 11c is shown. Bars show percentage of disrupted 
triplex after 4000s. Error bars provide s. d. of the mean of two replicates. 
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Therefore, we coupled the helicase assay to a stopped-flow apparatus and resolved the entire 
DNA unwinding reaction in the presence of XPA and XPG (Fig. 12c). The unwinding was 
~4 and ~20 times faster in the presence of XPA and XPG, respectively (Fig. 12c). Strong 
stimulation of XPD by XPG explains a longstanding observation that XPG is required for 
efficient repair bubble opening, which is independent of its endonuclease activity113. We 
also tested the effect of NER factors on the XPB translocase activity (Fig. 12d). The activity 
was stimulated by all NER factors tested, however, the stimulation by XPA was 
exceptionally strong. In the presence of XPA, the percentage of disrupted triplexes increased 
from ~10% to ~80% after 4000 s (Fig. 12d). Even though the positive effect of XPA on 
DNA unwinding by TFIIH was known56, the stimulation of the XPD helicase and the XPB 
translocase activity by XPG and XPA, respectively, has not been reported before. This may 
be important for the lesion scanning step of NER which is mediated by TFIIH migration on 
the DNA while searching for the lesion56. 
 
2.2.2 Core TFIIH-XPA-XPG-DNA complex formation and cryo-EM structure 
determination 
 
In order to reveal the structural basis of XPB and XPD stimulation by XPA and XPG we 
formed the core TFIIH-XPA-XPG complex on a bifurcated DNA scaffold for cryo-EM. We 
chose bifurcated DNA as a nucleic acid scaffold because it mimics one half of a DNA repair 
bubble formed during NER65 and it provides a binding substrate for both XPB and XPD. 
The complex was formed by mixing core TFIIH with excess DNA, XPA and XPG, and 
purified on a sucrose gradient (Fig. 13a). An XPG endonuclease mutant was used for the 
complex formation to prevent DNA cleavage during the sample preparation. All proteins 
comigrated on a sucrose gradient in apparently stoichiometric amounts, indicating that the 
complex was efficiently formed (Fig. 13a). For cryo-EM particles were crosslinked with 
glutaraldehyde which was added to the sucrose gradient197. After the gradient centrifugation, 
crosslinking was stopped with lysine and aspartate, which stochastically adds charges to the 
particles and improves the particle orientation distribution within the vitrified sample. The 
sample was visualized by a Titan Krios cryo-electron microscope and images showed nicely 
spaced individual particles of the correct size (Fig 13b). We collected a large data set of 
approximately 9000 micrographs. The micrographs were pre-processed in Warp205 and 
particles were picked with a retrained BoxNet205. We used the first 300 000 particles auto-
picked during the data collection for ab-initio reconstruction in CryoSPARC206. 
Interestingly, one ab-initio class already showed clear core TFIIH features and the 
reconstruction was not biased by using an already existing structure as input model (Fig. 
13d). After further processing in CryoSPARC206 and RELION207 (Methods), we obtained a 
cryo-EM map at a global resolution of 3.6 Å according to the gold-standard Fourier shell 
correlation (FSC) 0.143 criterion with an applied B-factor of -110.02 Å-2 (Fig 15b).  
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Figure 13 | Cryo-EM data processing. 
(a) Core TFIIH-XPA-XPG-DNA complex formation for cryo-EM. Sucrose gradient fractions from the control 
without glutaraldehyde were analyzed by SDS-PAGE and Coomassie staining. The fraction marked by the 
pink frame, but in the presence of glutaraldehyde, was used for structure determination. (b) Representative 
micrograph shows nicely spaced individual particles. (c) Thirty representative 2D classes obtained after the 
final 3D classification. (d) Processing tree for structure determination of the TFIIH-XPA-DNA complex. 
Particle class-distribution after 3D classification is indicated next to the corresponding map. The final map 
obtained by global refinement is color coded by subunits as indicated. 5 focused classifications used to improve 
different parts of the structure are shown over the gray TFIIH silhouette for context. Classes used for the 
refinement are indicated with colored background and the refined structure is shown next to the corresponding 
3D classes. 
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However, as seen from the 2D classes (Fig. 13c) and local resolution estimation (Fig. 15c) 
many peripheral parts of the complex were flexible and less well resolved. To improve the 
resolution of several TFIIH subunits, we performed focused classifications and refinements 
(Fig. 13d). This resulted in considerably improved maps for many regions in the TFIIH core, 
which facilitated model building (Methods).  
The final cryo-EM map revealed densities corresponding to all core TFIIH subunits 
except p62, for which only some secondary structure elements contacting p34 and XPD 
subunits were visible (Fig. 14). The p62 subunit was also not visible in the previously 
reported human TFIIH model182 and it was proposed to act as a flexible molecular glue that 
spreads around the TFIIH core. However, due to the higher resolution obtained in our study, 
we were able to expand the previous model of the human TFIH core182 by modelling or de 
novo building the N-terminal extension (NTE) domain and part of the damage recognition 
domain (DRD) of XPB, most of the p52 subunit and the interface between the subunits p34 
and 44 comprised of two zinc fingers and a RING domain (Figs. 14, 35). The newly built 
parts show how XPB is attached to the TFIIH core and explain previous biochemical 
observations (section 3.2).  
 We observed an additional EM density corresponding to the nucleic acid scaffold 
used for the complex formation (Figs. 13,14,15,16). We were able to trace the entire 
bifurcated DNA, which was coated with DNA repair proteins (Figs. 14, 16). XPB was bound 
to the DNA duplex, consistent with its role as a DNA translocase69 (Fig. 11c), and XPD was 
bound to the DNA single strand, consistent with its role as a DNA helicase72,73 (Fig. 11b). 
To my knowledge, this is the first structure of a DNA translocase and a DNA helicase sharing 
the DNA scaffold.  Interestingly, XPB helicase motifs preferentially contact the 5’-3’ DNA 
strand (Fig. 16c), suggesting that this is the strand XPB tracks on. The same DNA strand 
extends into the XPD helicase (Fig. 16a, c). Thus, both XPB and XPD use the same DNA 
strand for DNA migration, which has interesting implications for DNA repair bubble 
opening and XPD loading during the initial stages of NER (section 3.5). The EM density 
also revealed XPA which binds the duplex-single strand junction (Figs. 14, 18). However, 
XPG density was not observed and the protein probably dissociated during the sample 











Figure 14 | Structure of human TFIIH-XPA-DNA complex. 
(a) Domain organization of XPA and human TFIIH subunits. Residues at domain borders are indicated. Solid 
and dashed black lines mark residues modeled as atomic and backbone structures, respectively. DRD, damage 
recognition domain; NTE, N-terminal extension; BSD, BTF2-like, synapse-associated and DOS2-like 
domains; VWFA, von Willebrand factor type A domain. (b) Cylindrical representation of the structure. 











Figure 15 | Cryo-EM map quality. 
(a) Angular distribution plot for particles contributing to the final reconstruction. Number of particles assigned 
to a particular orientation is color-coded as indicated. (b) Fourier shell correlation plots for the final and 
focused-classified maps. (c) Local resolution estimates for the final map. (d-i) Examples of the final map 
quality. (d) Additional XPA density (purple) contacting p52 dimerization domain and TTDA/p8 is observed at 
lower resolution and it was not used for model building. XPA is shown as purple spheres and TFIIH subunits 
are color coded as in Fig. 14. (e) Cryo-EM density corresponding to the bifurcated DNA scaffold. Close-up 
view of the double stranded DNA region shows a clear separation of the density corresponding to phosphates, 
ribose and DNA bases. (f) De novo built interface between the XPB and p52 subunits. Bulky side chains were 
used to assign the protein register. (g) Individual beta-strand from the second helicase lobe of XPD. The high 
map quality allows the protein backbone tracing and the placement of side-chains. (h) Cryo-EM density for the 
extended XPA helix directs the placement of the secondary structure element in the lower resolution map. 
PSIPRED tool predicts the formation of the long helix with high confidence. (i) Cryo-EM density for the XPA 











Figure 16 | Detailed analysis of XPB and XPD bound to the DNA. 
(a) Ribbon representation of XPB (pink) and XPD (yellow) bound to the DNA. (b) Domain organization of 
XPB (left) and XPD (right). Domains are color coded as indicated. (c) Helicase motifs colored for XPB (left) 
and XPD (right) according to133. In the XPB structure it is clearly visible that the 5’-3’ DNA strand interacts 
with the helicase motifs. (d) Schematic representation of XPB-DNA contacts. Schematic representation of 
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2.2.3 Structural rearrangements in TFIIH upon activation for DNA repair 
 
A structure of TFIIH immunopurified from human cells was reported recently182. Aside from 
the core TFIIH subunits, the structure also revealed secondary-structure elements which 
belong to the kinase module subunit MAT1. In particular, a long MAT1 helix spans between 
XPB and XPD, and a helical bundle in MAT1 stacks onto XPD (Fig. 4, 22). The kinase 
module was shown to inhibit DNA repair by preventing TFIIH to engage DNA72,73. Thus, 
the comparison of our core TFIIH-XPA-DNA structure, which represents an NER 
intermediate, to that of the kinase bound TFIIH reveals the structural basis of TFIIH 
activation for DNA repair (Fig. 17).   
 
 
Figure 17 | Large-scale structural changes in TFIIH upon activation for repair. 
(a) The core TFIIH-DNA structure shown for context and color-coded as in Fig. 14. (b-d) Superpositions of 
different TFIIH subunits before and after DNA binding show inter-and intra-subunit flexibility. The structure 
in the absence of DNA was modeled by fitting TFIIH domains from our structure into the EM density for the 
kinase-bound TFIIH182 for easier comparison, since our structure contains several domains not built in the 
previous TFIIH model182. TFIIH structure in the absence of DNA is always shown in gray. (b) The structures 
with and without the DNA were aligned on the ATPase lobe 1 of XPB. XPD swings ~80 Å during DNA loading 
(R272 in corresponding structures was used for the distance measurement). (c) Internal rearrangements in XPB. 
XPB domains are color-coded as follows: NTE and DRD domains in dark pink, ATPase lobe 1 in pink and 
ATPase lobe 2 in hotpink. Binding to DNA duplex induces closure of XPB ATPase lobes and substantial 
rearrangement of accessory domains DRD and NTE. (d) Flexile interface between p44 and p34 comprised of 
several Zn-fingers supports the large-scale movement of XPD during the DNA loading. 
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 The structure of the TFIIH core presented here is more complete compared to the 
structure of the TFIIH core bound to the kinase module182 and contains several newly built 
domains (Fig. 35). Thus, for an easier comparison between the two structures we docked 
individual domains from our structure into the EM density of the kinase-bound TFIIH182, 
followed by real-space refinement in PHENIX208 (Fig. 17). Remarkably, the core TFIIH 
undergoes a huge conformational rearrangement between the two states with a substantial 
intra- and inter-subunit reorganization (Fig. 17). The most prominent movement is the 
repositioning of the XPD helicase which has to swing for more than 80 Å to grasp the DNA 
(Fig. 17b). We also observed a rearrangement in the XPB translocase. The two XPB ATPase 
lobes close on the DNA duplex and the two accessory domains NTE and DRD rotate in 
opposite directions (Fig. 17c). The rotation of the DRD domain is important because this 
domain is one of the anchor points for the kinase on the TFIIH core182. A major source of 
the core TFIIH flexibility is the interface between the p34 and p44 subunits which is 
comprised of two intertwined zinc fingers (Fig. 17d). The p44 subunit latches on p34 subunit 
with the RING domain but the rest of its body is free to rotate. Since p44 couples XPD to 
the rest of the TFIIH core, the flexibility of p44 enables the high degree of mobility observed 
for the XPD helicase. The plasticity of the TFIIH ring which couples the enzymatically 
active subunits XPB and XPD might allow TFIIH to participate in very different biological 
roles64.  
 
2.2.4 XPA interactions with core TFIIH and DNA 
 
XPA is the smallest NER protein, yet mutations in XPA cause the most severe symptoms of 
Xeroderma pigmentosum83. Despite decades of structural and biochemical investigation of 
XPA, its role in NER is still unclear. XPA is considered to be the main scaffolding protein 
in NER because it interacts with most of the other NER factors85-96. Our structure reveals the 
position of XPA within the NER machinery and the mode of its interaction with TFIIH and 
DNA. The structure also explains how XPA strongly stimulates XPB translocase activity as 
observed in our biochemical assays (Fig. 12d).  
   XPA contains an N-terminal zinc finger and a DNA-binding domain with an 
extended helix and an intercalating ß-hairpin (Fig. 14). XPA forms an elongated arch over 
DNA that bridges between XPB and XPD (Fig. 14). XPA binds XPB and XPD with its 
extended helix and its intercalating hairpin, respectively. The XPA C-terminus further 
extends towards the p52 dimerization domain and TTDA. This could only be visualized 
when the EM-density was filtered to a lower resolution (Fig. 15d) due to the high flexibility 
of the structure in this region, but the interaction was additionally confirmed with 
crosslinking mass-spectrometry (Fig. 23c). Also, the interaction between XPA and TTDA 
explains why TTDA is required for XPA recruitment to the growing NER machinery in 
vivo209. Overall, the position of XPA between the core TFIIH ATPases and its elongated 
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shape might allow XPA to act as a scaffold which interacts with proteins at both junctions 
of a DNA repair bubble83.  
 
 
Figure 18 | XPA-DNA interactions. 
(a) Ribbon representation of the XPA-DNA structure. XPA intercalating hairpin is shown in orange and the 
rest of XPA is shown in purple. (b) Electrostatic interactions between XPA and the DNA junction. DNA 
nucleotides are indicated as circles. Patches of positively charged residues in proximity to the DNA backbone 
are indicated. Residues that are mutated in Xeroderma pigmentosum are highlighted in yellow. Mutation of 
encircled residues decreases DNA affinity. (c) DNA duplex tunnel formed by XPA and XPB. Blue, white and 
red color indicates positive, neutral and negative electrostatic surface potential, respectively. Created with 
UCSF Chimera210. (d) Two positions of DNA in the tunnel. Tightly bound DNA is in blue, dissociated DNA 
in yellow, ATPase lobe 1 of XPB in pink, ATPase lobe 2 in hotpink, and XPA in purple. 
 
XPA binds to the duplex-single strand junction positioned between XPB and XPD 
which is consistent with previous biochemical data82 (Fig. 14, 18a). During lesion scanning 
by XPD, this junction is located 5’ of the lesion site and represents the 5’ edge of the repair 
bubble71. The XPA intercalating hairpin inserts at the duplex-single strand junction and the 
conserved W175 located at the tip of the hairpin stacks against a DNA base of the DNA 3’-
extension at the junction (Figs. 15i, 18a,b).  Interaction between XPA and DNA is mostly 
electrostatic in nature. We observed several patches of positively charged residues near the 
sugar phosphate backbone which recognize different structural elements of the DNA 
junction (Fig. 18b). Mutations in several of the residues located in these patches were 
reported to cause Xeroderma pigmentosum83. In addition, many of the residues were 
previously shown to be important for DNA binding by XPA81. Precise positioning of XPA 
at the presumed 5’ edge of the DNA repair bubble may provide a reference point for the 
organization of the NER assembly83 as the assembly grows around the site of the DNA 
damage. 
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Our structure also suggests how XPA stimulates XPB translocation (Fig. 12d). XPB 
is not a processive enzyme and readily dissociates from DNA69,211. However, in our structure 
DNA is held in a positively charged DNA duplex tunnel that is formed between the extended 
helix of XPA and the XPB ATPase (Fig. 18c). XPA may thus retain DNA near the XPB 
active site. Indeed, our cryo-EM data revealed an alternative state of the complex with the 
DNA duplex disengaged from XPB but retained by the XPA extended helix (Figs. 13d, 18d). 
Thus, by trapping the DNA within the duplex tunnel, XPA may stimulate the XPB 
translocase activity and retain the NER machinery on the DNA during lesion scanning and 
processing.  
 
2.2.5 XPD-DNA interactions  
 
The crystal structure of the archaeal XPD-DNA complex was previously reported, however, 
only a short DNA fragment bound to the ATPase lobe 2 was observed71. The 5’ end of the 
short fragment was directed towards the ATPase lobe 2 and the 3’ end towards the ATPase 
lobe 1, which suggested the polarity of DNA binding to XPD. Here we reveal the full 
trajectory of DNA through the human XPD helicase in the context of the TFIIH core (Figs. 
14, 19). Focused classification and focused refinement with a mask around XPD 
significantly improved the cryo-EM map quality for this TFIIH subunit (Fig. 15b, 3.5 Å final 
resolution), which was important for visualization of DNA-protein contacts (Fig. 19b-d). We 
could resolve the density corresponding to individual bases and the sugar phosphate 
backbone in the areas where DNA is stabilized by interactions with the helicase. However, 
between the ATPase lobes, the density for DNA worsened presumably due to higher 
flexibility of the DNA. 
The structure elucidates details on how XPD binds the DNA (Fig. 19). XPD consists 
of two ATPase lobes and the ATPase lobe 1 contains two inserted accessory domains, the 
Arch domain and the iron-sulphur (FeS) domain (Fig. 19a)78. The structure reveals extensive 
interactions between the 5’ end of the DNA and the ATPase lobe 2 of XPD (Fig. 19c). Aside 
from multiple positively charged residues that engage the sugar-phosphate backbone, many 
contacts with the DNA bases are also formed, such as base stacking with the side chains of 
F508 and Y627 (Fig. 19c). In addition, the bases emerging from the helicase base stack with 
the side chain of W175 in XPA (Fig. 19c). This mode of interaction with the DNA is unusual 
for the SF2-family helicases which generally engage only the sugar-phosphate 
backbone212,213. It may be that extensive contacts with the DNA by XPA and XPD facilitate 
DNA bubble formation and XPD loading during the initial stages of NER. 
The structure further suggests how XPD recognizes the lesion during DNA scanning. 
The DNA single strand extends into a pore formed by the ATPase lobe 1, the FeS domain, 
and the Arch domain (Fig. 19a). The sugar-phosphate backbone is bound by residues in the 
FeS domain, including R112, which is frequently mutated in Trichothiodystrophy214, and 
Y192 and R196, which are implicated in DNA lesion sensing215 (Fig. 19b, d). These 
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interactions guide the DNA strand towards the FeS cluster which may be involved in the 
detection of DNA lesions74,216,217. Interestingly, R112 bridges the FeS cluster and DNA by 
interacting with the Fe-ligand C134 (Fig. 19d), which might be important for the lesion 
detection via DNA-mediated charge transfer74,216. Also, the FeS cluster is flanked by two 
protein pockets that are lined with aromatic residues Y158, F161 and F193 (Fig 19d), and 
may proof-read DNA bases, as observed for base excision DNA repair218. 
 
  
Figure 19 | XPD-DNA interactions. 
(a) Ribbon representation of DNA-bound XPD. XPD domains ATPase lobe 1, FeS, Arch, and ATPase lobe 2 
are in green, yellow, orange, and medium purple, respectively. DNA is in dark blue, plug element in red and 
FeS cluster in pink (b) Schematic representation of XPD-DNA interactions. The DNA-contacting residues 
mutated in human diseases are indicated. (c) Close-up view of the interactions between the DNA and the 
ATPase lobe 2. The amino acid residues are color-coded as in (a). XPA W175 is shown in green. (d) XPD-
DNA contacts near the FeS cluster. The residues implicated in lesion sensing are shown in brown and the 
aromatic residues lining the FeS cluster in pink. The FeS cluster is indicated by the dotted red circle. 
 
2.2.6 XPD inhibition by the kinase module and activation by XPA 
 
We could reproduce the known repression of the XPD helicase activity by the TFIIH kinase 
module72,73,84 in our helicase assay (Fig. 20a). To prevent that the ATPase activity of CDK7 
inhibits XPD helicase by depleting the ATP levels, we performed the assays in the presence 
of an ATP regenerating system comprised of the phosphoenolpyruvate and the pyruvate 
kinase (Methods). However, it is still unclear if the repression is a result of the kinase module 
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binding or XPD phosphorylation by CDK7. To test this, we designed and purified two 
variants of the kinase module which contain the catalytically impaired CDK7 kinase219. We 
confirmed the lack of kinase activity for the kinase module variants by measuring their 
ability to phosphorylate the C-terminal domain of the largest RNA polymerase II subunit 
(Fig. 20b), which is a natural CDK7 substrate during transcription initiation220,221. We found 
that catalytically inactive variants of the TFIIH kinase module could also repress XPD 
helicase activity, showing that repression does not require the kinase activity of CDK7 (Fig. 
20a). In addition, we found that both XPA and XPG could relieve the kinase-mediated 
repression of XPD in a concentration-dependent manner (Fig. 20c). These observations 
show that XPA and XPG counteract the repressive effect of the kinase module on XPD, most 
likely by interrupting the kinase module binding to XPD.  
 
 
             
Figure 20 | XPD regulation by the kinase module. 
 (a) Effect of kinase module variants on XPD helicase activity. Core TFIIH was incubated with a 2-fold excess 
of the kinase module and helicase activity was monitored as in Fig. 11b. The helicase activity of the ATPase 
deficient XPD-K48R mutant is shown as a control. Bars show the percentage of unwound product after 300s 
for two replicates. Error bars represent s.d. from the mean values. (b) Activity of kinase module variants. 
Different kinase module variants were incubated with the dephosphorylated yeast RNA-polymerase II and the 
phosphorylation status of the C-terminal domain of Rpb1 was probed by Western blotting. CDK7:T170A 
exhibits a much weaker kinase activity compared to the wild type CDK7, while the CDK7:D137R mutant is 
kinase dead. (c) Effect of increasing concentrations of XPA and XPG on XPD helicase activity in the presence 
of kinase module (0.25 μM core TFIIH, 0.5 μM kinase module, 0.375, 0.75, 1.5 or 3 μM XPA or XPG). 
Otherwise as in (a). 
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A comparison of our structure with the previous TFIIH structures shows how the kinase 
module represses XPD activity. In previous TFIIH structures70,182, a region in the XPD Arch 
domain forms a ‘plug’ (residues 273-325) which occupies the DNA pore of XPD (Fig. 21b). 
The plug would clash with DNA in the XPD pore (Fig. 21c), but is displaced and mobile in 
our structure (Fig. 21a). The kinase module subunit MAT1 contacts the plug and may 
stabilize it in the XPD pore (Fig. 21b), explaining how the kinase module impairs binding 
of core TFIIH to single stranded DNA73 and inhibits XPD helicase activity. In addition, a 
loop in the yeast counterpart of p62 extends into the XPD active site during transcription 
initiation70 and is predicted to interfere with the observed DNA trajectory through the 
helicase. Thus, multiple strategies are put into place to inhibit XPD when its helicase activity 
is not required.  
 
 
Figure 21 | Structural basis for XPD inhibition by the kinase module. 
(a) Side view of XPD bound to DNA. XPD domains ATPase lobe 1, FeS, Arch, and ATPase lobe 2 are in 
green, yellow, orange, and medium purple, respectively. DNA is in dark blue. A black circle depicts the DNA 
pore. (b) Side view of XPD bound to the kinase module (PDB code 5OF4)181. The plug in the Arch domain is 
in dark red, the kinase module subunit MAT1 in blue. (c) Overlay of XPD bound to the DNA and XPD bound 
to the kinase module with a zoom-in on the clash between the DNA and the plug. 
 
Structural comparisons also suggest how XPA relieves XPD inhibition by the kinase 
module (Fig. 20c). XPA stabilizes TFIIH in a new conformation in which the two ATPases 
are drastically reoriented (Fig. 22). This conformation is incompatible with MAT1 binding 
as observed in the previous TFIIH structure181. The docking sites of MAT1 on XPB and 
XPD increase in distance for ~30 Å in the TFIIH conformation stabilized by XPA. In 
addition, the modeled trajectory of MAT1 in the TFIIH-XPA-DNA structure would clash 
with the XPA zinc finger (Fig. 22). This explains how XPA facilitates kinase module 
removal upon NER induction in vivo84. Taken together, MAT1 and XPA stabilize two 
entirely different conformations of TFIIH, which contain the repair helicase XPD in an 
inactive or an active state, respectively. 
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Figure 22 | Structural basis for XPD activation by XPA. 
Kinase-bound core TFIIH (upper panel, produced from the previous structure182 as described in Fig. 17) and 
DNA-bound core TFIIH-XPA (lover panel) structures are shown. The structures are color-coded as in Fig. 14, 
MAT1 kinase module subunit is shown in blue. Front views (left) show that MAT1 and XPA bridge the core 
TFIIH ATPases in the kinase-bound structure and in the DNA-bound structure, respectively. Side views (right) 
were aligned on XPD and show how XPB and XPD reorient during DNA binding. Distance between the 
docking site of MAT 1 on XPB (red circle, Q190 residue was used for distance measurement) and XPD (blue 
circle, V365 was used for distance measurement) on both structures is indicated. The distance increases 
significantly after DNA-binding which would induce the kinase module rearrangement on the core TFIIH and 
may facilitate kinase module dissociation in vivo84. The MAT1 helix trajectory that spans between XPB and 
XPD was modeled in the DNA-bound structure (dotted blue line) and suggests a potential clash with XPA. 
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2.2.7 XPG binding to the core TFIIH-XPA-DNA complex  
Since XPG was not visible in our structure, we located it in a core TFIIH-XPA-XPG-DNA 
complex by chemical crosslinking (Fig. 23a). The quality of the obtained crosslinking 
network was validated by mapping the crosslink sites on the core TFIIH-XPA-DNA 
structure, which showed that 85% of crosslink sites fall within the permitted crosslinking 
distance of 30 Å (Fig. 23b). XPA-TFIIH crosslinks match the XPA position on the TFIIH 
core observed in our structure (Fig. 23c), further validating the crosslinking results.  
 
Figure 23 | Crosslinking mass-spectrometry network of the core TFIIH-XPA-XPG-DNA complex. 
(a) Schematic representation of the crosslinking network. Crosslinks between XPA and core TFIIH are shown 
in purple, the disordered XPG C-terminus and core TFIIH in blue, and XPG N-terminal region and core TFIIH 
in brown. Crosslinks between the core TFIIH subunits are in gray. Only crosslinks with a score above 6 are 
shown. The list of inter-subunit crosslinks is provided in the Supplemental Table 2. Domain abbreviations as 
in Fig. 9. (b) Validation of crosslinking sites. Crosslinks with a score above 6 were mapped onto core TFIIH-
XPA-DNA structure. Colored rods connecting crosslinked residues represent permitted (blue) or non-permitted 
(red) crosslinking distances, and lysine residues are shown as blue spheres. 85% of mapped crosslinks fall 
within the permitted crosslinking distance. Created with UCSF Chimera210 and Xlink Analyzer222 (c) XPA 
crosslinks mapped onto core TFIIH-XPA-DNA structure. XPA crosslinks are shown as purple spheres. 
Schematic representation of XPA with mapped crosslinks is shown above the structure. (d) XPG crosslinks 
mapped onto XPD-DNA structure. XPD domains are color coded as in Fig. 19, the MAT1 subunit of the kinase 
module is shown in blue. The position of the MAT1 subunit was modeled based on the previous TFIIH 
structure182. XPG crosslinks are shown as brown spheres. Schematic representation of XPD with mapped 
crosslinks is shown above the structure.  
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The disordered XPG C-terminus crosslinks mostly to XPB and p52 subunits and the 
structured XPG N-terminus specifically crosslinks to the FeS and Arch domains in XPD, 
including the regulatory plug element (Fig. 23a, d). This is in agreement with the observation 
that XPG strongly stimulates XPD helicase activity (Fig. 12c), possibly by increasing the 
mobility of the interface between the Arch and FeS domains, which is required for the 
efficient DNA unwinding by XPD223. In addition, XPG crosslinks overlap with the binding 
site of the kinase module on XPD (Fig. 23d), suggesting that XPG competes with the kinase 
module for XPD binding to relieve the kinase inhibition of XPD (Fig. 20c). It is still 
uncertain if the kinase module dissociates before or concomitant to XPG recruitment to the 
NER machinery84. However, since XPG displaces XPC63, sequesters the docking site for the 
inhibitory kinase module on XPD (Fig. 23d) and strongly stimulates XPD helicase activity 
(Fig. 12c), XPG may aid XPA in initiating the lesion scanning step of the NER reaction 
pathway. Moreover, XPG binds XPD close to the presumed 3’ repair bubble junction located 
near the FeS cluster in XPD, which is in agreement with the observation that XPG makes 
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2.3 Reconstitution and analysis of TCR intermediates 
 
2.3.1 Biochemical characterization of TCR initiation 
 
TCR is initiated by an RNA-polymerase II (RNAP) arrested on a DNA lesion152,153. The 
most important group of DNA lesions removed by TCR are the lesions induced by UV-
irradiation, such as cyclobutane pyrimidine dimers (CPD) and pyrimidine-pyrimidone 6–4 
photoproducts (6-4PP), which accumulate in human skin after sun exposure225-230. Thus, in 
order to reconstitute TCR initiation in vitro we purified the mammalian RNAP from pig 
thymus and also produced a synthetic oligonucleotide that contained the physiological TCR 
substrate CPD (Methods).  
 A CPD contains a cyclobutane ring which forms between the two neighboring 
thymine bases upon UV-irradiation231. Organic synthesis of a chemical CPD analogue 
(called CPD throughout the thesis) was previously described232, however, we modified 
several synthesis steps in order to improve the final yield (Fig. 24, Methods). The lesion was 
synthesized in a form suitable for solid-phase DNA synthesis. Thus, we used a CPD building 
block to synthesize a 14-nucleotide long DNA strand with a centrally positioned CPD lesion 
(Table 12). A longer DNA scaffold was needed for the assembly of the RNAP elongation 
complex, so we expanded the short CPD-containing oligonucleotide on both the 3’ and 5’ 
end by enzymatic ligation with two additional oligonucleotides (Methods). The final DNA 
strand was purified on a sequencing gel to ensure DNA length homogeneity and to remove 
the shorter ligation byproducts. 
We verified that the CPD lesion arrests the RNAP progression51,233,234 in our in vitro 
transcription system (Fig. 25). We assembled a ternary complex between the purified pig 
RNAP, the template DNA strand (TS) which contained a CPD lesion and the RNA primer 
which was 5’ labeled with a Cy5 dye. As a control, we used an identical TS lacking the 
lesion. We finalized the formation of the elongation complex by the addition of the non-
template DNA strand (NTS) and we monitored the extension of the RNA primer by RNAP 
in the presence of increasing concentrations of NTP (Fig. 25). The transcription products 
were resolved on a sequencing gel alongside a marker produced by alkaline hydrolysis of a 
synthetic RNA which was identical in sequence to the expected RNA transcript of our model 
DNA (Fig 25). Many bands corresponding to the abortive transcription products were 
observed, as was expected in the absence of elongation factors which chaperone RNAP or 































Detailed description in Methods. 
 
Additionally, a strong signal from the RNA primer was observed because an excess of the 
nucleic acid scaffold with regard to RNAP had to be used to maximize the efficiency of the 
elongation complex formation (Fig. 25). In control reactions lacking the CPD lesion we 
observed the full-length RNA products made by run-off transcription of the DNA template 
(Fig 25). However, in the presence of a CPD lesion we detected the accumulation of shorter 
RNA products, 53-55 nucleotides in length. The 53 nucleotides long RNA is a product of an 
RNAP arrest in front of the CPD lesion, whereas further addition of one and two nucleotides 
extends the RNA transcript to the first and second thymidine in the CPD lesion (Fig. 25). 
However, no significant transcription was observed past the lesion site indicating that a CPD 
indeed poses a permanent block to the elongating RNAP, which is in agreement with 
previous studies51,233,234 and validates out in vitro TCR system.  
Figure 24 | Organic synthesis of a chemical CPD analogue. 




Figure 25 | Testing the CPD-containing DNA scaffold. 
 
The next step in reconstituting the TCR initiation was to demonstrate that the RNAP 
arrested on a CPD lesion can be recognized by TCR-specific factors, as shown in vivo by 
pull-down experiments139. We have established purification protocols for two major TCR-
specific proteins CsB and CsA, as well as the two additional proteins UVSSA and Usp7 
which were implicated in TCR only recently130-132 (Methods, Fig. 26a). CsA alone is 
insoluble so we purified it in a binary complex with DDB1, its protein partner within the E3 
ubiquitin ligase involved in TCR145. Interestingly, we observed that the TCR-specific factors 
form a stable complex even in the absence of RNAP, as all factors comigrated on a sucrose 
gradient in apparent stoichiometric amounts (Fig. 26b). In addition, in the presence of an 
RNAP that was transcribed into a CPD lesion, the TCR-specific factors shifted into lower 
fractions of the sucrose gradient, indicating that the factors formed a complex with the 
arrested RNAP (Fig. 26b).  
Figure 25 | RNAP is arrested by a CPD 
lesion. Schematic representation of the DNA 
scaffold with or without the site-specific 
CPD lesion is shown above the gel. RNA is 
labeled with a 5’ Cy5 dye (purple star), and 
the CPD lesion is indicated by the yellow 
square. Lengths of the expected RNA 
products are indicated. The gel shows the 
products of the in vitro transcription reaction 
using the lesion-free or the CPD-containing 
DNA in the presence of increasing NTP 
concentrations. The RNA was separated on a 
denaturing sequencing gel alongside a 
sequencing marker. The lesion-free DNA 
was transcribed until the run-off (full length) 
product was made. In the presence of a CPD 
lesion, 3 discrete RNA products of 53, 54 
and 55 nucleotides were observed. The 
zoom-in panel shows the magnified arrest 
bands. The schematic on the right shows 
where on the DNA scaffold RNAP did 
arrest: the 53 nucleotides long RNA 
corresponds to the arrest in front of the CPD 
lesion (indicated with T=T), the 54 
nucleotides long RNA incorporated a 
nucleotide opposite to the first thymidine (T) 
in the CPD lesion and the 55 nucleotides 
long RNA opposite to the second T. With 
increasing NTP concentrations more of the 
RNA transcripts were elongated to 55 
nucleotides.  
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Figure 26 | Complex formation between the RNAP and TCR–specific factors. 
(a) Purified TCR-specific factors (CsB, CsA-DDB1, UVSSA and Usp7) were analyzed by SDS-PAGE and 
visualized by Coomassie staining. (b) Binding of TCR-specific factors to RNAP. (above) TCR-specific factors 
were mixed in equimolar ratio and separated on a 10 – 30% sucrose gradient. The gradient was fractionated in 
200 µl fractions and each fraction was analyzed by SDS-PAGE followed by Coomassie staining. All factors 
comigrate in apparently stoichiometric amounts which indicates that they form a complex. (below) The same 
protein mixture was incubated with purified pig RNAP transcribed into a CPD lesion and analyzed by a 10-
30% sucrose gradient as above. The peak fractions for the TCR-specific proteins were located in lower fractions 
of the gradient in the presence of RNAP (peak fractions are indicated by the green frames) which indicates that 
TCR-specific factors bind RNAP. (c) The crosslinking network between RNAP and the TCR-specific factors. 
The complex was formed as in (b) but purified by size exclusion chromatography and crosslinked with BS3. 
CsA-DDB1 is shown in yellow, CsB in pink, UVSSA in green and the RNAP subunits in gray. Selected 
domains are shown in blue. Crosslinks between RNAP and CsB or UVSSA are shown in pink or green, 
respectively. The list of inter-subunit crosslinks is provided in the Supplemental Table 3. 
 
To determine which of the factors directly interact with RNAP, we chemically 
crosslinked the lesion arrested RNAP with the CsB-CsA-DDB1-UVSSA complex and 
analyzed the protein interaction sites with mass-spectrometry (Fig. 26c). The crosslinking 
network of the TCR initiation complex shows that CsB and UVSSA mediate the interaction 
with RNAP. The two factors are bridged by CsA, consistent with previous 
immunoprecipitation studies237,238. CsB primarily binds the second largest RNAP subunit 
Rpb2, as was observed for the yeast CsB homologue Rad26138. Most of the crosslinks were 
mapped between the RNAP protrusion and the N-terminus of CsB (Fig. 26c). Since the N-
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terminal region of CsB autoinhibits the ATPase activity of the protein239, binding to RNAP 
might relieve this autoinhibition and activate the enzymatic activity of CsB.  
Surprisingly, UVSSA occupies even more of the RNAP surface compared to CsB 
and strongly crosslinks to the lobe and the clamp regions in RNAP (Fig. 26c). To confirm 
that UVSSA directly interacts with RNAP we probed the interaction by analytical size-
exclusion chromatography (Fig. 27a). UVSSA coelutes with RNAP despite being much 
smaller than RNAP, which indicates that UVSSA binds RNAP even in the absence of other 
TCR-specific factors. We have also identified UVSSA as a novel positive transcription 
elongation factor because we observed that UVSSA stimulates the RNA extension by RNAP 
in vitro, as previously reported only for CsB137 (Fig. 27b). In addition, the crosslinking data 
showed that UVSSA binds near the RNAP pore, a known binding site for TFIIS240 (Fig. 
26c), which suggests that these factors might functionally interact. TFIIS is a well-studied 
elongation factor which stimulates intrinsic RNAP endonuclease activity156-159 in order to 
rescue backtracked RNAP complexes and stimulate transcription elongation241. We have 
indeed observed that UVSSA strongly enhances the TFIIS effect on transcription elongation 
in vitro (Fig. 27c), which might be important during TCR for the transcription restart after 
lesion removal from the DNA. 
        
Figure 27 | The effect of CsB and UVSSA on transcription in vitro. 
(a) UVSSA forms a complex with RNAP. The chromatogram shows the size-exclusion elution profile of the 
RNAP-UVSSA mixture. Fractions were analyzed by SDS-PAGE and the proteins were visualized by 
Coomassie staining. UVSSA (~ 70 kDa) coelutes with the much larger RNAP (~ 500 kDa) indicating that 
UVSSA and RNAP form a gel-filtration stable complex. (b) In vitro transcription assay (0.8 pmol RNAP) was 
performed in the presence of increasing concentrations of CsB (left, the highest amount was 30 pmol of CsB, 
followed by a half-log dilution series) or UVSSA (right, the highest amount was 30 pmol of UVSSA, followed 
by a half-log dilution series). Control reactions without the addition of NTPs or corresponding factors are 
indicated. Both CsB and UVSSA stimulate transcription in vitro as seen by the increase in the amount of full-
length RNA products and the decrease in the amount of shorter RNA products. (c) UVSSA stimulates TFIIS 
activity. We determined the TFIIS concentration which moderately stimulates RNAP transcription (100 nM; 
third lane which contains TFIIS but not UVSSA) and we performed the in vitro transcription reaction with 
increasing amounts of UVSSA (as in (b)). The observed transcription stimulation was much stronger than in 
the presence of UVSSA alone, likely due to the stimulatory effect of UVSSA on TFIIS. 
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Since we were able to reconstitute the initiation of TCR in vitro, we tried to solve the 
cryo-EM structure of the lesion arrested RNAP decorated with TCR-specific factors. We 
tried different combinations and truncations of TCR factors, different DNA scaffolds (longer 
upstream or downstream DNA, or both), post-translational modification of RNAP 
(phosphorylation and ubiquitination), different crosslinking strategies, detergents and 
support materials for particles on cryo-EM grids (carbon and graphene oxide), as all those 
factors can influence the complex formation and stability. However, we did not observe any 
additional density on RNAP after the 3D reconstruction of the complex. It could be that the 
complex falls apart during the sample vitrification or it is too flexible and heterogeneous for 
cryo-EM. 
 
2.3.2 The fate of lesion-arrested RNAP 
 
  The lesion-arrested elongation complexes are highly cytotoxic because they lead to 
cell-cycle arrest and can ultimately trigger programmed cell death120,242-245. In addition, the 
large RNAP footprint on the DNA prevents the repair enzymes to access the lesion123,234. It 
is thus necessary to quickly identify and remove the arrested elongation complexes. Several 
fates for the arrested RNAP can be envisioned (Fig. 3). First, RNAP can efficiently transcribe 
over some smaller lesions which may lead to mutagenesis if a wrong nucleotide is paired 
with the modified DNA base246. Second, RNAP can be degraded by the proteasome. Several 
components of the TCR machinery undergo ubiquitination, which includes RNAP mono- 
and poly-ubiquitination by Nedd4 and the elongin complex148,160. Third, RNAP can be 
pushed forward to transcribe across the transcription-blocking lesion which destabilizes the 
elongation complex and induces RNAP dissociation from the DNA80. Fourth, RNAP can be 
pushed backwards on the DNA far enough to expose the lesion to repair80. This would also 
allow the restart of transcription after the lesion has been removed. 
 We confirmed that RNAP alone cannot transcribe past a CPD lesion51,233,234 (Fig. 
25). However, both CsB and UVSSA stimulate the RNAP elongation in vitro, so we tested 
if these factors could chaperone transcription across the lesion. We assembled the elongation 
complex on a CPD-containing DNA scaffold and added CsB or the CsB-CsA-DDB1-
UVSSA complex to the reaction before starting the RNA extension (Fig. 28a). Even in the 
presence of TCR-specific factors we did not detect any significant transcription past the site 
of the CPD lesion. However, we observed a stronger signal for the 54 and 55 nucleotides 
long RNA products with increasing CsB concentrations, suggesting that RNAP was able to 
translocate onto the CPD lesion more efficiently in the presence of CsB (Fig. 28a), as shown 
before137. This effect was even stronger in the presence of UVSSA, likely due to the 
synergistic effect of CsB and UVSSA on transcription elongation.  
 Next, we tested if the TCR-specific factors can dislodge the RNAP arrested on a CPD 
lesion (Fig. 28b). We designed an assay which allows us to separate the DNA-bound RNAP 
from the dissociated RNAP. We formed the elongation complex with the CPD containing 
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TS and the biotinylated NTS. The biotin-tag on the NTS was used to immobilize the RNAP 
on the streptavidin-coated beads. An in vitro transcription reaction was performed to position 
the RNAP in front on the CPD lesion. The lesion-arrested RNAP was coupled to a solid 
support and the unbound RNAP was washed away. We added a large excess of TCR-specific 
factors to the reaction, followed by incubation at 37 °C for 3 h. The reaction was 
supplemented with ATP to support the CsB translocase activity which may be necessary to 
drive the RNAP dissociation from the DNA. After the removal of the supernatant, the DNA 
bound proteins were specifically eluted with DNase I. We visualized the protein composition 
in the supernatant and the eluate by SDS-PAGE and Coomassie staining (Fig. 28b).  The 
supernatant contained the excess of TCR-specific factors.  
 
           
Figure 28 | TCR-specific factors do not stimulate transcription past the CPD lesion nor the dissociation 
of the lesion-arrested RNAP from the DNA template. 
 (a) In vitro transcription (2.8 pmol RNAP) of a CPD-containing DNA scaffold in the presence of increasing 
concentrations of CsB (5, 10 and 20 pmol) or the CsB-CsA-DDB1-UVSSA complex (5, 10 and 20 pmol). The 
RNA products were resolved on a denaturing sequencing gel and visualized by fluorescence scanning of the 
labeled RNA. RNAP arrested on a CPD lesion as observed by the appearance of 53-55 nucleotides long RNA 
products. No significant transcription past the CPD lesion was observed in the presence of the TCR factors. 
(b) Schematic representation of the pull-down assay used to determine if TCR-specific factors can dissociate 
the CPD-arrested RNAP from the DNA. RNAP was transcribed into a CPD lesion, coupled to streptavidin 
beads and incubated with ATP and 6x excess of TCR-specific factors. After a wash, DNA-bound proteins were 
specifically eluted with DNase I. Supernatant (S) and elution (E) fractions were analyzed by SDS-PAGE and 
Coomassie staining. RNAP subunits were only detected in the DNA-bound fractions, suggesting that TCR-
specific factors cannot dissociate CPD arrested RNAP from the DNA. 
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However, the RNAP was only present in DNase elution fractions indicating that TCR-
specific factors cannot dislodge the lesion-arrested RNAP from the DNA (Fig. 28b). 
Moreover, the TCR factors coeluted with the RNAP in apparently stoichiometric amounts 
suggesting that the factors did bind the RNAP in the assay. 
Thus far we excluded RNAP removal from the lesion site by transcription read-
through or dissociation from the DNA (Fig. 28). Next, we investigated if RNAP could be 
actively pushed backwards during TCR. Active RNAP backtracking would require an ATP-
driven motor protein to push or pull the RNAP in the direction opposite to the direction of 
transcription154. Three ATPases from the SF2-superfamiliy of helicases suitable for such 
task are involved in TCR: CsB, XPB and XPD133. CsB can be excluded because CsB 
stimulates forward RNAP movement in vitro (Fig. 27b)137. Thus, we tested the effect of 
TFIIH, which contains both XPB and XPD, on transcription. We used a DNA scaffold that 
is transcribed with a medium efficiency in order to easily detect the RNAP stimulation or 
inhibition by accessory factors. After screening the several naturally occurring arrest 
sequences247, we decided to use the pML5-4NR sequence as we observed a ladder of 6 
discrete bands after transcribing the sequence in our in vitro transcription system (Fig. 29a). 
In the presence of TFIIH or TFIIH core we observed a very subtle stimulation of 
transcription (Fig. 29a). However, our previous biochemical characterization of the core 
TFIIH ATPases showed that XPA and XPG NER factors are required for the optimal activity 
of XPB and XPD (Fig. 12). We showed that XPA and XPG alone do not affect the RNA 
extension (Fig. 29 b, c). In the presence of XPG, TFIIH again showed a modest stimulation 
of RNAP activity, suggesting that a strong stimulation of the XPD helicase activity by XPG 
(Fig. 12) does not change the effect of TFIIH on transcription (Fig. 29b). In contrast, in the 
presence of XPA which stimulates both XPD56 and XPB (Fig. 12) we observed a much 
stronger transcription stimulation by TFIIH and almost all RNA products were extended to 
the length of the run-off transcript (Fig. 29c). It may be that the increased translocase activity 
of XPB on the DNA duplex in the presence of XPA drives RNAP forward when TFIIH binds 
the upstream DNA and translocates into the RNAP, which might reactivate stalled or 
backtracked elongation complexes. Surprisingly, in the presence of both XPA and XPG, 
TFIIH caused transcription inhibition, as observed by the accumulation of short RNA 
products (Fig. 29d). The in vitro transcription was specifically inhibited at the first pause site 









Figure 29 | Core TFIIH inhibits transcription in the presence of XPG and XPA. 
(a-d) Naturally occurring pML5-4NR arrest DNA sequence247 was used for the in vitro transcription reactions. 
Transcription of this sequence produces a ladder of 6 distinct bands we could monitor in the presence of 
additional factors. RNA products were resolved by denaturing PAGE and visualized by fluorescence scanning. 
Gels are representative of 2 experimental replicates. (a) Transcription reaction (0.8 pmol RNAP) was 
performed in the presence of increasing amounts of TFIIH or core TFIIH (2, 5 and 10 pmol). (b) The effect of 
XPG on transcription in the absence or presence of TFIIH (as (a) + 6, 15 and 30 pmol of XPG). (c) The effect 
of XPA on transcription in the absence or presence of TFIIH (as (a) + 6, 15 and 30 pmol of XPA). (d) The 
effect of XPA and XPG on transcription in the absence or presence of TFIIH (as (a) + 6, 15 and 30 pmol of 
XPA and XPG). Bar graph shows the quantification of a band corresponding to the first paused RNA product 
(below) and the quantification of bands corresponding to the elongation past the first pause site (above) for 
different concentrations of additional factors. The error bars show s.d. of the mean values for 2 experimental 
replicates. 
 
From the previous assay it is unclear what the underlying mechanism of transcription 
inhibition by the TFIIH-XPA-XPG complex is. The complex could arrest RNAP 
progression, dissociate the RNAP from the DNA or push the RNAP backwards (Fig. 30a). 
We designed a biochemical assay to differentiate between those three scenarios (Fig. 30a,b). 
We performed the in vitro transcription assay using biotinylated DNA scaffold containing 
the arrest sequence in the presence of core TFIIH, XPA and XPG. The RNAP inhibition was 
efficiently reproduced because we observed a large amount of short RNA products and 
almost no run-off transcripts (Fig. 30c, lane 1). We purified the inhibited elongation 
complexes by coupling the DNA to streptavidin beads and extensively washing the beads to 
remove NTPs and NER factors. We briefly incubated the inhibited elongation complexes 
with TFIIS. TFIIS induces the intrinsic RNAP endonuclease activity156-159 and can be used 
to reveal the nature of the RNAP inhibition (Fig. 30a). If the inhibited complexes are arrested 
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or dislodged from the DNA, RNA cannot be cleaved by RNAP because the active site of the 
RNAP accommodates the RNA 3’ end or no RNA, respectively. However, if the inhibited 
elongation complexes are backtracked, RNAP will cleave the RNA and produce shorter 
RNA products (Fig. 30a). Indeed, after incubation with TFIIS, we observed RNA shortening 
(Fig. 30c, lane 2) suggesting that RNAP was in a backtracked state. The backtracking was 
substantial because the cleaved RNA was 3 nucleotides shorter than the RNA primer used 
for the elongation complex assembly. Also, as the initial RNA primer produced a 10 base 
pair DNA-RNA hybrid, the backtracking proceeded until the minimal length of a stable 
DNA-RNA hybrid of 7 base pairs 248,249 was reached which could limit the extent of 
backtracking in the experimental system.  
    
Figure 30 | Core TFIIH induces RNAP backtracking in the presence of XPG and XPA. 
(a) Possible mechanisms of RNAP inhibition by the core TFIIH-XPA-XPG complex. RNAP could be arrested, 
dissociated from the DNA or backtracked (pushed backwards). During backtracking the RNA 3’end is threaded 
through a pore in RNAP but the RNA-DNA hybrid is still held by the RNAP active site155. Thus, only the 
backtracked RNAP is sensitive to the addition of TFIIS which induces the RNAP endonuclease activity156-159 
and shortens the bound RNA. (b) Schematic of the experimental setup. (c) RNAP was preincubated with an 
excess of core TFIIH, XPA and XPG, followed by the addition of NTPs. After the immobilization of elongation 
complexes on streptavidin beads and extensive washing, we observed a strong accumulation of a short RNA 
product corresponding to the first pause site, indicating efficient transcription inhibition (lane 1). The addition 
of TFIIS induced the cleavage of RNA, suggesting that the RNAP was in the backtracked state (lane 2). When 
the reaction was again supplemented with NTPs, the cleaved RNA was extended (lane 3). (d) In vitro 
transcription reaction performed in the presence of the increasing amounts of core TFIIH, XPA and XPG (as 
in Fig. 29d), and constant amounts of TFIIS (0.5 pmol). The expected transcription inhibition by the core 
TFIIH-XPA-XPG complex was not observed in the presence of TFIIS probably because TFIIS reactivated the 
backtracked elongation complexes which resumed transcription in the presence of NTPs.  
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To determine if the backtracked RNAPs are still transcription-competent, we supplemented 
the TFIIS treated complexes with NTPs. We observed the elongation of cleaved RNA upon 
the addition of NTPs (Fig. 30c, lane 3) suggesting that the backtracked RNAP can be 
reactivated by TFIIS to continue transcription. To further demonstrate that active RNAP 
backtracking mediates transcription inhibition, we performed the transcription assay in the 
presence of backtracking factors (core TFIIH, XPA and XPG) and TFIIS. In the presence of 
TFIIS alone we observed the accumulation of the full-length RNA and the disappearance of 
bands corresponding to aborted transcription, consistent with the role of TFIIS in 
transcription elongation241 (Fig. 30d). Moreover, after the addition of increasing amounts of 
backtracking factors, the transcription was no longer inhibited (Fig. 30d). Thus, in the 
presence of TFIIS and NTPs the backtracked complexes are rescued and can continue 
transcription until the run-off RNA products are made. 
 We showed that core TFIIH actively backtracks stalled elongation complexes in the 
presence of XPA and XPG (Fig. 30c), however, it is unclear which of the two core TFIIH 
ATPases pushes RNAP backwards. To differentiate between the activity of the XPD helicase 
and the XPB translocase we performed the in vitro transcription assay with the core TFIIH 
containing the ATPase deficient XPD point mutant73 or in the presence of the XPB inhibitor 
triptolide200,201 (Fig. 31). The loss of XPD helicase activity did not affect the transcription 
inhibition but the XPB inactivation abolished the ability of TFIIH to backtrack RNAP. To 
test if the XPD presence is required for the TFIIH backtracking function, we tested the core 
TFIIH hexamer which lacks the XPD subunit in the transcription assay (Fig. 31). 
Transcription inhibition was not affected by the absence of XPD further confirming that 
XPB is the TFIIH subunit responsible for RNAP backtracking.  
 
Figure 31 | XPB translocase pushes RNAP backwards. 
In vitro transcription reaction was performed in the presence of increasing concentrations of core TFIIH, XPA 
and XPG as in Fig. 29d (black triangle) which inhibited transcription as observed by the RNAP arrest at the 
first pause site. The same reaction was performed with the core TFIIH containing XPD:K48R inactive mutant73 
(yellow triangle) but no difference to the wild type core was observed. However, in the presence of the drug 
triptolide which inhibits XPB200,201, we did not observe the transcription inhibition (green triangle). When the 
reaction was performed with the hexameric TFIIH assembly which lacks the XPD subunit, the transcription 
inhibition was again observed (purple triangle), suggesting that XPB is necessary and sufficient for the RNAP 
backtracking. Bar graph shows the quantification of the RNA corresponding to the first pause site and the bars 
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   2.3.3 Active RNAP backtracking exposes DNA lesions to repair 
 
We have shown that the core TFIIH can push the stalled RNAP backwards in the presence 
of XPA and XPG (Fig. 30c). However, it is unknown if the backtracking is efficient enough 
to expose DNA lesions to repair. RNAP arrested by a CPD sequesters ~18 nucleotides of the 
DNA downstream of the lesion51,233. In addition, XPG cleaves the DNA 5 nucleotides 3’ of 
the lesion during NER107,111. Thus, RNAP has to be pushed backwards for more than 23 
nucleotides to fully expose the lesion to repair enzymes.  
We designed a biochemical assay which allowed us to determine the RNAP position 
on the DNA after backtracking at single-nucleotide precision (Fig 32a). We assembled the 
elongation complex using a CPD-containing DNA scaffold and a fluorescently labeled RNA. 
Upon the addition of NTPs, the RNAP transcribed into the CPD lesion, as we observed the 
appearance of the 53 nucleotides long RNA products (Fig 32b).  
       
Figure 32 | Active RNAP backtracking by XPB exposes CPD lesions to repair. 
(a) Schematic representation of the experimental design used for measuring the extent of RNAP backtracking 
at a single nucleotide resolution. (b) In vitro transcription reaction (2.8 pmol RNAP) on a CPD containing 
DNA scaffold produced 53 nucleotides long RNA products, as in Fig.25. After the incubation with increasing 
amounts of the core TFIIH, XPA and XPG (2.2, 4.4 and 8.8 pmol) and RNA cleavage induction by TFIIS (0.5 
pmol) we observed the 24 nucleotides long cleavage products, suggesting that RNAP was backtracked for 29 
nucleotides. (c) Backtracking was also observed when core TFIIH containing XPD inactive mutant73 was used, 
but not in the presence of triptolide which inhibits XPB200,201. Thus, XPB is responsible for pushing the RNAP 
backwards.  
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In the next step, we added the backtracking machinery composed of the core TFIIH, XPA 
and XPG to the lesion-arrested RNAP and incubated the reaction with ATP to enable 
backtracking. Finally, after the RNAP endonuclease activity was triggered by TFIIS, we 
observed the appearance of 24 nucleotides long RNA cleavage products. Since the RNA 
cleavage is mediated by RNAP, we can conclude that the RNAP active site was pushed 
backwards for 29 nucleotides with increasing amount of the backtracking machinery (Fig. 
32b). Thus, the backtracking is sufficient for the complete removal of RNAP from the lesion 
site. The backtracking was also observed when the XPD inactive mutant was used, but the 
effect was abolished when XPB translocase was inhibited by triptolide (Fig 32c).  
     
Figure 33 | Crosslinking mass-spectrometry network of the RNAP-core TFIIH–XPA–XPG complex and 
the effect of DNA lesions on XPB translocase activity. 
(a) Core TFIIH subunits are color-coded as in Fig. 14, XPG is in brown, XPA in purple and RNAP subunits in 
gray, except Rpb5 is in green and Rpb9 in orange. XPA and XPG crosslinks to the core TFIIH are shown with 
purple and brown lines, respectively. Crosslinks between XPA and RNAP are shown with thick purple lines 
and between XPB and RNAP with thick pink lines. The list of inter-subunit crosslinks is provided in the 
Supplemental Table 4. Domain abbreviations as in Fig. 9. (b) Selected crosslink sites for XPA (purple spheres) 
and XPB (pink spheres) were mapped onto the RNAP structure (PDB code: 5FLM)123 and cluster around the 
downstream DNA (dashed black circle). RNAP subunits are shown in gray, except Rpb5 is in green and Rpb9 
in orange, DNA is in blue. (c) XPB translocase assay performed as in Fig. 11c. (left) Schematic representation 
of scaffolds used to check if a lesion mimic (internal biotin) placed in the 5’-3’ or the 3’-5’ DNA strand can 
inhibit the XPB translocase activity. Position of the internal biotin is indicated with red squares. (middle) 
Representative fluorescence traces of the core TFIIH translocation on corresponding scaffolds (the color of the 
trace matches the color of the frame around the corresponding scaffold). XPB cannot translocate efficiently 
when biotin is installed in the 5’-3’ DNA strand and the biotin located in the 3’-5’ DNA strand has no effect 
on XPB translocation. (right) Bar graph shows the percentage of triplex disrupted after 4000 s for 2 independent 
replicates. Error bars represent s.d. from the mean values.    
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To gain insight into the architecture of the RNAP backtracking complex we obtained 
a protein interaction network within the purified RNAP-core TFIIH-XPA-XPG complex by 
chemical crosslinking and mass-spectrometry (Fig. 33a). The complex was assembled by a 
large-scale in vitro transcription and backtracking reaction on a CPD containing DNA 
scaffold, followed by the removal of excess NER factors and NTPs via size-exclusion 
chromatography (Methods). Many crosslinks were detected within the core TFIIH–XPA–
XPG complex and between the RNAP subunits, however, crosslinks between the repair 
proteins and RNAP were rather scarce. It may be that the interface between RNAP and the 
backtracking machinery is quite small and largely mediated by DNA. Also, the complex 
with RNAP might be unstable and accompanied by a high rate of TFIIH dissociation, which 
could lead to more inefficient crosslinking. XPA crosslinks to the core TFIIH ATPases, 
TTDA and the N-terminus of p52 subunit, which is consistent with the structure we 
presented here (Fig. 14). XPG crosslinks to XPB and XPD, which is similar to other 
crosslinking data we acquired (Fig. 23).  Interestingly, the XPB and XPA crosslink sites map 
to Rpb1, Rpb2, Rpb5 and Rpb9 RNAP subunits, mostly around the downstream DNA (Fig. 
33b). This suggests that XPB binds the downstream DNA during TCR and pushes the lesion-
arrested RNAP backwards by translocating on the DNA duplex towards RNAP.   
Since we observed that the backtracking of lesion arrested RNAP proceeds for 
exactly 29 nucleotides (Fig. 32b), it is tempting to speculate that XPB pushes RNAP 
backwards until it encounters the lesion. This would suggest that a lesion in the 5’-3’ DNA 
strand inhibits the XPB translocase activity while XPB migrates on the downstream DNA 
towards RNAP. To test this, we performed a double-strand DNA translocase assay using 
DNA templates which contain an internal biotin as a DNA lesion mimic placed in the 5’-3’ 
or the 3’-5’ DNA strand (Fig. 33c). Indeed, we observed a strong inhibition of XPB 
translocase activity when the lesion mimic was located in the 5’-3’ DNA strand but not when 
it was located in the 3’-5’ DNA strand, as also shown for the yeast XPB homologue Ssl269. 
Thus, during TCR, the XPB translocase activity might be employed for the removal of 
RNAP from the lesion site and for the subsequent verification of the lesion in the template 
strand. After the lesion verification, XPB may dissociate from the DNA and provide the 
space for lesion processing by the canonical NER pathway. 
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3. DISCUSSION AND OUTLOOK  
 
3.1 First structure of an NER intermediate 
 
A mechanistic framework for the NER pathway was established through decades of fruitful 
biochemical, functional and genetic research, which identified the major protein players and 
defined the main steps of the NER reaction pathway (Fig. 2)20,106. However, despite the large 
amount of existing data, we do not know how NER works on a molecular level. It is 
unknown, for instance, how TFIIH opens the DNA repair bubble or how XPA facilitates the 
kinase module dissociation from the TFIIH core. Even more fundamental features of NER, 
such as how TFIIH binds DNA or where XPA is located in the NER assembly, are a matter 
of debate in the current literature20,83,106. The lack of structural insight became an obvious 
bottleneck in NER research which could not be surpassed due to difficulties in the 
preparation of NER complexes for structural analysis. To overcome this barrier, we have 
established and optimized the production of recombinant human NER factors and performed 
a systematic biochemical analysis of the central NER component TFIIH. This allowed us to 
trap and, for the first time, solve the structure of an NER intermediate.  
We focused on a lesion scanning step of the NER pathway which is mediated by the 
migration of the TFIIH core on DNA while searching for a lesion. Our biochemical 
characterization identified two additional NER factors XPA and XPG to be important for 
this process by stimulating the XPB translocase and the XPD helicase activity (Fig. 12). We 
solved the cryo-EM structure of the core TFIIH-XPA complex bound to the edge of a repair 
bubble at 3.6Å (Fig. 14), which represents the minimal lesion scanning NER intermediate, 
and mapped the position of XPG by crosslinking mass-spectrometry (Fig. 23). The newly 
gained structural and functional knowledge greatly extends our understanding of the NER 
pathway (Fig. 34), as discussed in the following sections. We improved the existing structure 
of the TFIIH core (section 3.2) and explained human disease mutations (section 3.3). The 
structure elucidates the long-debated architecture of XPB, XPD and XPA on DNA and 
explains how XPA anchors the NER machinery to DNA, how the kinase module inhibits 
TFIIH helicase activity and how XPA facilitates kinase module dissociation and commits 
TFIIH to repair (sections 3.4 and 3.6). Our results redefine the previously assigned roles for 
XPA and open new questions for the role of XPB (section 3.5). Finally, our protocols for the 
purification of NER components and the preparation of NER complexes for cryo-EM can 
now be applied, with only minor adjustments, for the characterization of other NER 
intermediates which will hopefully lead to a complete molecular mechanism of the NER 
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3.2 Extended model of the human TFIIH core and comparison to other 
TFIIH structures 
 
A breakthrough in TFIIH structural biology occurred a year ago, when cryo-EM structures 
of human TFIIH182 and yeast TFIIH bound to the pre-initiation complex (PIC)70 were 
reported. However, due to resolution limitations (4.4Å for the human and ~6Å for the yeast 
TFIIH), most parts of the structures were created by homology modelling and some parts of 
TFIIH could not be built at all. We solved the core TFIIH structure at higher resolution (3.6 
Å) which allowed us to correct sequence registers for the previous human TFIIH model182 
and to additionally build most of the p52 subunit, the DRD (damage recognition domain) 
and the NTE (N-terminal extension) of XPB and the p34-p44 interface comprised of two 
zinc fingers and a ring domain (Fig. 35a).  
These expansions reveal how XPB is recruited to the TFIIH core. The main XPB-
core TFIIH interaction surface is formed between the NTE of XPB and the clutch domain in 
p52 (Fig. 35b). Due to high resolution of our structure in this region, we were able to build 
both domains de novo. Interestingly, the two domains are strikingly similar in structure and 
consist of four α-helices and a β-sheet which is formed by four antiparallel β-strands (Fig. 
35b). The two domains are oriented sheet-to-sheet and form an extensive hydrophobic 
interface. The interface is functionally important because it was shown that structure-
destabilizing mutations in the NTE of XPB weaken the XPB-p52 interaction and impair 
TFIIH repair activity68. In addition, p52 stimulates XPB to hydrolyze ATP and this activity 
is dependent on the presence of the clutch domain68. Since we did not observe any p52 
density extending towards the active site of XPB, the interaction with p52 likely stabilizes a 
more active XPB conformation. 
 
 
Figure 35 | Extension of the previous model for the human TFIIH core. 
(a) Parts of the TFIIH core present in the previous TFIIH model182 are shown in gray and structural elements 
additionally built or modeled in our study are colored as indicated. (b) XPB is anchored to the TFIIH core via 
interactions with p52 and TTDA subunits. XPB NTE is shown in pink, DRD in light pink, ATPase lobe 1 in 
purple, ATPase lobe 2 in medium purple, p52 clutch in dark cyan and TTDA in light brown. XPB is outlined 
by the black dashed line. Bulky hydrophobic side chains at the XPB-p52 interface are shown as sticks.  
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The second XPB attachment point to the TFIIH core is the interaction between the ATPase 
lobe 2 in XPB and the smallest TFIIH subunit TTDA (Fig. 35b). TTDA is essential for DNA 
repair and mutations in this TFIIH subunit lead to severe disorders in humans 250-252. Since 
TTDA has no enzymatic activity, mutations in this subunit most likely destabilize the core 
TFIIH-XPB interface which may result in a decreased enzymatic activity of XPB, as shown 
in vitro68,252. 
 Interestingly, the conformation of the TFIIH core observed in the context of DNA 
repair differs significantly from conformations of free TFIIH182 or TFIIH engaged in 
transcription initiation70 (Fig. 36). The core TFIIH seems to be very flexible and can adapt 
to different requirements for the complex in transcription and DNA repair64. Different TFIIH 
conformations are trapped by external factors which mostly bind the core ATPases XPD and 
XPB70,182 (Fig. 36). During transcription initiation, the XPB and p62 subunits interact with 
TFIIE directly, while XPD interacts with the RNAP stalk and TFIIE via the kinase module70. 
These interactions force the TFIIH core to widen70,, which breaks the contact between XPB 
and XPD and destabilizes the long MAT1 helix observed in free TFIIH182 (Fig. 36). Aside 
from this core widening, conformations of the free and the PIC-bound TFIIH are very 
similar. In contrast, for DNA repair TFIIH has to dramatically rearrange (Fig. 17) and change 
its composition84. Both XPB and XPD have to reorient to simultaneously bind the edge of a 
repair bubble (Fig. 14) and this process is facilitated by XPA which wraps around the DNA 





Figure 36 | Different conformations of the TFIIH core in transcription and DNA repair. 
(left) The human TFIIH structure during transcription initiation was modeled by aligning human subunits with 
the corresponding subunits of the yeast TFIIH bound to PIC (PDB:5OQJ)70. (middle) Human TFIIH was 
modeled by fitting individual domain from our structure into the EM density of the kinase-bound TFIIH 
(EMDB:3802)182. TFIIH subunits and accessory factors are color-coded as indicated. 
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Due to this rearrangement, the kinase module dissociates from the TFIIH core84, which in 
turn de-represses XPD helicase activity and initiates lesion scanning 56,73. The reorientation 
of XPB and XPD is enabled by substantial inter- and intra-subunit rearrangements in p34, 
p44 and p52 (Fig. 17). It may be that the modular architecture of the TFIIH complex emerged 
to support, restrict and guide the rearrangement of enzymatically active subunits for the 
essential, yet very different roles of TFIIH in transcription and DNA repair64. 
 
3.3 Structural etiology of Xeroderma pigmentosum and 
Trichothiodystrophy 
 
Mutations in the XPD helicase mainly cause two human diseases with markedly different 
symptoms: Xeroderma pigmentosum (XP) and Trichothiodystrophy (TTD)40,214, and in rare 
cases XP is additionally coupled with the Cockayne syndrome (CS)77. XP patients are 
extremely sensitive to the UV-irradiation and readily develop skin cancer, while TTD 
patients suffer from mental and growth retardation, accelerated aging and decreased 
fertility214. This can be explained by the dual role for XPD in DNA repair and 
transcription214. During DNA repair, XPD helicase activity is required for the repair bubble 
opening and lesion scanning 65,73,224,253-255, while in transcription XPD has a structural role 
and couples TFIIH to the PIC70,198. Milder XP symptoms are likely caused by a defect in 
DNA repair and the more severe TTD symptoms by a defect in transcription214. Since we 
solved the core TFIIH structure at significantly higher resolution compared to previous 
models (Fig. 15)70,182 and XPD helicase in our structure is bound to DNA (Figs. 16, 19), we 
can precisely map XP and TTD disease mutations and discuss the structural basis for disease 
development.  
          Interestingly, the XP mutations214,256,257 cluster around DNA in the ATPase lobe 2 of 
XPD (Fig. 37a). Several of the affected residues (R683, R511 and S541) directly interact 
with the DNA phosphate backbone (Fig. 37b). It is worth noting that mutations in R683, 
which binds the third to the last nucleotide exiting XPD (Fig. 37b), account for 64% of all 
XP mutations in XPD and for 55% of mutations in TFIIH overall256.  An additional two 
mutations, D681N and Y542C, are found directly adjacent to DNA contacting residues: 
D681 forms a salt bridge with R683 and Y542 is located next to S541. Y542 stabilizes the 
loop containing S541 by interacting with V599, which is not possible when the bulky Y543 
residue is replaced with a smaller cysteine in XP (Fig. 37b). Overall, the direct disruption of 
XPD-DNA contacts by these mutations, as seen in our structure, would impair the XPD 
helicase activity and NER, as also shown in vitro for D234N, S541R and R683W 
mutations256. Interestingly, another residue mutated in XP, R601, is located next to DNA but 
the side chain of the residue points away from the DNA backbone (Fig. 37b). However, 
R601 is placed next to the helicase motif Va133 and the long side chain of R601 forms a salt 
bridge with D655 and a cationic pair with H659, both of which are located in a helix carrying 
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the helicase motif VI133. Thus, substitution of R601 with a leucine or a much bulkier 
tryptophan in XP would disrupt these interactions and misalign helicase motifs, leading to 
XPD helicase impairment and XP phenotype. G602 is a direct neighbor of R601 and the 
substitution to a less flexible aspartate found in XP patients would probably have similar 




Figure 37 | DNA-bound TFIIH core at 3.6Å reveals structural etiology of Xeroderma pigmentosum (XP) 
and Trichothiodystrophy (TTD). 
(a) XP and TTD mutations214,256,257mapped onto XPD-DNA structure are shown as pink and blue spheres, 
respectively. XP mutations cluster around DNA in the ATPase lobe 2 of XPD and TTD mutations cluster at 
the XPD-p44 interface. A XP-TTD overlap patient carries 2 mutations258, shown as brown spheres. (b) Zoom-
in on XP mutations in the direct vicinity of DNA. Residues mutated in XP are highlighted in pink and their 
interaction partners in white. Helicase motifs VI and Va are shown in yellow and green, respectively. (c) XPD-
p44 interface. A single helix in XPD is affected by four different TTD mutations. Mutated residues are 
highlighted in blue. G713 and A725 are depicted as blue spheres. The helix carrying TTD mutations interacts 
with p44 via two salt bridges, R722 (XPD) - D75 (p44), and K718 (XPD) - D73 (p44). (d) R112 residue 
frequently mutated in TTD interacts with the DNA backbone and residues surrounding the iron sulfur cluster. 
(e) R658 residue mutated in TTD engages in the interaction network between the ATPase lobes. 
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In addition to affecting the structural role of R601, the G602D mutation also introduces a 
negative charge into the DNA-binding groove of XPD, which may be particularly disruptive 
for the XPD structure and function, and could explain why this mutation also leads to severe 
CS symptoms214. 
In contrast to XP, all but one TTD mutations214 map to regions of our structure further 
away from the DNA trajectory (Fig. 37a). Most of the mutations are located at the XPD-p44 
interface. This interface is the main attachment point of XPD to the rest of the TFIIH 
core259,260, but it is surprisingly small and could be particularly vulnerable to destabilizing 
mutations. Since XPD plays an important structural role during transcription initiation70, a 
disruption of the XPD-p44 interface and the dissociation of XPD may cause a transcription 
defect and a TTD disease phenotype256. Interestingly, a single XPD helix (residues 711-725) 
is affected by four different TTD mutations (G713R, R722W, A725P and R487G) (Fig. 37c). 
This helix is an important contact point between XPD and p44 because R722 and K718 in 
the helix form salt bridges with D75 and D73 located in a p44 loop (residues 68-76). The 
R722W mutation directly disrupts one of the two salt bridges. The G713R mutation likely 
destabilizes the helix because G713 is located in a hydrophobic pocket where a long arginine 
side chain cannot be accommodated nor neutralized (Fig. 37c). The R487G mutation can 
also be explained based on our structure. Even though R487 is distant from the helix in the 
primary structure, it engages in cation–π interaction with F728 located two residues away 
from the helix (Fig. 37c). This R487-F738 interaction might keep the helix stacked against 
XPD and disruption of this interaction would likely displace the helix and weaken the XPD-
p44 interface. An A725P substitution might have a disruptive effect on the helix because 
prolines have poor helix-forming propensities, and this substitution may also affect the 
neighboring R487-F738 interaction (Fig. 37c). Several other destabilizing substitutions to 
proline residues (R616P, A594P and A592P) are located at the XPD-p44 interface (Fig. 37a).  
The R658H and R658C TTD mutations do not map to the XPD-p44 interface but to 
the site between the ATPase lobes of XPD (Fig. 37e). R658 participates in the extensive 
interaction network of polar residues between the lobes, which includes salt bridges with 
D240 located in the opposite lobe and D655 located in the same lobe. Thus, a mutation in 
R658 might destabilize the structure of XPD by disrupting the contacts between the lobes 
which may perturb the scaffolding role of XPD in transcription initiation and lead to TTD.  
R112H is the only TTD mutation in the vicinity of DNA. It was shown that TFIIH carrying 
the R112H mutation is helicase dead and completely inactive in NER256,261, and patient-
derived cell lines are extremely UV-sensitive, which is a typical feature of XP. The helicase 
impairment of XPD by a R112H mutation is supported by our structure which shows that 
R112 directly binds the DNA phosphate backbone (Fig 37d). However, the same mutation 
causes a mild defect in basal transcription in vitro and mild TTD symptoms in patients256,261. 
Since R112 is located in front of the iron-sulfur cluster, the long side chain of the residue 
may shield the cluster from the reactive species in the solvent. In addition, R112 interacts 
with F193 and Y192 and contributes to the structural stability of the FeS domain (Fig. 37d). 
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It was indeed shown in yeast that this mutation results in the loss of the iron-sulfur cluster262, 
which may destabilize the entire protein76. Structural destabilization of XPD would explain 
the effect of this mutation on transcription and the TTD phenotype in patients.  
An interesting case of a patient with a hybrid XP/TTD phenotype was reported 
relatively recently258. Aside from the typical TTD clinical features such as brittle hair, the 
patient also developed skin cancer, which is specific to XP258. The sequence analysis of the 
XPD gene revealed two different mutations: A725P and Y18H (Fig. 37a). We already 
described how the A725P mutation leads to destabilization of the XPD-p44 interface and a 
TTD phenotype. However, the side chain of the Y18 residue is located only ~ 4Å away from 
the Q-motif/Q21 which was predicted to bind ATP133. The Y18H mutation might thus affect 
the ATP hydrolysis and the XPD helicase activity, which could explain the XP phenotype.  
In summary, we could map most of the XP and TTD mutations onto our XPD-DNA 
structure and we described the molecular interactions surrounding the affected residues. We 
provided the structural basis for how XP and TTD mutations impair the XPD structure and 
function, and TFIIH integrity, thus leading to human disease development. 
 
3.4 Role of XPA in NER and activation of TFIIH for repair 
 
XPA is an essential NER factor comprised of an N-terminal zinc finger and a C-terminal 
DNA-binding domain83. The DNA-binding activity of XPA has been extensively studied 
over the past decades83. It was initially shown that XPA binds damaged DNA duplexes with 
a higher affinity than non-damaged DNA93,263-267, which led to the conclusion that XPA may 
be involved in the initial lesion recognition. A crystal structure of the yeast XPA homologue 
Rad14 bound to a damaged DNA duplex100 further suggested that XPA binds DNA lesions 
as a dimer and recognizes the lesion-induced DNA bending rather than the lesion itself. 
However, the role for XPA in the initial DNA recognition was challenged by later 
observations: (i) XPC binds the damaged DNA with a much higher affinity compared to 
XPA26,46,62,268 which makes XPC a likelier candidate for the initial lesion sensing , and (ii) 
XPA joins the NER assembly only after TFIIH is recruited and the DNA opening takes 
place61,63,87. Moreover, it was shown that XPA strongly binds duplex-single strand 
junctions82 and kinked DNA structures81. This large amount of somewhat conflicting data is 
difficult to reconcile because no structural information on XPA in the context of NER is 
available up to date. Thus, it is unknown how XPA interacts with the DNA repair bubble 
and how this interaction is influenced by other NER factors, such as TFIIH. 
 Our cryo-EM structure of TFIIH-XPA bound to a bifurcated DNA which mimics one 
half of a repair bubble (Fig. 14), helps to explain the above mentioned observations. The 
structure shows that XPA interacts with several TFIIH subunits and wraps around the 
duplex-single strand junction formed between the XPB translocase which binds the DNA 
duplex and the XPD helicase which binds the single-stranded DNA overhang (Fig. 14). 
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Thus, DNA-bound TFIIH is the actual XPA substrate during NER. This explains the high 
binding affinity of XPA for duplex-single strand junctions82, as well as why the stable XPA 
integration into the NER complex occurs only after TFIIH initiates the repair bubble 
opening63. Assuming that a DNA lesion is located in the portion of DNA scanned by the 
XPD helicase, as suggested by previous biochemical work56,73, our structure also reveals that 
XPA demarcates the 5’ edge of the repair bubble. Furthermore, it was shown that XPA 
recruits the XPF-ERCC1 endonuclease to the growing NER assembly63,96. This is in good 
agreement with the position of XPA at the 5’ edge of the bubble because XPF-ERCC1 is 
known to cleave DNA 5’ of the lesion, only 3-8 nucleotides away from the edge of the repair 
bubble109,110.  
Interestingly, the DNA binding mode of XPA during NER closely resembles the 
binding mode observed in the crystal structure of the Rad14 dimer (yeast XPA homologue) 
bound to the damaged DNA duplex100 (Fig. 38). In our structure XPA inserts the 
intercalating /-hairpin at the duplex-single strand junction and uses W175 at the tip of the 
hairpin to stack against a base in the single-stranded overhang (Fig. 18a, b). Rad14 similarly 
uses F262 (which corresponds to W175 in XPA) located in the /-hairpin to stack against the 
last base pair of the DNA duplex. However, even though a fully complementary DNA duplex 
was used for crystallization, Rad14 unpairs the terminal bases with the hairpin which creates 





Figure 38 | Comparison between Rad14 bound to the damaged DNA duplex and XPA bound to the 
duplex-single strand junction. 
(left) The crystal structure of Rad14 (yeast XPA homologue) bound to the DNA duplex damaged with cisplatin 
(PDB-5A39)100. Rad14 is shown in pink, the 5’-3’ DNA strand in orange and the 3’-5’ DNA strand in yellow. 
The DNA damage (cisplatin) and the unpaired terminal nucleotide are indicated by dashed circles.  Rad14 does 
not interact with the DNA damage but rather binds the edge of the DNA duplex and unpairs the terminal bases. 
(right) The XPA structure presented here is superimposed onto the Rad14 structure. XPA is shown in purple, 
the 5’-3’ DNA strand in dark blue and the 3’-5’ DNA strand in light blue. The DNA binding mode, including 
the position of the unpaired terminal nucleotide and the intercalating hairpin, between the two structures is 
strikingly similar. This suggests that the Rad14 structure bound to the damaged DNA reflects the tendency of 
the protein to bind duplex-single strand junctions, which may be the primary role for XPA during the DNA 
repair, rather than lesion recognition. 
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Thus, the crystal structure likely reflects XPA binding to the edge of a repair bubble rather 
than the lesion recognition by XPA. Also, in our structure a single copy of XPA makes 
specific contacts to several TFIIH subunits: the XPA hairpin interacts with XPD, the 
extended helix bridges XPB ATPase lobes and the flexible C-terminus extends towards 
TTDA and p52 dimerization domain (Fig. 14, 15d). Thus, it is very unlikely that XPA could 
be integrated into the NER complex as a dimer.    
Aside from providing a topological information on XPA binding to the repair bubble, 
our structure also implies how XPA activates TFIIH for repair. A decade ago it was shown 
by pull-downs and Western blotting that XPA facilitates dissociation of the kinase module 
from the TFIIH core during the course of NER84. However, no mechanistic explanation 
could be provided for this observation. Our structure has revealed that XPA, together with 
the bound DNA, stabilizes an entirely novel TFIIH conformation which markedly differs 
from the conformation of the kinase-bound TFIIH (Fig. 17). Moreover, the XPA-induced 
re-orientation of XPB and XPD would break the contacts between the TFIIH core and the 
kinase module, thus resulting in kinase module dissociation84 (Fig. 22). This marks a major 
checkpoint in NER because the kinase module dissociation de-represses XPD helicase 
activity73 and initiates the lesion scanning step of the NER reaction pathway, thereby 
committing TFIIH to repair.  
XPA binds kinked DNA structures, such as 3-way and 4-way junctions with a very 
high affinity81. Since injured nucleotides distort the DNA backbone, it was suggested that 
XPA senses DNA kinks during lesion scanning and verifies the presence of a lesion20. 
Residues involved in such a verification process were mapped to the DNA-binding domain 
of XPA81. However, our structure shows that XPA binds the 5’ edge of the repair bubble, 
while the lesion recognition by XPD helicase presumably occurs at the 3’ edge 73,253-255. It is 
therefore very unlikely that XPA can reach the modified DNA backbone during lesion 
verification. In addition, it was never experimentally shown that XPA binds damaged DNA 
single-strands with a higher affinity compared to unmodified DNA, which also argues 
against the lesion verification role for XPA in NER. 
 In summary, based on our functional and structural data, and the existing literature, 
we can propose a model for how XPA functions in NER. XPA joins the NER assembly after 
TFIIH is recruited to the lesion site by XPC61,63,87. XPA anchors TFIIH to the DNA by 
trapping the DNA duplex between the ATPase lobes of XPB (Fig. 18). XPA strongly 
stimulates the XPB translocase activity (Fig. 12) required for repair bubble opening65,252. 
The bubble opening creates the optimal DNA binding substrate for XPA which inserts the 
/-hairpin at the 5’ edge of the bubble (Fig. 18). By chaperoning TFIIH-DNA interactions 
and bridging the re-oriented core TFIIH ATPases (Fig. 14), XPA stabilizes a novel TFIIH 
conformation which is no longer compatible with kinase module binding (Fig. 22). The 
kinase module dissociation removes a plug element from the DNA-entry pore in XPD (Fig. 
21) which enables XPD to bind the DNA single-strand and start unwinding the DNA while 
searching for a lesion (Fig. 20). XPA facilitates lesion scanning by stimulating the XPD 
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helicase activity56 (Fig. 12), most likely by preventing TFIIH dissociation from the DNA. 
Upon lesion recognition by the XPD helicase65,73,224,253-255, XPA is ideally located at the 5’ 
edge of a repair bubble to recruit XPF-ERCC1 endonuclease63,96 and to complete the 
assembly of the dual-incision complex.  
 
3.5 Role of XPB in NER and the problem of repair bubble opening  
 
The TFIIH core contains two ATPases, XPB and XPD64, that belong to the SF2-type family 
of DNA helicases133. XPD has been extensively studied and its robust 5’-3’ helicase activity 
was demonstrated many times71-73,78, including here (Figs. 11, 12). In contrast, the enzymatic 
activity of XPB is still a matter of debate. A 3’-5’ helicase activity was shown for archaeal 
XPB in isolation67 and the same, although much weaker activity was demonstrated for the 
human XPB within the TFIIH complex73. Recently it was shown that the yeast XPB 
homologue Ssl2 acts as a DNA translocase140. We observed that the XPB ATPase activity 
is stimulated by double-stranded DNA rather than DNA single-strands. Therefore, XPB 
most likely acts as a translocase (Fig. 11). We confirmed the XPB translocase activity in our 
FRET-based translocase assay, but we could not detect any significant 3’-5’ helicase activity 
even at high core TFIIH concentrations (Fig. 11). Moreover, we showed that the XPB 
translocase activity is modulated by XPA, an additional NER factor, which strongly 
stimulates XPB translocation in vitro (Fig. 12). Our TFIIH-XPA-DNA structure provides 
the molecular basis for such stimulation: XPA interacts with both ATPase lobes of XPB and 
wraps around the DNA, thereby trapping DNA between XPA and XPB (Fig. 18). This may 
prevent XPB dissociation from the DNA and increase XPB processivity. In addition, XPA 
physically links the XPB ATPase lobes with TTDA and p52 which may stabilize the XPB-
core TFIIH interface (Figs. 14, 15d, 23c, 35b) and stimulate the XPB enzymatic activity68.  
 The role for XPB in NER is not fully understood. It is unlikely that XPB translocase 
activity plays a major role in lesion scanning, as it was shown that the XPD helicase activity 
drives this step of NER71-73,78. Also, as we monitored the XPB translocase and the XPD 
helicase activity in real time and in the same conditions, we observed that XPD is the 
dominant motor which migrates on DNA much faster and with higher efficiency compared 
to XPB (Fig. 12).  Thus, migration of the NER complex on DNA during lesion scanning 
would be dictated by XPD unwinding in 5’-3’ direction, as previously suggested56. However, 
XPB might be important for the processivity of lesion scanning because XPB and XPA form 
a positively charged DNA duplex tunnel (Fig. 18c) which could retain the NER machinery 
on DNA.  
 XPB might play an important role during the initial repair bubble opening. It was 
shown that the ATPase activity of XPB is essential for this process since ATPase deficient 
XPB mutants do not support the repair bubble opening in vitro65,252. Moreover, it was 
demonstrated that only the ATPase and not the helicase activity of XPB is required for 
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NER68. This led to the current model for the repair bubble opening in which XPB acts as an 
“unusual DNA helicase” which undergoes large scale conformational changes during ATP 
hydrolysis to wrap around DNA and induce DNA melting67,68. This model can be challenged 
by several observations made in our study. First, the conclusion that the helicase activity of 
XPB is not required for the bubble opening, therefore XPB works as an “unusual helicase”, 
is most likely invalid because XPB in general does not unwind the DNA (Figs. 11, 12). It 
may be that the helicase activity of XPB detected in some of the previous studies was a result 
of a small amount of contaminating proteins which co-purified with TFIIH. Second, XPB 
does translocate on DNA duplexes and this activity was not assayed in the context of the 
repair bubble opening. Third, we observed that XPA strongly stimulates XPB translocase 
activity in vitro. It was shown that XPA facilitates and stabilizes bubble opening252, further 
suggesting that XPB translocase activity might govern the process. Finally, the DNA 
wrapping function of XPB is based on a structure-function analysis of the archaeal XPB 
homologue67. Based on the biochemical observations it was suggested that XPB first binds 
destabilized DNA and subsequently closes its ATPase lobes via a large conformational 
change which could further melt the DNA67. However, comparison between free and DNA-
bound XPB in the context of TFIIH (Fig. 17c) shows that XPB undergoes a very minimal 
conformational change while binding DNA, which involves a subtle closure of the ATPase 
lobes around the DNA and a rotation of the DRD and NTE domains. It could be that p52 
and TTDA stabilize the closed XPB conformation (Fig. 35b) and prevent the large 
conformational change observed in the crystal structure of isolated XPB 67.  
 Based on the data presented here, we can speculate that XPB uses its double-stranded 
DNA translocase activity (Fig. 11c) to open DNA in analogy to the transcription bubble 
opening during transcription initiation69,70,211 (Fig. 39). XPC tightly binds 11 base pairs of 
the DNA duplex 3’ of the lesion site26 and recruits TFIIH 5’ of the lesion56 (Fig. 39). TFIIH 
is therefore correctly positioned for XPD to engage the damaged DNA strand after DNA 
opening and to unwind the DNA towards the lesion56. Moreover, our structure shows that 
XPD and XPB share the tracking strand (Fig. 16c) which suggests that XPB also tracks on 
the damaged DNA strand. Upon TFIIH recruitment to the lesion site by XPC, XPB may bind 
the DNA duplex 5’ of the lesion (Fig. 39). Since XPC rotationally fixes the DNA duplex 3’ 
of the lesion26 and physically interacts with TFIIH151,194 (Fig. 9), XPB would need to 
translocate in the 3’-5’ direction on the damaged DNA strand to pump the DNA between 
XPC and XPB, which would lead to underwinding of DNA and DNA opening (Fig. 39). 
This is very similar to the proposed model for DNA opening by TFIIH in transcription70, 
only the position of XPC is replaced by the PIC. It might be that the DNA opening function 
was first employed by TFIIH to facilitate DNA repair, but was later adopted by the 
transcription machinery as an additional gene expression regulatory mechanism, since not 
all promotors depend on TFIIH for activation269. However, the main uncertainty of the 
proposed model is the polarity of XPB translocation, which is very difficult to assay and is 
still a matter of debate69,70.  Structural comparison to the Chd1 translocase and the NS3 
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helicase indeed suggests a 3’-5’ polarity of XPB70. In contrast, biochemical analysis of yeast 
Ssl2 suggests a 5’-3’ polarity because XPB translocation is inhibited when an obstacle is 
inserted in the 5’-3’ DNA strand69. However, we solved the XPB-DNA structure at high 
enough resolution to visualize protein DNA contacts and we observed that XPB tightly 
interacts with both DNA strands of the duplex (Fig. 16d). Thus, it is uncertain which contact 
would be affected by the obstacle in DNA and if the results of the polarity assay were 
accurately interpreted. The problem of the repair bubble opening could be answered by 
solving XPB-DNA structures in different stages of the translocation cycle. This would 
provide a molecular movie of XPB migration on DNA and reveal the XPB polarity. Repair 
bubble opening could be further investigated in vitro by using single molecule fluorescence 
assays and magnetic tweezers to monitor the dynamics of NER proteins and the dynamics 







Figure 39 | A possible role for XPB in DNA opening. 
(left) Possible architecture of the core-TFIIH-XPC-Rad23b complex after the TFIIH recruitment to the lesion 
site (similar model for this complex was proposed in a recent review199). The crystal structure of the yeast 
XPC-Rad23 homologue (Rad4-Rad23, PDB-2QSG)26 and the core TFIIH structure solved in this study were 
modeled on the same DNA, which was possible because both structures were determined in the presence of 
DNA. TFIIH subunits are color coded as in Fig. 14, XPC (Rad4) is shown in violet red and Rad23 in olive 
green. The CPD lesion that was present in the DNA scaffold bound to XPC26 is indicated by the purple star. 
TFIIH interacts with XPC via the PH domain in the p62 subunit151,194 (Fig. 9), which is indicated in brown. 
The position of the PH domain was modeled based on the TFIIH-PIC structure70. XPC binds the DNA 3’ of 
the lesion site26 and recruits TFIIH 5’ of the lesion site. In this model, XPB translocates on the damaged DNA 
strand in 3’-5’ direction (away from XPC). However, since TFIIH interacts with XPC, and XPC is anchored 
to DNA, XPB does not move forward but rather pushes the DNA duplex towards XPC. As a result, a DNA 
underwinding occurs between XPB and XPC which is resolved by DNA melting and the repair bubble 
formation. Interestingly, in this model there is enough space between XPB and XPC to accommodate XPA. 
XPA strongly stimulates the XPB translocase activity and might facilitate the repair bubble opening (Fig. 12d). 
(right) Upon DNA melting, XPD is ideally positioned to engage the damaged DNA strand and to start 
unwinding the DNA duplex in the 5’-3’ direction towards the lesion. Since XPD is the dominant TFIIH motor 
(Fig. 12), the NER complex will migrate in the 5’-3’ direction independently of the XPB translocase activity. 
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3.6 Positive and negative regulation of XPD helicase activity 
 
XPD is the only TFIIH subunit which undergoes both negative and positive regulation56,73. 
During the transcription initiation, XPD helicase activity is suppressed by the kinase 
module56,73. We have shown that this effect is mediated by the kinase module binding since 
kinase deficient variants of the module suppress the XPD helicase activity equally well as 
the kinase active variant (Fig. 20). Comparison between XPD structures in the repressed182 
and the activated state (Fig. 21) reveals how kinase module binding suppresses XPD helicase 
activity. The kinase module subunit MAT1 binds the XPD Arch domain182 and stabilizes a 
structural element we named the plug in the DNA-entry pore of XPD. The plug would 
prevent XPD to load onto DNA because it clashes with the DNA trajectory through the 
helicase (Fig. 21). In addition, a loop in the p62 subunit enters the active site of repressed 
XPD, as seen in the TFIIH-PIC structure70, where it might mimic DNA and additionally 
prevent XPD from binding to DNA. However, since the helicase activity of the core TFIIH 
is still quite robust (Fig. 11), the contribution of p62 is likely minor.  
 In contrast to transcription initiation, the XPD enzymatic activity is essential for 
repair181. We systematically investigated the effect of known NER factors on XPD helicase 
activity and we identified two factors with a stimulatory effect, XPA and XPG. The role for 
XPA in XPD stimulation was previously observed 56,73. However, XPG is a newly identified 
XPD regulator. In the presence of XPG, DNA unwinding by XPD is much faster and more 
efficient, even compared to the unwinding facilitated by XPA (Fig. 12). It is likely that the 
mechanism of stimulation by XPA and XPG is quite different. XPA has a very small 
interaction surface with XPD (Fig. 14) and might facilitate the DNA unwinding by 
stabilizing TFIIH-DNA interactions and anchoring the complex to DNA (Fig. 18). However, 
as seen in our crosslinking network (Fig. 23), XPG strongly interacts with the ATPase lobe 
1 of XPD and might directly affect the XPD helicase cycle, in analogy to other 
helicases271,272. This XPG function in NER has gone undetected probably because it affects 
the kinetics of the NER reaction which is difficult to assay in vitro unless the step is isolated, 
as done in our study. Thus, by displacing the XPC lesion sensor from the DNA63,194 and 
strongly stimulating XPD helicase activity (Fig. 12), XPG may facilitate efficient transition 
from the repair bubble opening to lesion scanning.  
 
3.7 Novel insights into the mechanism of TCR and a first case of active 
RNA-polymerase backtracking in eukaryotes 
 
TCR is an NER sub-pathway which relies on actively transcribing RNAP for the initial 
lesion detection120,152,153. Despite decades of TCR research surprisingly little is known about 
the underlying mechanisms80. Several protein factors were identified which are essential for 
TCR but are not required for GGR120,152,153. Thus, it was generally accepted that these TCR-
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specific factors orchestrate the initial steps of TCR until the canonical NER machinery takes 
over to perform the DNA excision. However, there is currently very little experimental data 
showing how or if TCR-specific factors participate in the repair reaction80. The main 
bottleneck in TCR research is the difficulty to isolate numerous protein factors involved, 
which includes TCR-specific factors, RNAP and canonical NER factors, as well as the lack 
of mechanistic understanding of the process to guide experimental designs. In this study we 
successfully purified all components involved in the core TCR reaction and we established 
an experimental system that allows us to monitor the fate of the lesion-arrested RNAP.  
Arrested elongation complexes sequester the lesion site233 and need to be removed 
for the repair to take place. This seems to be the central, but still unresolved mechanistic 
problem in TCR. In bacteria, a dedicated protein Mfd recognizes arrested elongation 
complexes and dislodges RNAP from the site of damage by pushing the RNAP 
forward273,274. Since CsB is also a translocase and pushes the RNAP forward137 (Fig. 27), it 
might act in TCR in a similar way. It was shown that CsB cannot dislodge nucleotide starved 
elongation complexes50, but it is unknown if the same conclusion can be applied to the 
lesion-arrested RNAP. In addition, we discovered that an additional TCR-specific factor 
UVSSA directly binds RNAP and stimulates transcription in vitro (Fig. 27). However, we 
found that neither CsB nor a CsB-UVSSA complex can dissociate the lesion-arrested RNAP 
from DNA, even after hours of incubation and a constant supply of ATP (Fig 28, 40). In 
addition, no transcriptional bypass of the lesion was observed, so CsB and UVSSA also 
cannot rescue arrested complexes by facilitating transcription past the lesion (Fig. 28, 40). It 
seems that the TCR mechanism is not conserved from bacteria to humans, because the Mfd-
mediated dissociation of arrested elongation complexes is the dominant TCR pathway in 
bacteria275. 
  Another possible scenario is that the lesion-arrested RNAP backtracks far enough to 
expose the lesion to repair enzymes80,120,153. A big benefit of such a strategy is that 
transcription can resume after the lesion has been removed. This would be particularly 
important in mammals because they have longer genes which require more time and energy 
to be transcribed276. Even though a mechanism of RNAP removal via backtracking was 
proposed in all recent reviews on TCR80,120,153, up to now there is no experimental data to 
support this model, probably due to the complexity of this multicomponent biochemical 
system. Furthermore, an active RNAP backtracking, i.e. pushing or pulling the RNAP 
backwards by an ATP-consuming motor protein, has to my knowledge never been 
demonstrated in eukaryotes. Here we show that TFIIH can push the lesion-arrested RNAP 
backwards (Figs. 30, 40). Surprisingly, this activity is mediated by the XPB translocase and 
further requires the presence of two additional NER factors, XPA and XPG (Figs. 29, 31). 
The requirement for XPA is easy to rationalize because XPA strongly stimulates the XPB 
translocase activity (Fig. 12), which governs RNAP removal (Fig. 31). However, the role 
for XPG is still not clear. XPG strongly stimulates the XPD helicase activity (Fig. 12), 
however, neither XPD helicase activity nor XPD presence was required for efficient RNAP 
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backtracking (Fig. 31). We observed that in the absence of XPG, the TFIIH-XPA complex 
pushes RNAP forward, instead of backwards (Fig. 29c). This could be explained by a 
random XPB loading onto the DNA scaffold in our experimental setup. If XPB is loaded on 
the downstream DNA it would collide with the RNAP from the front and induce RNAP 
backtracking. However, if XPB is loaded on the upstream DNA, XPB would collide with 
RNAP from the back, which would push RNAP forward and rescue backtracked elongation 
complexes, resulting in an overall transcription stimulation. Since XPG presence specifically 
induces RNAP backtracking, we could speculate that XPG recruits TFIIH-XPA on the 
downstream DNA, potentially by interacting with RNAP. Thus, XPG may couple the 
backtracking machinery to RNAP. This would be in agreement with previous reports 
showing that XPG participates in transcription277 and directly interacts with the elongation 
complex278. In addition, after the backtracking XPG would be ideally positioned to cleave 
DNA 3’ of then lesion, as observed during the canonical NER reaction107,224.  
We also demonstrated that the core TFIIH-XPA-XPG complex pushes the lesion-
arrested RNAP backwards for 29 nucleotides (Figs. 32, 40), which is sufficient for a full 
clearance of the lesion site. It is still unclear why we observed such a discrete backtracking 
distance. It would be tempting to speculate that XPB stops pushing RNAP after reaching the 
lesion site. This would suggest a lesion verification role for XPB during TCR. Interestingly, 
during transcription initiation XPB is located ~30 nucleotides downstream of the RNAP 
active site70,198. If XPB is similarly positioned during DNA repair, the backtracking distance 
would suggest that XPB stops upon lesion encounter. Also, we showed that artificial DNA 
modifications can indeed arrest XPB translocation (Fig. 33c), which is in agreement with 
previous biochemical studies69. In summary, we have identified a novel step of the TCR 
reaction pathway which includes the active backtracking of lesion-arrested RNAP by a 
machinery comprised of core TFIIH, XPA and XPG. The process depends on the translocase 
activity of XPB and completely exposes DNA lesions to repair. Our results provide 
important mechanistic insights into the fate of the lesion arrested RNAP in eukaryotes.  
 Interestingly, the TCR mechanism differs significantly between bacteria and 
humans. In bacteria arrested elongation complexes are efficiently removed by Mfd protein 
which actively dislodges RNAP from DNA273,274. Even though it was demonstrated that the 
UvrD helicase can also facilitate repair by pulling the RNAP backwards165, the Mfd-
dependent TCR was shown to be the prevalent TCR strategy275. In contrast, a protein with 
an RNAP dislodging function has not been discovered in humans. In our study we have 
demonstrated that the canonical NER factors can recognize arrested elongations complexes 
and actively push the RNAP backwards to clear the lesion site for the repair enzymes (Fig. 
40). The backtracking strategy might have been disfavored in bacteria due to transcription-
translation coupling279. The pioneering ribosome might even be physically linked to the 
RNAP280 which would make backtracking very challenging. In contrast, the human TCR 
machinery might have evolved to preserve RNA transcripts, as genes are much longer in 
humans compared to bacteria. For example, the human dystrophin gene is 2.8 mega-bases 
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long and it takes almost 16 h to transcribe281, thus it would be very energetically expensive 
to abort the transcription every time a lesion is encountered. Repurposing already existing 
NER factors for the RNAP backtracking, as observed in our biochemical analysis, would 
offer further advantages: (i) the repair machinery is already present when the lesion is 
uncovered and there is no need for additional recruitment steps, (ii) specific positioning of 
the TCR machinery on the downstream DNA might establish which DNA strand carries the 
lesion and (iii) XPB translocase activity could be employed for lesion verification.  
                             
 
Figure 40 | New insights into the mechanism of human TCR. 
TCR-specific factors CsB and UVSSA stimulate transcription elongation137 (Fig. 27). A UV-induced CPD 
lesion (indicated by the blue square) arrests RNAP migration on the DNA51,233,234 (Fig. 25). TCR-specific 
factors cannot facilitate transcription past the lesion nor dissociate the arrested RNAP from the DNA (Fig. 28a, 
b), however, the factors favor the addition of nucleotides opposite to the lesion (Fig. 28a) which may change 
the RNAP conformation and favor the recruitment of downstream repair factors. The backtracking machinery 
comprised of the TFIIH core, XPA and XPG binds the arrested RNAP and pushes it backwards (Figs. 29, 30). 
The backward translocation of RNAP is mediated by the XPB translocase activity (Fig. 31) which is strongly 
stimulated by XPA (Fig. 12). XPG most likely couples the core TFIIH-XPA complex to RNAP. The RNAP is 
pushed backwards for 29 nucleotides (Fig. 32) which is sufficient to fully expose the lesion site to repair 
enzymes. The active RNAP backtracking might stop when XPB translocase encounters the lesion (Fig. 33c), 
which might verify the presence of the lesion and initiate the canonical NER pathway.  
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Finally, it is important to note that we characterized RNAP backtracking in vitro and, even 
though important basic principles of the reaction were uncovered, it is still unclear to which 
extent this process occurs in vivo. Moreover, backtracked RNAP could still be a target for 
proteasomal degradation and might not resume with transcription after the repair is 
completed. Exciting future research, driven by advancement in structural282 and systems 
biology approaches283, will further elucidate the mechanism of TCR. 
 
 
3.8 Towards a complete molecular mechanism of human NER 
  
NER is one of the most important DNA repair pathways because it has a very broad substrate 
specificity and it can eliminate many different types of DNA lesions19,106. Unfortunately, 
DNA-modifying chemotherapeutics, such as the frequently used cisplatin284,285, are also very 
good NER substrates286. Moreover, cancer cells can intensify NER as a mean to resist 
chemotherapy287. Understanding the molecular mechanism of NER and gaining a structural 
insight into reaction intermediates will be instrumental for the design of potent NER 
inhibitors which can boost the efficiency of existing anti-cancer medications288. NER can 
also serve as a paradigm for the investigation of diseases caused by a dysregulation in the 
response to DNA damage because defects in NER cause a striking variety of clinical 
features20. The work described here provides a basis for the complete structural 
characterization of the core NER reaction. In addition, we described several structure-based 
mechanisms underlying NER and we biochemically characterized completely novel step of 
the NER reaction pathway. However, future research will address several pending open 
questions, as follows.  
  Extensive functional and biochemical analysis of GGR elucidated the order of 
assembly of NER factors and outlined the general sequence of events on the path to lesion 
excision20,106. However, a structure-based molecular mechanism of the NER reaction is 
lacking. Since we optimized the purification of all NER components and provided a general 
protocol for structure determination of TFIIH-bound repair factors (Methods), future 
structural work will mainly involve minor modifications, such as redesigning the DNA 
scaffold to capture different NER intermediates. Three structures in particular would be 
important to solve in order to complete the mechanism of GGR. First, a structure of XPC-
Rad23 bound to TFIIH. This structure would provide insight into the repair bubble opening 
and explain how TFIIH is properly oriented to initiate scanning on the damaged DNA 
strand199. Second, a structure of the lesion-arrested XPD helicase would provide the 
mechanism of lesion verification during NER23,73-75. It may be useful to test different types 
of lesions, such as bulky DNA modifications, intra-strand crosslinks and photo-lesions, since 
different lesion-recognition strategies might be employed. Third, a structure of the pre-
incision complex would uncover how the size of the excised DNA fragment is defined and 
how the structure-specific endonucleases XPG and XPF-ERCC1 are properly positioned to 
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cleave the damaged DNA strand at the positions observed in dual-incision assays 65,224. This 
structure might also shed light on the role of RPA, as it was suggested that the specific 
polarity of RPA binding to the non-damaged DNA strand orients endonucleases on the repair 
bubble105.  In addition, reparatory DNA synthesis has not been extensively researched, even 
though DNA replication and DNA ligation are in general well understood289. However, it 
would be interesting to investigate how 3’ and 5’ incision events are coordinated during the 
gap-filling and how NER factors are displaced from the site of damage.  
 In contrast to GGR, we are only beginning to understand the mechanism of TCR and 
many basic features of this repair pathway still need to be unraveled80. CsB has been at the 
focus of TCR research134 but its role still remains elusive. Here we showed that CsB does 
not directly participate in the TCR reaction since CsB cannot push RNAP over a photolesion 
CPD137 or dislodge lesion-arrested elongation complexes from the DNA, even in the 
presence of other TCR-specific factors (Fig. 28). However, a recent structure of the yeast 
CsB homologue Rad26 bound to the elongation complex revealed that CsB binds the 
upstream DNA138, which is usually occupied by the core transcription elongation factor 
DSIF290. The structure thus raises an interesting possibility that the function of CsB is to 
strip away elongation factors from the RNAP surface80, which would facilitate RNAP 
processing during repair. This could be easily tested in a reconstituted system, as the one 
described here, by a competition experiment between CsB and DSIF for binding the arrested 
RNAP. We also showed that core TFIIH, in complex with XPA and XPG, pushes the 
arrested RNAP backwards (Figs. 30, 32). Since all components are available in large 
amounts and high purity, it would be interesting to solve the cryo-EM structure of the RNAP 
backtracking complex. This would provide insights into how XPB translocase pushes RNAP 
backwards and how XPG can couple the backtracking-inducing machinery to the elongation 
complex. On a larger scale, it might be beneficial to make an attempt at reconstituting the 
entire TCR reaction in vitro and to investigate if RNAP can continue transcribing after the 
lesion is removed by repair enzymes. This would require isolation of the gap-filling 
machinery and the construction of a biochemical system that would allow simultaneous 
monitoring of transcription and DNA excision. Due to advancement of the genomic systems 
biology toolkit283, it would also be beneficial to develop strategies for monitoring TCR in a 
cellular context. Although a challenging task, such a system would give us a better overview 
on the dynamics of arrested elongation complexes in vivo, when other factors, such as 
chromatin, post-translational modifications and proteasomal degradation come into play.  
Overall, the first structure of an NER intermediate described here and protocols for 
the reconstitution of further steps along the NER pathway mark a milestone in structural 
biology of this important DNA repair pathway. It seems likely that several other structural 
snapshots of the NER machinery in action will be obtained over the next several years which 
will hopefully complete our understanding of NER.   
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4. MATERIALS AND METHODS  
4.1 Chemicals and consumables 
 
Table 2 | List of chemicals and consumables. 
Chemical/Consumable Manufacturer 
Acetic acid  Merck kGaA, Darmstadt, Germany  
Acrylamide/Bis Solution 19:1 ThermoFischer Scientific, Massachusetts, US  
Agarose, UltraPure ThermoFischer Scientific, Massachusetts, US  
Ammonium chloride Merck kGaA, Darmstadt, Germany 
Ammonium peroxodisulfate (APS) Merck kGaA, Darmstadt, Germany 
Ampicillin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Amylose Resin New England BioLabs GmbH, Frankfurt on Main, Germany 
ATP  Jena Biosciences GmbH, Jena, Germany 
Bromphenol Blue sodium salt Merck kGaA, Darmstadt, Germany 
Calf Intestinal Alkaline Phosphatase New England BioLabs GmbH, Frankfurt on Main, Germany 
Chloramphenicol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Deoxyribonucleotide (dNTP) mix New England BioLabs GmbH, Frankfurt on Main, Germany 
Dimethylformamide (DMF) Merck kGaA, Darmstadt, Germany 
Disodium hydrogen phosphate 
dihydrate 
Merck kGaA, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO= Merck kGaA, Darmstadt, Germany 
DNase I ThermoFischer Scientific, Massachusetts, US 
DpnI New England BioLabs GmbH, Frankfurt on Main, Germany 
DTT  Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Dynabeads MyOne Streptavidin T1 ThermoFischer Scientific, Massachusetts, US 
Econo-Pac Chromatography columns Bio-Rad Laboratories GmbH, Germany 
EcoRV-HF New England BioLabs GmbH, Frankfurt on Main, Germany 
Ethanol Merck kGaA, Darmstadt, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Merck kGaA, Darmstadt, Germany 
Gentamicin sulfate salt Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Glycerol Merck kGaA, Darmstadt, Germany 
HEPES Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
HiTrap Q column  GE Healthcare, Germany 
Hydrochloric acid  Merck kGaA, Darmstadt, Germany 
Imidazole Merck kGaA, Darmstadt, Germany 
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IPTG Carl Roth GmbH, Karlsruhe, Germany  
Kanamycin sulfate  ThermoFischer Scientific, Massachusetts, US 
L-lactic Dehydrogenase Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Magnesium chloride hexahydrate Merck kGaA, Darmstadt, Germany 
NADH Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
NTP solution ThermoFischer Scientific, Massachusetts, US 
Phosphoenolpyruvate (PEP) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Phusion High Fidelity DNA Pol. New England BioLabs GmbH, Frankfurt on Main, Germany 
PmeI New England BioLabs GmbH, Frankfurt on Main, Germany 
Potassium chloride Merck kGaA, Darmstadt, Germany 
Potassium hydroxide Merck kGaA, Darmstadt, Germany 
Proteinase K New England BioLabs GmbH, Frankfurt on Main, Germany 
Pyruvate kinase from rabbit muscle Roche Diagnostics Deutschland GmbH, Manheim, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
T4 DNA ligase New England BioLabs GmbH, Frankfurt on Main, Germany 
Slide-A-Lyzer Dialysis Cassettes ThermoFischer Scientific, Massachusetts, US 
Sodium acetate Merck kGaA, Darmstadt, Germany 
Sodium bicarbonate Merck kGaA, Darmstadt, Germany 
Sodium chloride Merck kGaA, Darmstadt, Germany 
Sodium hydroxide Merck kGaA, Darmstadt, Germany 
SspI New England BioLabs GmbH, Frankfurt on Main, Germany 
Sucrose Merck kGaA, Darmstadt, Germany 
SwaI New England BioLabs GmbH, Frankfurt on Main, Germany 
TBE Buffer, 10x ThermoFischer Scientific, Massachusetts, US 
TEMED Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
UltraPure DNase/RNase -Free 
Distilled Water 
ThermoFischer Scientific, Massachusetts, US 
Urea Merck kGaA, Darmstadt, Germany 
X-Gal Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Xylene cyanol FF Merck kGaA, Darmstadt, Germany 
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4.2 Buffers and growth media  
 
Table 3 | List of buffers. 
Buffer Composition Application 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 pH 7.4, 1.76 mM KH2PO4 pH 7.4 
Western blotting 
TBE 89 mM Tris, 89 mM boric acid, 2 mM EDTA 
denaturing urea 
PAGE 




50 mM potassium acetate, 30 mM Tris-acetate, 10 
mM magnesium acetate, 100µg/ml BSA, pH 7.9 
LIC cloning 
NEB 3.1 
100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 
100µg/ml BSA, pH 7.9 
LIC cloning 
T4 ligase (NEB) 
50 mM Tris-HCL, 10 mM MgCl2, 10 mM DTT, 1 





50 mM potassium acetate, 30 mM Tris-acetate, 10 





141 mM Tris, 106 mM Tric-HCl, 2% LDS, 10 % 
glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue 
G, 0.127 mM Phenol Red, ph 8.5 
SDS-PAGE 
 
Table 4 | List of growth media for E. coli and insect cells. 
Media Composition Supplier Application 
LB 1% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 0.5% (w/v) NaCl 
in house 
made 
E. coli cultures 
2X YT 
1.6 % (w/v) Bacto tryptone, 1 % 




E. coli protein 
expression 
Gibco® Sf-900TM III 
SFM 
low-hydrolysate, serum-free, 






supplemented with L-glutamine 
and Kolliphor® P188 
Expression 
Systems 
Sf21 and Hi5 cultures 
 
 




Table 5 | List of antibiotics and supplements for E. coli cultures. 
Antibiotics/Supplements Stock concentration Final concentration 
Kanamycin 50 mg/ml 50 µg/ml 
Ampicillin 100 mg/ml 100 µg/ml 
Chloramphenicol 34 mg/ml 34 µg/ml 
Gentamycin 10 mg/ml 10 µg/ml 
X-Gal 150 mg/ml 150 µg/ml 
IPTG 1 M 1 mM 
 
4.3 Bacterial and insect cell strains 
 
Table 6 | Bacterial strains used in this study. 
Bacterial strain Genotype Supplier Application 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F’ proAB lacIqZ∆M15 Tn10 
(Tetr)] 
Agilent cloning 
BL21-Codon       
Plus(DE3)-RIL 
E. coli B F- ompT hsdS(rB- mB-) dcm+ Tetr E. 













F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80dlacZ∆M15 ∆lacX74 endA1 recA1 deoR 
∆(ara, leu)7697 araD139 galU galK λ- rpsL 







Table 7 | Insect cell strains used in this study. 
Strain Species Source Application 
Sf9 
Spodoptera 
frugiperda Life Technologies 




















Table 8 | Vectors produced for protein expression in this study. 
Insert gene Vector Tag Antibiotic resistance 
Expression 
system 
CsB 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
DDB1 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
CsA 438A no tag Ampicillin insect cells 
UVSSA 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
Usp7 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
TFIIS* 1C N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Kanamycin E. coli 
TFIIS 
(D282AE283A) 1C 
N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Kanamycin E. coli 
XPD 438C N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Ampicillin insect cells 
XPD 
(K48R) 438C 
N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Ampicillin insect cells 
XPB 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
p62 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
p52 438A no tag Ampicillin insect cells 
p44 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
p34 438A no tag Ampicillin insect cells 
TTDA 438A no tag Ampicillin insect cells 
CKD7 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
CDK7 
(D137R) 438B 
N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
CDK7 
(T170A) 438B 
N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
MAT1 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
Cyclin H 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
XPG 438C N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Ampicillin insect cells 
XPG 
(E791A) 438C 
N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Ampicillin insect cells 
XPC 438C N-terminal 6X His tag, MBP tag, 
TEV cleavage site 
Ampicillin insect cells 
Rad23b 438A no tag Ampicillin insect cells 
XPF 438B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin insect cells 
ERCC1 438A no tag Ampicillin insect cells 
RPA1 14 B N-terminal 6X His tag, TEV 
cleavage site 
Ampicillin E. coli 
RPA2 14 A no tag Ampicillin E. coli 
RPA3 14 A no tag Ampicillin E. coli 
XPA 438B N-terminal 6X His tag, TEV cleavage site Ampicillin insect cells 
Genes (or their mutated counterparts) on the same colored background were combined into single vectors.  
*cloned by Seychelle M. Vos 
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4.5 Gel electrophoresis 
 
Gel electrophoresis was used for the analytical or preparative separation of proteins or 
nucleic acids.  
 
4.5.1 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used during cloning for the identification of vectors 
containing the insert of choice and for the purification of vectors and their digested products 
depending on their subsequent application. Agarose gel was prepared by mixing agarose 
with TAE buffer; 1% (w/v) of agarose was used in most cases but the percentage of agarose 
was increased up to 2% (w/v) for the separation of shorter DNA fragments. The agarose 
suspension was boiled until the agarose was fully dissolved. Agarose solution was then 
cooled to approximately 50 °C and supplemented with 1µl/ml of SYBRTMSafe DNA Gel 
stain (Invitrogen) to allow for a later visualisation of DNA under the ultraviolet light. Gels 
ware left to slowly polymerase at RT. Samples for electrophoresis were mixed with the 6x 
DNA Loading Dye (NEB) and directly used for gel loading. The 1kb DNA Ladder size 
standard (NEB) was run alongside the samples. Samples were run at 100 – 150 V until the 
desired separation of DNA products was achieved. GEL iX20 Imager system (Intas) was 
used for the final DNA visualization.    
 
4.5.2 Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was used for the analytical separation of proteins according to their size during 
protein expression and purification, and many biochemical assays. Samples were mixed with 
the NuPAGETM LDS Sample Buffer (4x, Thermo Fischer Scientific), heated to 95 °C for 3 
min and loaded onto the pre-case gradient NuPAGE 4-12% Bis-Tris Protein Gels 
(Invitrogen). The PageRulerTM Prestained Protein Ladder (Thermo Fischer Scinetific) or 
Precision Plus ProteinTM Dual Color Standard (Bio-Rad) molecular weight standards were 
run alongside the sample, depending on the expected sizes of proteins of interest. Gels were 
run at 150-200 V in 1x MOPS or 1x MES buffer (Invitrogen) for a better separation of 
proteins in the higher or lower molecular weight range, respectively. Proteins were stained 
with Instant Blue (Invitrogen) for several hours while shaking and destained with ddH2O 
until the background staining was no longer visible. Gels were scanned with the Epson 
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4.5.3 Denaturing urea polyacrylamide gel electrophoresis  
 
Denaturing urea PAGE was used for the analytical separation of RNA after transcription and 
backtracking assays. Gel solution was prepared by mixing urea (8M final) and the 40% 
Acrylamide/Bis solution, 19:1 (Thermo Fischer Scientific, 20% final) in 1X TBE buffer 
(Carl Roth). The solution was incubated in a water bath operating at 50 °C and occasionally 
mixed until the urea was dissolved. The gel solution was supplemented with ammonium 
persulphate and TEMED, and poured into the gel gaskets compatible with the XCell 
SureLockTM Mini-Cell Electrophoresis System (Thermo Fisher Scientific). Gels were left 
to polymerase for 30 min at RT. Gels was pre-run at 300V for 15 min to remove the 
polymerization agents and to heat up the gel which facilitates the RNA separation. Samples 
were heated to 95 °C for 3 min and 6 ul of sample was loaded per gel lain. Gels were run in 
1x TBE buffer at 300V for 90 min. RNA products were visualized using the 6-FAM or the 




Vectors encoding the full-length human CsB, CsA, DDB1, UVSSA, Usp7, XPA, XPC, 
Rad23b, XPG, XPF, ERCC1, RPA1, RPA2, RPA3, XPB, XPD, p62, p52, p44, p34, MAT1, 
Cdk7, CycH and TTDA were ordered from the Harvard Medical School PlasmID Repository 
and used as a template for gene amplification by PCR. The human TFIIS gene optimized for 
expression in E. coli was ordered from IDT. Cloning into the MacroBac vector series (438A, 
B and C, 14A, 14B and 1C) was performed as previously described (including sections 4.6.1-
3, and Tables 9-11)190. 
 
4.6.1 Polymerase chain reaction (PCR) 
 
Standard PCR reactions were used for the amplification of genes received from the PlasmID 
Repository. This step was also used to introduce overhangs around the amplified genes 
(Table 9)190 for the subsequent ligation-independent cloning of genes into vectors for protein 
expression in E. coli or insect cells (sections 4.6.2 and 4.6.3). The Phusion High-Fidelity 
DNA polymerase (NEB) was used for the DNA amplification. A typical PCR reaction of 50 
µl contained dNTPs (200 µM), forward primer (0.5 µM), reverse primer (0.5µM), template 
DNA (50 ng) and Phusion DNA polymerase (1 unit) in Phusion HF buffer (NEB). The PCR 
reaction was performed in a Professional TRIO Thermocycler® (Biometra) according to a 
program in Table 10. After the PCR reaction was completed, the reaction was supplemented 
with the 6x DNA Loading Dye (NEB) and the reaction products were separated by agarose 
gel electrophoresis alongside a molecular weight marker to confirm that a PCR product of 
the correct size was produced. If the PCR reaction was successful, the PCR product was 
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extracted from the gel for subsequent cloning steps. The DNA bands were visualized by a 
BST-20G-D2R BlueLED BioTransilluminator (Biostep) and a gel piece containing the DNA 
band of interest was cut out of the gel, placed into a tube and weighted. DNA was purified 
from the gel using the QIAquick Gel Extraction kit (Qiagen) according to the manufacturer’s 
instructions.  
 
Table 9 | Overhang sequences for the ligation-independent cloning. 
Tag Sequence Vector Directionality 
v1 F TACTTCCAATCCAATGCA 1C, 14B forward 
vBac TACTTCCAATCCAATCG 438A,B,C forward 




v2 F TTTAAGAAGGAGATATAGATC 14A forward 
v2 rv TTATGGAGTTGGGATCTTATTA 14A reverse 
 
Table 10 | PCR program used for gene amplification. 
Step Temperature Time 








20s / kb 
Final extension 72 °C 10 min 
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4.6.2 Ligation-independent cloning (LIC) 
 
Ligation-independent cloning (LIC) was performed as previously described190. LIC relies on 
the complementary sequences which flank the insert and the targeted site in the destination 
vector. The sequences allow specific annealing of the insert and the linearized targeted 
vector after each component was treated with the T4 polymerase exonuclease activity which 
produces single stranded overhangs driving the annealing reaction. Bacteria transformed 
with such an annealed product will seal the gap remaining after the annealing, thereby 
removing the need for the in vitro ligation step.  
In the previous section we described the preparation of the insert for LIC by tagging 
the genes of interest with specific sequences in a PCR reaction. Targeted vectors were 
linearized with restriction enzymes190. 438A, B and C, 1C and 14B vectors were digested 
with SspI-HF (NEB) and the 14A vector with EcoRV-HF (NEB). A typical digestion 
reaction of 50 µl contained 2 µg of DNA and 100 units of restriction enzyme in the CutSmart 
buffer (NEB). The reaction was incubated at 37 °C for 5 h. After the digestion, the linearized 
vector was purified by agarose gel electrophoresis as described above. Both purified inserts 
and linearized vectors were treated with T4 polymerase (purified in house) in a LIC reaction. 
A LIC reaction was assembled as described in Table 11190 and incubated at 22 °C for 30 
min. In case of vectors linearized by SspI, the LIC reaction was performed in the presence 
of dGTP for vectors and dCTP for inserts. In case of vectors linearized by EcoRV, the LIC 
reaction was performed in the presence of dCTP for vectors and dGTP for inserts. The T4 
polymerase was inactivated by elevating the temperature to 75 °C for 10 min. After the LIC 
reaction, the vector (2 µl) and the insert (2 µl) were combined and incubated for 1h at RT. 
The mixture was directly used for the transformation of chemically competent XL1-Blue 
cells (see section 4.6.5). 
 
Table 11 | LIC reaction for purified inserts and target vectors. 
Component Stock concentration Volume 
Purified vector/insert 10 ng/µl 10 µl 
dGTP/dCTP 25 mM 2µl 
T4 DNA pol buffer 10x 2µl 
DTT 100 mM 1µl 
T4 DNA polymerase  0.4 µl 
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4.6.3 Assembly of multiple genes into a single vector by LIC reactions 
 
For the efficient expression of multi-subunit protein complexes, we cloned all subunits of a 
complex into a single vector, as previously described190. Different strategies were used to 
produce vectors for the protein expression in insect cells and in E. coli190. For insect cells 
we used the 438 vector series190. We combined 2 genes by digesting the acceptor plasmid 
with Swa1 (NEB) to create the “vector” DNA, and the donor plasmid with Pme1 (NEB) to 
create the “insert” DNA. A typical digestion reaction of 15 ul contained 0.5 ug of DNA, 0.5 
µl of enzyme in CutSmart Buffer (NEB) for Pme1 or Buffer 3.1 (NEB) for Swa1. Pme1 
digestion was performed for 2 h at 37 °C and Swa1 digestion for 2 h at 25 °C. Reaction 
products were separated by agarose gel electrophoresis and the desired DNA products were 
gel extracted with the QIAquick Gel Extraction kit (Qiagen). The purified vector and the 
insert DNA were combined (2 µl each at 10 ng/µl), incubated at RT for 30 min and used for 
the transformation of chemically competent XL1-Blue cells. The vector containing 2 genes 
was then used for a subsequent round of gene joining by LIC and so on, until all genes were 
combined on a single vector.   
 For protein expression in E. coli, we used the 14A and 14B vectors. The acceptor 
plasmid (0.5 µg) was digested with NotI (NEB) and PacI (NEB) in CutSmart Buffer for 2.5 
h to at 37 °C create the “vector” DNA. After the digestion, the 20 µ l reaction was 
supplemented with Calf Intestinal Alkaline Phosphatase (CIP, NEB, 5 units) and incubated 
for 5 min at 37 °C. The donor plasmid was digested with NotI (NEB) and AsiSI (NEB) in 
CutSmart Buffer for 2.5 h at 37 °C to create the “insert” DNA. Both digestion reactions were 
separated by agarose gel electrophoresis and the DNA products of interest were gel extracted 
with the QIAquick Gel Extraction kit (Qiagen). 10 ul of the purified insert DNA (10 ng/	µl) 
and 4 µl of the vector DNA (10 ng/	µl) were mixed with 400 units of T4 ligase (NEB) in a 
T4 ligase buffer (NEB) and incubated for 30 min at RT. 6 ul of the ligated vector and the 
insert DNA were used for the transformation of chemically competent XL1-Blue cells (see 
section 4.6.5). The vector containing 2 genes was then used as donor vector and combined 
with additional genes in the next round of cloning.  
 
4.6.4 Round-the-horn side-directed mutagenesis  
 
Round-the-horn side-directed mutagenesis is an easy and convenient way to introduce 
mutations, insertions and deletions into any position in the vector of choice. Mutagenesis 
relies on 2 primers which amplify the entire plasmid in a linear form. The 3’ end of each 
primer has to be complementary to the target sequence on the vector, however, the 5’ ends 
can be modified to carry a single nucleotide mutation, several mutations or an insertion. 
Since the plasmid is linearized during the reaction, the recircularization by DNA ligation is 
required prior to transformation of competent bacterial cells.  
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 Here we used the round-the-horn mutagenesis to create various point mutants; 
TFIIS:D282AE283A, XPD:K48R, CDK7:D137R, CDK7:T170A and XPG:E791A. The 
primers were created to have annealing temperature around 60 °C with IDT OligoAnalyzer 
Tool. The primers were 5’ phosphorylated to facilitate the final ligation step. A standard 
PCR reaction (Table 10) was performed for the vector amplification, only the extension step 
was prolonged to allow enough time for the synthesis of longer DNA fragments. After the 
vector amplification by PCR, the reaction was supplemented with DpnI (NEB) and 
incubated for 3 h at 37 °C to remove the template DNA. Amplified vectors were purified by 
agarose gel electrophoresis and gel extraction. Extracted DNA (50 ng) was mixed with 40 
units of T4 ligase (NEB) in a T4 ligase buffer (NEB) and incubated at 16 °C for 2 h. The 
ligated product was directly used for the transformation of chemically competent XL1-Blue 
cells. 
 
4.6.5 Transformation of chemically competent cells  
 
100 µl of chemically competent XL1-Blue, BL-21 (DE3)-RIL or Rosetta (DE3) cells were 
thawed on ice, supplemented with DNA (200 ng when quantification was possible) and 
gently mixed. The cells were incubated on ice for 30 min, followed by a heat shock at 42 °C 
for 45s and a recovery on ice for 2 min. The bacterial suspension was supplemented with 
900 µl of LB medium (Table 4) at RT and shaken at 400 rpm and 37 °C in a ThermoMixer® 
C (Eppendorf). After 1-2 h of shaking the suspension was spun down and most of the 
supernatant was discarded, except for 100 µl which was used to resuspend the bacterial 
pellet. Bacterial suspension was plated on a pre-warmed LB agar plates supplemented with 
the appropriate antibiotics. The plates were incubated at 37 °C overnight.  
 
4.6.6 Isolation of vector DNA from bacterial cultures  
 
After transformation of bacteria with a vector of interest and selection on LB agar plates 
containing antibiotics, single colonies were picked and used to inoculate 30 ml of LB 
medium (Table 4) supplemented with antibiotics. The bacterial suspension was shaken at 37 
°C overnight. Next, bacterial cells were harvested by centrifugation (2500g, 10 min, RT) 
and plasmid DNA was isolated by using the QIAprep Spin Miniprep kit (Qiagen) according 
to the manufacturer’s protocol. DNA was quantified with a Nanodrop-2000 
spectrophotometer (Thermo Scientific), flash frozen in liquid nitrogen and stored at -80 °C. 
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4.7 Protein Expression 
 
4.7 1 Protein expression in E. coli  
 
RPA heterotrimeric complex was expressed and purified from Rosetta cells (Table 6), as 
described previously291. TFIIS and inactive TFIIS:D282AE283A mutant were expressed as 
follows. After the transformation of BL21 (DE3) RIL (Table 6) and selection on LB agar 
plates, a colony was used for the inoculation of 500 ml LB medium (Table 4) supplemented 
with kanamycin (30 µg/ml) and chloramphenicol (34 µg/ml). The culture was grown 
overnight at 37 °C while shaking. The next day 6L of 2x YF (Table 4) medium supplemented 
with kanamycin (30 µg/ml) and chloramphenicol (34 µg/ml) was inoculated with 180 ml of 
the overnight culture and grown at 37 °C until the OD600 of 0.4 – 0.5 was reached. Next, the 
temperature was lowered to 18 °C and the cells were induced with IPTG (0.5 mM final). 
The cells were shaken at 18 °C overnight. Cells were harvested by centrifugation (7000g at 
4°C for 20 min) and the supernatant was discarded. Cells were resuspended in the lysis buffer 
(400 mM NaCl, 20 mM Tris-HCl pH 7.9, 10 % glycerol (v/v), 1 mM DTT, 30 mM imidazole 
pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml 
benzamidine), flash-frozen in liquid nitrogen and stored at -80 °C.    
 
4.7.2 Protein expression in insect cells 
 
Protein expression in insect cells included several steps after the genes of interest were 
cloned into the respective 438 vectors: transformation of electrocompetent DH10EMBacY 
cells, isolation of the bacmid DNA, production of V0 and V1 viruses and protein expression 
in Hi5 cells, as previously described292,293.  
 
4.7.3 Transformation of electrocompetent DH10EMBacY cells 
 
100 µl of electrocompetent DH10EMBacY cells were thawed on ice and gently mixed with 
the 500 ng of DNA dissolved in ddH2O. Cells were incubated with the DNA for 15 min on 
ice and then transferred to a pre-chilled BIORAD Gene®/MicroTM Pulser cuvette (0.1 cm 
width). Electroporation was performed with a single pulse (25µF, 1.8 kV). Cells were 
immediately supplemented with 900 µl of LB medium (Table 4) at RT and transferred to a 
15 ml culture tube. Cells were incubated at 37 °C for 5 h while shaking. After the incubation, 
50 µl of transformed cells was plated on the LB agar supplemented with gentamycin (10 
µg/ml), X-Gal (150 µg/ml) and IPTG (1mM) for blue-white selection. If the integration of 
the desired DNA into the bacmid DNA was successful, the colonies would appear white, 
and if the integration was unsuccessful the colonies would turn blue. The plates were 
incubated for 36 h at 37 °C for a reliable blue-white selection. Single white colonies were 
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picked and restreaked on the LB agar supplemented with gentamycin (10 µg/ml), X-Gal 
(150 µg/ml) and IPTG (1mM). If the colonies were still white after incubation at 37 °C for 
36 h, we preceded with the isolation of bacmid DNA.  
 
4.7.4 Isolation of bacmid DNA  
 
White colonies were used to inoculate 5 ml of LB medium (Table 4) supplemented with 
gentamycin (10 µg/ml). The bacterial culture was grown overnight at 37 °C while shaking. 
After the incubation, the cells were harvested by centrifugation (3000g at 4 °C for 10 min). 
The bacterial pellet was resuspended in 250 µl of P1 buffer (QIAprep Spin Miniprep kit, 
Quiagen), followed by the addition of 250 µl of P2 buffer (QIAprep Spin Miniprep kit, 
Quiagen) and incubation at RT for 5 min. After the incubation, 350 µl of N3 buffer (QIAprep 
Spin Miniprep kit, Quiagen) was added and the mixture was centrifuged at 21 000g and 4 
°C for 10 min. The supernatant was transferred to a fresh 1.5 ml tube and centrifuged for 
another 10 min to remove the remaining precipitates. The supernatant was supplemented 
with 700 µl of cold isopropanol and gently mixed. The bacmid DNA was precipitated at -20 
°C overnight. Next day, the DNA was pelleted by centrifugation at 21 000g and 4 °C for 15 
min. The pellet was washed with 500 µl of cold 70% ethanol. After the ethanol removal, the 
pellets were covered with 30 µl of fresh 70% ethanol and stored at -20 °C until the 
transfection of insect cells.  
 
4.7.5 Transfection of Sf9 cells with bacmid DNA and V0 virus production 
 
All consecutive steps were performed under a sterile hood (Biowizard Golden Line, Kojair) 
because the insect cell cultures are extremely susceptible to fungal infections. The 
precipitated bacmid DNA was transferred into a sterile hood and the ethanol was removed. 
The DNA pellets were left to dry for 10-15 min followed by the addition of 20 µl of water 
without resuspending the DNA to prevent DNA fragmentation. For transfection, the X-treme 
GENETM 9 transfection agent (10 µl) was mixed with Sf-900TM III SFM medium (100 µl). 
The transfection agent solution was added to the dissolved bacmid DNA and the solution 
was further diluted with 200 µl of the Sf-900TM III SFM medium. The solution was 
incubated at RT for 1h. In the meantime, the Sf9 cells were prepared for the transfection. 
Density of the Sf9 cell culture and the cell viability was determined with the CASY® Modell 
TT Cell Counter and Analyzer System equipped with a 150 mm capillary (OMNI Life 
Science) according to manufacturer`s instructions. The cell density was adjusted to 1.0x106 
cells/ml and 3 ml of cells was added to each of the 6 wells in a 6-well plate (Greiner). Cells 
were incubated at 27 °C until the bacmid DNA was ready for transfection. The 300 µl of the 
bacmid solution was then added to 2 wells containing Sf9 cells in a dropwise manner (150 
µl od solution was added per well). Typically, two bacmid solutions were prepared for a 
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particular DNA construct. As a control, one well contained the non-transfected cells and one 
well contained only the medium. Transfected cells were incubated at 27 °C in the dark 
without agitation. Efficiency of transfection was monitored with a fluorescence microscope 
(Leica). Since the bacmid DNA also contains the EYFP gene driven by the same viral 
promotor that drives the expression of the gene of interest, increase in fluorescence was 
indicative of a successful transfection. Usually, the cells were incubated for 2-3 days before 
the fluorescence increased. If a reasonable number of fluorescent cells was observed (at least 
50 cells per well) before the fourth day, the supernatant containing the V0 virus was removed 
in the sterile hood, transferred to a 10 ml tube and stored at 4 °C in the dark.  
 
4.7.6 V1 virus production 
 
V0 virus is still too weak to be used for a protein expression, so the virus is further propagated 
to produce the stronger V1 virus. 25 ml of the Sf9 or Sf21 insect cell culture (Table 7) at a 
density of 1.0x106 cells/ml was infected with 0.5-3 ml of the corresponding V0 virus. After 
the infection, the density, the cell viability and the YFP fluorescence was monitored daily. 
The first day at which the cells do not divide is considered the day of proliferative arrest 
(DPA). Ideally, the cells divided once after the infection with the V0 virus, followed by DPA. 
However, if the initial virus is weak, the DPA is reached only after several days. In the 
meantime, cells were kept at the density of 1.0x106 cells/ml. When DPA was reached, cells 
were usually grown for additional 48-72 h which was accompanied by an increase in cell 
diameter (from 25 to 28 µm for Sf21 cells and from 18 to 20 µm for Sf9 cells), a decline in 
cell viability and an increase in YFP fluorescence. The level of YFP was monitored with an 
Infinite® M1000 Pro micro-plate reader (Tecan) using excitation and emission wavelengths 
of 514 nm and 527 nm, respectively. When the viability dropped below 90 % (usually around 
80 – 85 %), the cells were harvested by centrifugation (320g, 15 min, 4 °C). The supernatant 
(V1 virus) was decanted in the hood into a 50 ml falcon tube and stored at 4 °C in the dark.  
 
4.7.7 Protein expression (V2 virus production) 
 
V1 virus was used for the large-scale protein expression. Here we used primarily Hi5 cells 
for protein expression as Hi5 cells tend to produce larger amounts of protein. 600 ml of Hi5 
cell culture at the cell density of 1.0 x 106 cells/ml was infected with 0.3 – 2 ml of V1 virus, 
depending of the strength and the age of the virus. Usually the amount of the V1 virus added 
to Hi5 cells was optimized so that the cells divided exactly once before the DPA. Here, we 
used only one virus for infecting Hi5 cells, except for the expression of the core TFIIH when 
two viruses were used, one encoding subunits XPB, p62, p52, p44, p34 and TTDA, and one 
encoding XPD. The cell density, the cell viability and the YFP levels of infected cells were 
monitored daily. The cell density was kept at 1.0 x 106 cells/ml throughout the expression 
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period. After the DPA was reached, cells were propagated for additional 48 – 72 h. When 
the cell viability dropped between 80 and 85 %, cells were harvested by centrifugation (238g, 




4.8 Protein purification 
 
The RPA complex291, the TFIIH kinase module297 and the pig RNAP290 were purified as 
described before. Here we provide detailed purification protocols for the human TFIIS, the 
core TFIIH, XPC-Rad23b, XPA, XPG, XPF-ERCC1, CsB, CsA-DDB1, UVSSA and Usp7. 
All purification steps were performed at 4 °C and all buffers were filtered and thoroughly 
degassed immediately before use. 
 
4.8.1 TFIIS and TFIIS:D282AE283A inactive mutant 
 
Frozen bacterial cell pellets were thawed in a water bath operating at 30 °C. Cells were 
opened by sonication: 2x 2.5 min at 60% power (5s on, 5s off) with a cooling step on ice 
between the sonication rounds of 5 min. The lysate was centrifuged for 45 min at 18 000xg 
and 4 °C. The clarified lysate was loaded onto GE HisTrap HP 5 mL column (GE Healthcare, 
Little Chalfont, United Kingdom) pre-equilibrated in lysis buffer (400 mM NaCl, 10 % 
glycerol (v/v), 20 mM Tris-Cl pH 7.9, 1 mM DTT, 30 mM imidazole pH 8.0, 0.284 μg/ml 
leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml benzamidine). The 
column was washed with 10 CV of a high salt buffer (as lysis buffer but with 1M NaCl), 
followed by a wash with the lysis buffer for additional 5 CV. Protein was eluted with a 
gradient from 0-100 % elution buffer  (400 mM NaCl, 10 % glycerol (v/v), 20 mM Tris-Cl 
pH 7.9, 1 mM DTT, 500 mM imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml 
pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml benzamidine) in 6 CV. Elution fractions 
were analysed on NuPAGE 4-12 % Bis – Tris Protein Gels (Invitrogen) run in MES buffer 
(Invitrogen) and the TFIIS containing fractions were pulled. The protein solution was 
supplemented with 2 mg of TEV protease and dialysed against 1L of the lysis buffer lacking 
imidazole overnight. Dialysed solution was passed through a freshly charged GE HisTrap 
HP 5 mL column (GE Healthcare, Little Chalfont, United Kingdom) pre-equilibrated in the 
lysis buffer without the imidazole and elution fractions were collected. Elution fractions 
were again analysed by SDS-PAGE and appropriate fractions were pulled and concentrated 
to a final volume of 2 ml with Amicon Millipore 15 ml concentrator (10,000 MWCO). 
Concentrated solution was loaded onto a HiLoad 16/600 Superdex 75 PG (GE Healthcare) 
pre-equilibrated in the size-exclusion buffer (400 mM NaCl, 10 % glycerol (v/v), 20 mM 
Tris-Cl pH 7.9 and 1 mM DTT) and 500 μl fractions were collected. Fractions containing 
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the pure TFIIS, as visualised by SDS-PAGE and staining with Instant Blue (Invitrogen), 
were pulled and concentrated with the Amicon Millipore 15 ml concentrator (10,000 
MWCO). The concentrated protein solution was supplemented with glycerol to reach final 
30% of glycerol (v/v), aliquoted, flash frozen in liquid nitrogen and stored at -80 °C. 
 
4.8.2 Core TFIIH and core TFIIH containing XPD:K48R point mutant 
 
Cells were thawed in a water bath operating at 30 °C and opened by sonication. The lysate 
was clarified by centrifugation (18,000g, 30 min), followed by ultracentrifugation (235,000g, 
60 min). The clarified lysate was filtered using 0.8 µm syringe filters (Millipore) and loaded 
onto HisTrap HP 5 mL (GE Healthcare, Little Chalfont, United Kingdom). The column was 
washed with 10 CV of lysis buffer, followed by 20 CV of high salt wash (800 mM KCl, 
20 % glycerol (v/v), 20 mM KOH-HEPES pH 7, 5 mM β-mercaptoethanol, 30 mM 
imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 
0.33 mg/ml benzamidine). Column was washed again with 5 CV of lysis buffer and protein 
was subsequently eluted with a gradient of 0–80% elution buffer (400 mM KCl, 20 % 
glycerol (v/v), 20 mM KOH-HEPES pH 7, 5 mM β-mercaptoethanol, 500 mM imidazole 
pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml 
benzamidine). Fractions were checked on NuPAGE 4-12 % Bis – Tris Protein Gels 
(Invitrogen) for the presence of all core TFIIH subunits and appropriate fractions were pulled 
and mixed with 10 ml of amylose resin (New England BioLabs) pre-equilibrated in washing 
buffer (400 mM KCl, 20 % glycerol (v/v), 20 mM KOH-HEPES pH 7, 5 mM β-
mercaptoethanol, 2 mM MgCl2 and 10 μM ZnCl2). The protein solution was incubated with 
the beads for 1h while rotating. The amylose resin was poured into Econo-Pac 
Chromatography columns (BioRad) and washed with 5 CV of washing buffer. The protein 
was eluted with the washing buffer containing 100 mM maltose. The protein-containing 
fractions were pooled, mixed with 2 mg of TEV protease and dialysed against 2 L of dialysis 
buffer overnight (250 mM KCl, 20 % glycerol (v/v), 20 mM KOH-HEPES pH 7, 5 mM β-
mercaptoethanol, 2 mM MgCl2 and 10 μM ZnCl2). The dialysed sample was applied to 
DEAE (GE Healthcare) and heparin columns (GE Healthcare) in tandem and washed with 
20 CV of dialysis buffer. After the removal of DEAE column, protein was eluted with a 
gradient of elution buffer 0-100% (1M KCl, 20 % glycerol (v/v), 20 mM KOH-HEPES pH 
7, 5 mM β-mercaptoethanol, 2 mM MgCl2 and 10 μM ZnCl2). Peak fractions were pooled, 
concentrated with the Amicon Millipore 15 ml 100,000 MWCO centrifugal concentrator and 
applied to the Superose 6 increase 10/300 GL column (GE Healthcare) equilibrated in a 
storage buffer (400M KCl, 20 % glycerol (v/v), 20 mM KOH-HEPES pH 7.0, 5 mM β-
mercaptoethanol, 2 mM MgCl2). Peak fractions were again concentrated, aliquoted, flash 
frozen and stored at -80 °C. The TFIIH hexamer lacking the XPD subunit was purified as 
the full TFIIH core, only the amylose affinity step was omitted.  
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4.8.3 CsB, UVSSA, Usp7, XPA, XPG, XPF-ERCC1, XPC-Rad23b 
 
Cells were thawed in a water bath operating at 30 °C and opened by sonication. The CsB, 
UVSSA, Usp7, XPF:ERCC1, XPG, XPC-Rad23b and XPA containing lysate was applied 
onto GE HisTrap HP 5 mL (GE Healthcare, Little Chalfont, United Kingdom) equilibrated 
in lysis buffer (400 mM NaCl, 20 mM Tris-HCl pH 7.9, 10 % glycerol (v/v), 1 mM DTT, 
30 mM imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF 
and 0.33 mg/ml benzamidine). In case of XPA all downstream steps were performed in the 
presence of 5 mM β-mercaptoethanol and 10 μM ZnCl2 instead of 1 mM DTT. The column 
was washed with 20 CV of high salt buffer (800 mM NaCl, 20 mM Tris-HCl pH 7.9, 10 % 
glycerol (v/v), 1 mM DTT, 30 mM imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml 
pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml benzamidine). After the 5 CV wash with 
lysis buffer, proteins were eluted with the elution buffer gradient 0-80% (400 mM NaCl, 20 
mM Tris-HCl pH 7.9, 10 % glycerol (v/v), 1 mM DTT, 500 mM imidazole pH 8.0, 
0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml 
benzamidine). Pulled peak fractions were processed differently for different proteins. CsB, 
XPF-ERCC1 and XPA containing protein solutions were directly mixed with 2 mg of TEV 
protease and dialysed against 1L of dialysis buffer (400 mM NaCl, 20 mM Tris-HCl pH 7.9, 
10 % glycerol (v/v), 1 mM DTT). XPG, XPC-Rad23b and UVSSA solutions were mixed 
with 10 ml of amylose resin (New England BioLabs) pre-equilibrated in dialysis buffer. 
Solutions were mixed for 1 hr and subsequently poured into Econo-Pac Chromatography 
columns (BioRad). Columns were washed with 10 CV of dialysis buffer followed by the 
elution with dialysis buffer containing 100 mM maltose. Protein containing fractions were 
pulled, mixed with 2 mg of TEV protease and dialysed against 1L of dialysis buffer. Dialysed 
solutions containing CsB, XPF-ERCC1, XPC-Rad23b, XPA, XPG and UVSSA were loaded 
on GE HisTrap HP 5 mL and flow through fractions were collected. Protein containing 
fractions were checked for contaminants on NuPAGE 4-12 % Bis – Tris Protein Gels 
(Invitrogen), pulled, concentrated with appropriate Amicon Millipore 15 ml centrifugal 
concentrator and applied onto Superdex 75 10/300 equilibrated in storage buffer (400 mM 
NaCl, 20 mM NaOH:HEPES pH 7.5, 10% glycerol (v/v), 10 μM ZnCl2 and 5 mM β-
mercaptoethanol) for XPA and Superdex 200 10/300 increase (GE Healthcare) equilibrated 
in a different storage buffer (400 mM NaCl, 20 mM NaOH:HEPES pH 7.5, 10% glycerol 
(v/v), 1mM DTT) for the rest of the proteins. Peak fractions were pulled, concentrated, 












Many attempts were made at purifyingCsA. We tried to optimise protein expression in 
various E. coli strains at various conditions, as well as in insect cells. However, protein was 
always insoluble. The solubility was increased by fusing CsA to the MBP tag, however, the 
protein precipitated when the tag was cleaved off. Thus, we tried co-expression of CsA with 
DDB1, which dramatically improved protein yield and solubility.  
Insect cells expressing CsA-DDB1 were thawed in a water bath operating at 30 °C 
and opened by sonication. CsA-DDB1 containing lysate was applied onto GE HisTrap HP 
5 mL (GE Healthcare, Little Chalfont, United Kingdom) equilibrated in lysis buffer (400 
mM NaCl, 20 mM Tris-HCl pH 7.9, 10% glycerol (v/v), 1 mM DTT, 30 mM imidazole pH 
8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml 
benzamidine). The column was washed with 5 CV of high salt buffer (800 mM NaCl, 20 
mM Tris-HCl pH 7.9, 10% glycerol (v/v), 1 mM DTT, 30 mM imidazole pH 8.0, 
0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml 
benzamidine), followed by 5 CV of low salt buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.9, 
10% glycerol (v/v), 1 mM DTT, 30 mM imidazole pH 8.0, 0.284 μg/ml leupeptin, 
1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml benzamidine). HisTrap column 
was then coupled to a 5 mL HiTrapQ HP column (GE Healthcare) and protein was eluted 
with a 0-100% gradient of elution buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.9, 10% 
glycerol (v/v), 1 mM DTT, 500 mM imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml 
pepstatin A, 0.17 mg/ml PMSF and 0.33 mg/ml benzamidine). HiTrapQ column was 
washed with 10 CV of low salt buffer and eluted with a 0 – 100% gradient of monoQ elution 
buffer (1M NaCl, 20 mM Tris-HCl pH 7.9, 10 % glycerol (v/v), 1 mM DTT, 500 mM 
imidazole pH 8.0, 0.284 μg/ml leupeptin, 1.37 μg/ml pepstatin A, 0.17 mg/ml PMSF and 
0.33 mg/ml benzamidine). MonoQ step was necessary to separate the CsA-DDB1 binary 
complex from the excess of DDB1. Subsequent steps including the dialysis in the presence 
of TEV protease, the reverse HisTrap and the size-exclusion chromatography via Superdex 
200 10/300 increase was done as described for CsB above.  
 
4.8.5 Protein quantification 
 
Absorption of protein solution after the final purification step and concentration was 
measured at 260 nm and 280 nm with a NanoDrop-200 spectrophotometer (Thermo 
Scientific). The ratio of absorption at 260 and 280 nm informed on the contamination of 
protein preparations with nucleic acids. Typically, a ratio of 0.5 – 0.7 was achieved for our 
protein preparations and was considered DNA- and RNA-free. Extinction coefficient for the 
particular protein or multi-protein complexes was calculated using the Expasy ProtParam 
software. Final concentration was calculated as a ratio of the measured absorbance at 280 
nm and the extinction coefficient. 
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4.9 DNA and RNA constructs  
All DNA and RNA constructs except from CPD-containing oligo (DNA22) were purchased 
from IDT, dissolved in ddH20 to final concentration of 100 μM, aliquoted, flash frozen in 
liquid nitrogen and stored at -80 °C. The CPD containing oligo was synthesised by Jan 
Seikowski in a collaboration with Prof. Claudia Höbatner (section 4.11.2). 
 
Table 12 | List of DNA constructs used in this study. 

















































DNA14 56-FAM/TTCTTTTCTTTCTTCTTTCTTT Translocase assay 
DNA15 TCTTCTTTTAAACACTATCTTCCTGCT Translocase assay 
DNA16 /5BiosG/CATTTCTTTCTTCTTTCTTTTCTT Translocase assay 
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DNA17 /5IABkFQ/AAGAAAAGAAAGAAGAAAGAAAT Translocase assay 

















































Table 13 | List of RNA constructs used in this study. 
RNA Sequence Application 
RNA1 UAUAUGCAUAAAGACCAGGC Analytical gel-filtration 
RNA2 FAM5/UAUA UUA UAA UUA GGA GUA GGG U Transcription assay 
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4.10 Biochemical assays 
 
4.10.1 Analytical gel filtration 
 
Analytical gel filtration was used to demonstrate the reconstitution of decametric TFIIH 
complex (Fig. 7) and to show that UVSSA binds the RNAP elongation complex (Fig. 27). 
For the TFIIH reconstitution we mixed 30 pmol of purified TFIIH core with 60 pmol of 
purified kinase module in a final reaction of 50 µl containing 200 mM KCl, 20 mM 
KOH:HEPES pH 7, 2 mM MgCl2, 10% glycerol and 5 mM β-mercaptoethanol. The reaction 
was loaded onto Superose 6 increase 3.2/300 column (GE Healthcare) pre-equilibrated in a 
buffer containing 150 mM KCl, 20 mM KOH:HEPES pH 7, 2 mM MgCl2, 5% glycerol and 
5 mM β-mercaptoethanol, and 50 µl fractions were collected. Peak fractions were analyzed 
on a pre-cast NuPAGE 4-12 % Bis-Tris gel (Invitrogen) in MOPS buffer (Invitrogen) and 
visualized by Coomassie staining.  
 For the analysis of UVSSA binding to RNAP, we first assembled the RNAP 
elongation complex. We annealed DNA6 (50µM final; Table 12) and RNA1 (50µM final; 
Table 13) in water by heating the reaction to 95 °C and slowly cooling (1°C/min) to 4°C in 
a thermocycler. We mixed 25 pmol of purified pig RNAP with 50 pmol of annealed 
DNA6:RNA2 and incubated at 30 °C for 10 min. Then we added 50 pmol of DNA7 (Table 
12) and incubated for additional 10 min at 30 °C. We mixed 75 pmol of purified UVSSA 
with elongation complexes in a final reaction of 50 µl containing 100 mM NaCl, 20 mM 
NaOH:HEPES pH 7.5, 10% glycerol and 1 mM DTT. The reaction was loaded onto 
Superose 6 increase 3.2/300 column (GE Healthcare) pre-equilibrated in buffer containing 
100 mM NaCl, 20 mM NaOH:HEPES pH 7.5, 2 mM MgCl2, 5% glycerol and 1 mM DTT, 
and 50 µl fractions were collected. Peak fractions were analyzed on a pre-cast NuPAGE 4-
12 % Bis-Tris gel (Invitrogen) in MOPS buffer (Invitrogen) and visualized by Coomassie 
staining. 
 
4.10.2 Fluorescence anisotropy 
 
The fluorescence anisotropy experiment was performed by my former master student 
Kristina Stakyte under my supervision. Fluorescence anisotropy was used for measuring the 
affinity of XPC-Rad23b complex for different DNA constructs. The fully complementary 
DNA was made by annealing DNA1 and DNA2 (Table 12), the DNA containing a central 3 
nucleotide mismatch by annealing DNA2 and DNA3 (Table 12), and the DNA containing a 
central bulky lesion mimic by annealing DNA4 and DNA5 (Table 12). A typical reaction of 
25 µl contained a corresponding DNA scaffold (10 nM) and XPC-Rad23b (10 µM highest 
concertation followed by a half-log dilution series) in a final buffer containing 100 mM 
NaCl, 20 mM NaOH:HEPES pH 7.5, 5% glycerol, 100 µg/ml BSA, 1 mM MgCl2 and 0.5 
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mM DTT. The binding reaction was incubated at RT for 10 min followed by the anisotropy 
measurement with the Infinite M1000 PRO plate reader (Tecan) with the following settings: 
excitation wavelength 470 nm, emission wavelength 518 nm and gain of 72. Fluorescence 
anisotropy binding data was analysed using GraphPad Prism Version 7. Curve fitting was 
performed on the average of three independent experiments by a single-site binding 
equation, as described before294:  
 
3 = 5678	(




where Bmax is the maximum specific binding, L is the DNA concentration, x is XPC-Rad23b 
concentration, and Kd,app is the apparent dissociation constant for XPC-Rad23b and DNA.  
 
4.10.3 Bulk ATPase assay 
 
The enzyme-coupled ATPase assay was performed in a similar way as previously 
described202. The assay uses two separate fast enzymatic reactions to couple ATP 
regeneration to NADH oxidation202. A typical reaction contained the protein of interest (100 
nM) resuspended in 30 ul of 80 mM potassium acetate, 20 mM KOH:HEPES pH 7, 5 mM 
magnesium acetate, 5 % glycerol (v/v), 0.2 mg/ml BSA, 3 mM phosphoenolpyruvate (PEP), 
0.3 mM NADH and the excess of the pyruvate kinase and lactate dehydrogenase enzyme 
mix (Sigma). The mixture was incubated for 10 min at 30 °C and the reaction was started by 
the addition of ATP solution (10 ul). ATP hydrolysis was monitored by measuring a decrease 
in the absorption at 340 nm with the Infinite M1000Pro reader (Tecan). Resulting curves 
were fitted to a linear model using the GraphPad Prism Version 6 to obtain the rates of ATP 
hydrolysis. The rates of ATP hydrolysis were plotted against the ATP concentration and 
fitted with a Michaelis-Menten model to extract the Vm, Km and kcat reaction parameters.  
 
4.10.4 Helicase assay 
 
The helicase assay was performed in a similar way as previously described73. DNA8 and 
DNA9 (Table 12) oligonucleotides were used for monitoring the helicase activity in the 5-
3’ direction and DNA10 and DNA11 (Table 12) were used for monitoring the helicase 
activity in the 3’-5’ direction. The DNA annealing reaction contained the fluorescent DNA 
primer (25 μM; DNA8, DNA10) and the quenching DNA oligo (37.5 μM; DNA9, DNA11) 
dissolved in water. The annealing was performed in a thermocycler by heating the DNA 
solution to 95 °C for 5 min, followed by slow cooling (1 °C/min) to 4 °C. A typical 
unwinding reaction (20 μl) contained 0.4 pmol of DNA duplex and 8 pmol of core TFIIH in 
100 mM KCl, 20 mM KOH:HEPES pH 7, 5% glycerol, 0.2 mg/ml BSA, 3 mM 
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phosphoenolpyruvate, 10 mM MgCl2, 1 mM DTT and the excess amount of pyruvate kinase 
(Sigma). When the effect of DNA repair factors on the unwinding was measured we 
supplemented the reaction with 24 pmol of the corresponding factor. The reaction mixture 
was preincubated at 26 °C for 10 min. The reaction was started by the addition of ATP (2 
mM final) and the unwinding was monitored at 26 °C by using the Infinite M1000Pro reader 
with the excitation wavelength 495 nm, the emission wavelength 520 nm and the gain of 
150. Percentage of unwound product was calculated by dividing the observed fluorescence 
intensity by the intensity of the fluorescent primer in the reaction buffer (mimicking the fully 
unwound DNA).  
The DNA unwinding monitored by stopped-flow was performed in the same buffer 
conditions and with the same final protein and DNA concentrations as above. The core 
TFIIH preincubated with XPA or XPG was rapidly mixed with equal volume of ATP (2mM 
final) in the SX-20MV stopped-flow apparatus (Applied Photophysics). FAM fluorescence 
was monitored upon the excitation at 465 nm after passing through a KV500 cut-off filter 
(Schott). All time courses shown represent average of 5 technical replicates. The initial rate 
of DNA unwinding was calculated using Prism 7 (Graphpad software) by fitting the initial 
linear part of the fluorescence trace. 
 
4.10.5 Translocase assay 
 
The translocase assay was performed in a similar way as previously described69. The 
annealing reaction (10 μl) contained DNA12 (30 μM) and DNA13 (25 μM) (Table 12) in 25 
mM MES pH 5.5 and 10 mM MgCl2. The reaction was heated to 95 °C for 5 min followed 
by slow cooling (1 °C/min) to 4 °C. After cooling, the reaction was supplemented with 1 μl 
of florescent DNA14 (9 μM final) (Table 12), heated to 57 °C and cooled down to 20 °C at 
the speed of 1 °C/min. Translocation reactions were preformed exactly as described for the 
helicase assay (section 4.10.4), only with the triplex DNA as a substrate. A higher core 
TFIIH input (75 pmol in 20 μl reactions) was used when the effect of triptolide on DNA 
translocation was tested. When the effect of a biotin as a lesion mimic on XPB translocase 
activity was tested, the roadblock in the 5’-3’ direction was made was mixing DNA13, 
DNA15 and DNA16, and the roadblock in the 3’-5’ direction by mixing DNA12, DNA17 
and DNA 18.  
 
4.10.6 Transcription assay 
 
The transcription assay was performed in a similar was as previously described123,295.The 
template strand (DNA19, 25 μM final) (Table 12) and RNA2 (25 μM final) (Table 13) were 
annealed in buffer containing 50 mM NaCl, 5 mM NaOH:HEPES pH 7.5 and 1 U/μl 
RNaseOUT Ribonuclease Inhibitor (Invitrogen) by heating the mixture to 95 °C for 5 min 
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followed by slow cooling (1 °C/min) to 4 °C. Elongation complexes was assembled by 
incubating a double molar excess of DNA19-RNA2 over the RNAP for 20 min at 30 °C, 
followed by the addition on the non-template strand (DNA20, Table 12), again at double 
molar excess over the RNAP, and additional incubation for 20 min at 30 °C. A typical 
transcription reaction (10 μl) contained 0.8 pmol of elongation complex and different 
amounts of factors of interest in 125 mM NaCl, 30 mM HEPES pH 7.5, 10 % glycerol, 3 
mM MgCl2, 20 μg/ml BSA and 1 mM DTT. Transcription reactions were pre-warmed at 
37 °C for 2 min followed by the addition of NTPs (0.2 mM final). The reaction was incubated 
for 10 min at 37 °C and quenched by the addition of 2x stop buffer (50 mM EDTA pH 8.0 
and 7M urea in 1x TBE buffer). Proteins in the reactions were digested with Proteinase K (2 
U/ml final, New England Biolabs) for 3 hrs at 37 °C. After the digestion, the reaction was 
heated up to 98 °C for 3 min and placed on ice. Reaction products were separated on 20 % 
urea denaturing PAGE (section 4.5.3) and visualized with a Typhoon FLA 9500 (GE 
healthcare Life Sciences). Assays were performed in duplicates or triplicates.  
 
4.10.7 Backtracking assay 
 
RNAP elongation complexes were assembled as described in the section 4.10.6 by using the 
following oligos: DNA25 (Table 12) as the CPD-containing template strand, DNA26 (Table 
12) as a control template strand without the lesion, DNA27 (Table 12) as the non-template 
strand and RNA3 (Table 13). Transcription was initiated by the addition of NTPs (0.25 mM 
final) and incubated for 30 min at 37 °C in the same buffer conditions as described in the 
section 4.10.6. In parallel, the backtracking-inducing complex was formed by mixing the 
core TFIIH with 3-fold molar excess of XPA and XPG. Backtracking reaction (10μl) was 
assembled by mixing transcribed RNAP complexes (2.8 pmol) with the backtracking 
inducing complex (2.2, 4.4 or 8.8 pmol) or TFIIH storage buffer in final buffer conditions 
as follows: 20 mM NaCl, 80 mM KCl, 10 % glycerol, 10 mM NaOH:HEPES pH 7.5, 6 mM 
MgCl2, 1 mM DTT, 3 mM PEP, 1 mM ATP and excess pyruvate kinase (Sigma). The 
reaction was incubated for 20 min at 37 °C, followed by the addition of TFIIS (0.5 pmol) 
and additional incubation of 1 min at 37 °C. The reaction was quenched with 10 ul of final 
reaction buffer supplemented with 50 mM EDTA and the TFIIS inactive mutant (50 pmol). 
Proteins in the reactions were digested with the Proteinase K (2 U/ml final, New England 
Biolabs) for 3 hrs at 37 °C. Sample was ethanol precipitated and resuspended in 1x TBE 
buffer supplemented with 7M urea. The resuspended sample was heated to 98 °C for 2 min 
and placed on ice. Reaction products were separated on a 9.6 % denaturing sequencing gel 
and the fluorescent signal was visualised with a Typhoon FLA 9500 (GE healthcare Life 
Sciences). Assays were performed in triplicates. 
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4.10.8 Bead-based RNAP assays 
 
Bead-based RNAP assays were used to monitor the RNAP polymerase dissociation from the 
CPD-containing DNA in the presence of TCR-specific factors (Dislodging assay) and to 
determine the fate of elongation complexes inhibited by the core TFIIH-XPA-XPG complex 




RNAP was transcribed into a CPD lesion as described in the section 4.10.7, only the DNA27 
(Table 12) contained a biotin tag on the 5’ terminus. The elongation complexes (15 pmol) 
were mixed with CsB (75 pmol) or CsB-CsA-DDB1-UVSSA complex (75 pmol) in a 70 μl 
reaction volume and final reaction conditions as follows: 100 mM NaCl, 20 mM NaOH-
HEPES pH 7.5, 6mM MgCl2, 10 % glycerol, 1 mM DTT, 0.2 mg/ml BSA, 2 mM PEP, 1 
mM ATP and pyruvate kinase (1 U/ml, Sigma). Reaction was incubated for 3 hrs at 37 °C, 
followed by the addition of 20 ul Dynabeads MyOne Streptavidine T1 (Invitrogen), pre-
blocked with 10 mg/ml BSA in the reaction buffer for 1 hr at 37 °C. The reaction mixture 
was incubated with the beads for 20 min at 37 °C while shaking. Beads were separated from 
the supernatant on a magnetic rack and resuspended in 20 μl reaction buffer supplemented 
with 5 mM CaCl2 and DNaseI (200 U/ml, New England Biolabs). The elution was performed 
at 37 °C for 30 min while shaking. The eluate was again separated from the beads on the 
magnetic rack. The supernatant and the eluate were analyzed on NuPAGE 4-12 % Bis – Tris 
Protein Gels (Invitrogen) and stained with InstantBlue (Sigma).  
 
Bead-based backtracking assay 
 
Elongation complexes were assembled as described in the section 4.10.6, only the DNA20 
(Table 12) was labelled with a 5’-terminal biotin. The elongation complexes (12 pmol) were 
mixed with 100 pmol of core TFIIH, 189 pmol XPG and 300 pmol XPA in a 70 ul reaction 
volume and final reaction conditions as follows: 20 mM NaCl, 80 nM KCl, 20 mM 
NaOH:HEPES pH 7.5, 6 mM MgCl2, 10 % glycerol, 1 mM DTT. Reaction was incubated 
for 10 min at 30 °C, followed by a 2 min incubation at 37 °C. Transcription was initiated by 
the addition of NTPs (final 0.2 mM GTP, CTP and UTP, 1 mM ATP) and the reaction was 
incubated for 20 min at 37 °C and stopped by placing on ice. Reaction was split in 3x 20 μl 
and each aliquot was mixed with 20 ul of ul Dynabeads MyOne Streptavidine T1 
(Invitrogen), which were blocked with 10 mg/ml BSA in the reaction buffer for 1 hr at 37 °C. 
Beads were shaken for 20 min at 37 °C and placed in a magnetic rack to separate the beads 
from the supernatant. The beads were washed 3 times with 100 μl of reaction buffer. After 
the wash, the first reaction was supplemented with 30 μl of washing buffer, the second 
reaction with 30 μl of washing buffer containing 40 nM TFIIS and the third reaction with 30 
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μl of washing buffer containing 40 nM TFIIS and 0.2 mM NTPs. Beads were incubated for 
2 min at 37 °C followed by supernatant removal on the magnetic rack. RNA was eluted by 
resuspending the beads in the washing buffer supplemented with 5 mM CaCl2 and DNaseI 
(200 U/ml, New England Biolabs) and incubation for 5 min at 37 °C. Supernatant was 
separated from the beads with the magnetic rack and mixed with 2x stop buffer (50 mM 
EDTA pH 8.0 and 7M urea in 1x TBE buffer). Reactions were digested with the Proteinase 
K (2 U/ml final, New England Biolabs) for 3 h at 37 °C. After the digestion, the reaction 
was heated up to 98 °C for 3 min and placed on ice. Reaction products were separated by 
20 % urea denaturing PAGE (section 4.5.3) and visualised with a Typhoon FLA 9500 (GE 
healthcare Life Sciences). 
 
4.10.9 Kinase activity assay  
 
We used the kinase activity assay to assess the activity of the kinase module variants 
containing CDK7:D137R or CDK7:T170A mutants. As CDK7 phosphorylates the C-
terminal domain of RNA polymerase II during transcription initiation, we used purified yeast 
RNA polymerase II296 dephosphorylated with lambda phosphatase during purification297 as 
a substrate in the assay. RNA polymerase II (50 nM final) was mixed with increasing 
concentrations of kinase module variants (30, 100, 220 and 500 nM final) in a final buffer 
conditions containing 100 mM KCl, 20 mM KOH:HEPES pH 7.5, 3 mM MgCl2, 5% 
glycerol and 5 mM β-mercaptoethanol, and preincubated for 2 min at 30 °C. Reactions were 
started by the addition of ATP (0.5 mM final) and quenched after 2 min at 30 °C with EDTA 
(100 mM) and 4X LDS buffer (Invitrogen). Reactions were run on 4-12% Bis-Tris gel in 
MOPS buffer (ThermoFisher Scientific) and transferred to nitrocellulose membranes (GE 
Healtcare Life Sciences). The membranes were blocked with 5% (w/v) milk in PBS buffer 
supplemented with 0.1% Tween 20 for 1h at room temperature. The membranes were treated 
with primary antibody (3E8, 1:25 dilution) in 0.25 % (w/v) milk in PBS supplemented with 
0.1 % Tween 20 and incubated at room temperature for 1 h. After several rounds of washing 
with PBS buffer supplemented with 0.1 % Tween 20, the membranes were incubated with 
HRP-conjugated anti-rat secondary antibody (1:5000 dilution, Sigma-Aldrich A9037) in 0.1 
% (w/v) milk in PBS supplemented with 0.1 % Tween 20 and incubated at room temperature 
for 1 h. Antibodies were detected with SuperSignal West Pico Chemiluminescent Substrate 
(ThermoFisher) and the membranes were scanned with ChemoCam Advanced Fluorescence 
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4.11 Synthesis of a CPD lesion and preparation of the CPD-containing 
DNA  
 
4.11.1 Organic synthesis of a CPD formacetal analogue 
 
Organic synthesis was performed by Jan Seikowski under the supervision of Dr. Vladimir 
Belov at the Max Planck Institute for Biophysical Chemistry. The synthesis of a CPD 
analogue in which the central phosphate is replaced with a formacetal bond (called CPD 
throughout the thesis) was synthesized as previously described298, with the following 
modifications: (i) for the detritylation of the building block B (Fig. 24) milder conditions 
were used – 20% HCOOH in dichloromethane/MeOH (10:6) at RT for 3h, (ii) for the 
cleavage of the 5’-O-pvaloyl and 3’-O-acetyl of the dimer, 0.15M sodium methoxide in 
MeOH (40°C for 10h) was used, followed by H+ ion exchange by Amberlite, (iii) for the 
tritylation of the deprotected dimer the reaction time was prolonged to 26h and 0.18eq 
DMAP was added as a catalyst and finally, (iv) for the preparation of the final 
phosphoramidite, dichloromethane was used as a solvent, instead of THF. The CPD 
analogue was incorporated into a short DNA fragment (DNA22, Table 12) by Jan Seikowski 
under the supervision of Prof. Claudia Höbartner (currently at the Institute for Organic 
Chemistry, University of Würzburg). 
 
4.11.2 Preparation of the CPD - containing DNA 
 
The short CPD-containing DNA (DNA22, Table 12) was extended on both sides by 
enzymatic ligation with two additional oligonucleotides for later application in transcription 
and backtracking assays. Enzymatic ligation was performed by annealing three DNA pieces 
to a complementary DNA split which brings DNA ends to be ligated in a close proximity 
and results in a formation of partial DNA duplex needed for the activity of the T4 DNA 
ligase. We annealed DNA21 (2 nmol), DNA22 (2 nmol), DNA23 (2 nmol) and DNA24 (2 
nmol) (Table 12) in water by heating the solution to 95 °C for 15 min followed by slow 
cooling to RT. Solution was supplemented with the T4 ligase buffer (NEB) and the T4 DNA 
ligase (5 units) and incubated at RT for 3 h. The reaction was quenched by the addition of 
2x STOP buffer (8 M urea in TBE buffer) and heated to 95 °C for 3 min. Ligation products 
were separated by denaturing urea PAGE (section 4.5.3) and visualized under UV–light. The 
full-length ligation product was excised from the gel with a scalpel. The gel slice was 
crushed by passing through a syringe, and the gel pieces were incubated in water overnight 
at 4 °C while shaking to extract the DNA. After the overnight incubation, the gel suspension 
was centrifuged and the supernatant was supplemented with potassium acetate (0.3 M, pH 
5.2) and 2 volumes of ice-cold ethanol. Solution was incubated at -20 °C for 2 h and the 
precipitated DNA was pelleted by centrifugation. The DNA pellet was washed with 500 ul 
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of 70% ice-cold ethanol, resuspended in ddH20, flash-frozen in liquid nitrogen and stored at 
-80 °C. 
 
4.12 Mass-spectrometric identification of crosslinking sites  
 
4.12.1 Sample preparation 
 
The XPC-Rad23b-core TFIIH-XPA-DNA complex (Fig. 9) was assembled as described in 
the section 4.13.1, only the complex was purified by the Superose 6 increase 3.2/300 column 
(GE Healthcare). The core TFIIH-XPA-XPG-DNA complex (Fig. 23) was assembled as 
described in the section 4.14.1, only the complex was purified by the Superose 6 increase 
3.2/300 column (GE Healthcare). The RNAP-UVSSA-CsB-CsA-DDB1 complex (Fig. 26) 
was assembled by transcribing the RNAP into a CPD lesion as described in the section 4.10.7, 
followed by the addition of the 1.5 molar excess of UVSSA, CsB and CsA-DDB1 over the 
RNAP in the assembly buffer containing 100 mM NaCl, 20 mM KOH:HEPES pH 7.5, 2 
mM MgCl2, 5% glycerol and 5 mM β-mercaptoethanol. The complex was purified by 
Superose 6 increase 3.2/300 column (GE Healthcare) equilibrated in the complex assembly 
buffer. The RNAP-core TFIIH-XPA-XPG complex (Fig. 33) was formed by first 
transcribing RNAP (100 pmol) into a CPD lesion as described in the section 4.10.7, followed 
by incubation with the core TFIIH (250 pmol), XPG (250 pmol) and XPA (250 pmol) at 30 
oC for 30 min in the final buffer containing 200 KCl, 20 mM KOH-HEPES pH 7.5, 10% 
glycerol, 6 mM MgCl2, 1 mM DTT and 2 mM ATP. The complex was purified by the 
Superose 6 increase 3.2/300 column equilibrated in buffer containing 200 KCl, 20 mM 
KOH-HEPES pH 7.5, 10% glycerol, 2mM MgCl2 and 1 mM DTT. For all complexes, the 
fractions from the size-exclusion chromatography were analyzed by SDS-PAGE and the 
fractions containing the complex of interest were pulled and crosslinked with BS3 (Thermo 
Fisher Scientific; 1mM final, 30 min at 30 oC). The crosslinking reaction was quenched with 
ammonium bicarbonate (100 mM final, 10 min at 30 oC) and the sample was processed for 
the mas-spectrometric analysis as describe below.  
 
4.12.2 Mass spectrometry  
 
All mass-spectrometry experiments were performed by Aleksandar Chernev under the 
supervision of Prof. Henning Urlaub at the Max Planck Institute for Biophysical Chemistry. 
Crosslinked proteins were in-solution digested, fractionated and analyzed as previously 
described295. Shortly – the sample was reduced with 10 mM dithiothreitol and alkylated with 
40 mM iodoacetamide, followed by overnight digestion with trypsin (1:20 w/w) at 37 oC in 
the presence of 1M urea. The digested peptides were purified by reverse phase C18 
chromatography and fractionated on a Superdex Peptide PC3.2/30 column (GE Healthcare) 
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with a flow rate of 50 µl/min 30% ACN, 0.1% trifluoroacetic acid (TFA) (v/v). 100 µl 
fractions were collected and analyzed over two hour gradient on Orbitrap Fusion Tribrid 
Mass Spectrometer (Thermo Scientific) with 120,000 resolution for survey scans and 30,000 
resolution of fragment spectra. Protein-protein crosslinks were identified with pLink 1.23299. 
Cross-linking figures were created with XiNet300 and Xlink Analyzer222. 
 
4.13 Negative stain electron microscopy of the XPC-Rad23b-core TFIIH-
XPA-DNA complex 
 
4.13.1 Complex formation 
 
The complex formation and the negative stain electron microscopy (section 4.13.2) were 
performed by my former master student Kristina Stakyte, under my supervision. DNA 
scaffold was prepared by annealing DNA4 (Table 12; 50 uM final) and DNA5 (Table 12; 50 
uM final) in water by heating the solution to 95 °C and slowly cooling to 4 °C in a 
thermocycler. Annealed DNA (250 pmol) was mixed with XPC-Rad23b (200 pmol) and 
incubated on ice for 20 min and at RT for 10 min. XPC-Rad23b-DNA complex was mixed 
with the core TFIIH (160 pmol) and XPA (400 pmol) in a final buffer containing 200 mM 
KCl, 20 mM KOH:HEPES pH 7.5, 2 mM MgCl2, 5 mM β-mercaptoethanol and 10 % 
glycerol (v/v). The reaction was incubated for 30 min on ice before in was loaded onto a 
sucrose gradient supplemented with glutaraldehyde, as previously described197. The sucrose 
gradient was prepared with BioComp Gradient Master 108 (BioComp Instruments) by 
mixing equal volume of heavy (30 % (w/v) sucrose, 150 mM KCl, 2 mM MgCl2, 5 mM β-
mercaptoethanol, 20 mM KOH-HEPES pH 7.5 and 0.1 % glutaraldehyde) and light solutions 
(10 % (w/v) sucrose, 150 mM KCl, 2 mM MgCl2, 5 mM β-mercaptoethanol and 20 mM 
KOH-HEPES pH 7.5) in 5 ml centrifugation tubes. After 16 h of centrifugation at 4°C and 
175, 000 xg the gradient was fractionated, and glutaraldehyde was quenched with lysine (50 
mM final). Fractions were analysed by SDS-PAGE and Coomassie staining. In parallel, the 
same sample was subjected to sucrose gradient centrifugation but in the absence of 
glutaraldehyde, to monitor the migration of the complex in the gradient.  
 
4.13.2 Negative staining and electron microscopy  
 
Quenched fractions from the sucrose gradient were directly used for negative staining. The 
staining solution was prepared by dissolving uranyl formate (2 % w/v) in double distilled 
water. Solution was vortexed for 15 min and centrifugated for 30 min at full-speed and 4 °C 
to remove any remaining uranyl formate precipitates. The staining solution was kept on ice 
and protected from light. Carbon coated copper mesh grids (S160-4, Plano) were glow-
discharged (30 s, 25 mA, 0.39 mbar) by using a PELCO easiGlow System (Ted Pella). 4 μl 
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of sample was incubated on a grid for various amounts of time to allow the particle 
adsorption on the carbon foil. Grids were first washed by floating on top of a double-distilled 
water droplet to remove access sucrose, followed by incubation on 3 consecutive droplets 
containing uranyl formate solution for 30 s. The excess stain was removed by blotting the 
EM grid with a filter paper and the sample was left to dry at RT protected from light. Images 
of the grids were acquired at RT in a CM200 FEG microscope (Philips) operated at 160 kV 
using a 4k x 4k CCD camera (TVIPS) with a two-fold binning of pixels. Images were 
acquired at a nominal magnification of 88 000x (2.51 Å / pix) with a defocus values ranging 
for -0.5 to -2.5 μm. Particles were picked semi-automatically using the EMAN2 software301. 
Subsequent image processing steps, including CTF correction, 2D and 3D-classifications 
and 3D refinements were performed with the RELION 2.0 package302,303.  
  
4.14 TFIIH-XPA-DNA structure determination 
 
4.14.1 Sample preparation 
 
Sample was prepared by mixing the pre-annealed DNA scaffold (DNA28 and DNA29; Table 
12) with core TFIIH, XPA and XPG(E791A) in 1.5:1:3:3 molar ratio in final buffer 
containing 150 mM KCl, 20 mM KOH:HEPES pH 7, 10 % glycerol, 2 mM MgCl2 and 5 
mM β-mercaptoethanol. XPG:E791A endonuclease mutant107 was used to prevent DNA 
cleavage during the sample preparation. The sample mixture was applied to a sucrose 
gradient in order to purify the complex from excess factors and fix it with glutaraldehyde, 
as previously described197. The sucrose gradient was prepared with BioComp Gradient 
Master 108 (BioComp Instruments) by mixing equal volume of heavy (30 % (w/v) sucrose, 
150 mM KCl, 2 mM MgCl2, 5 mM β-mercaptoethanol, 20 mM KOH-HEPES pH 7.5 and 
0.1 % glutaraldehyde) and light solutions (10 % (w/v) sucrose, 150 mM KCl, 2 mM MgCl2, 
5 mM β-mercaptoethanol and 20 mM KOH-HEPES pH 7.5) in 5 ml centrifugation tubes. 
After 16 h of centrifugation at 4°C and 175, 000 xg the gradient was fractionated and 
glutaraldehyde was quenched with lysine (50 mM final) and aspartate (20 mM final). 
Fractions were dialysed in Slide-A-Lyzer MINI Dialysis Devices (2ml and 20 kDa cut-off) 
(ThermoFisher Scientific) for 10 h against buffer containing 100 mM KCl, 20 mM KOH-
HEPES pH 7.5, 1 mM MgCl2, 1 mM DTT, 0.5% glycerol (v/v) and 0.004% n-octyl 
glucoside (w/v). Dialysed samples were immediately used for cryo-grid preparation. 4 ul of 
sample was applied to glow-discharged R2/2 gold grids (Quantifoil) which were blotted for 
5 s and plunge-frozen in liquid ethane with a Vitrobot Mark IV (FEI) operated at 4 °C and 
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4.14.2 Cryo-electron microscopy and image processing 
 
Micrographs of the sample were acquired on a FEI Titan Krios G2 transmission electron 
microscope with a K2 summit direct electron detector (Gatan). Data acquisition was 
automated with FEI EPU software package. Micrographs were acquired at a nominal 
magnification of 130,000x (1.05 Å per pixel) using a dose rate of 4.55 e- per Å2 per s over 
the time of 9 s which resulted in a total dose of 41 e- per Å2 fractionated over 40 frames. 
CTF correction, motion correction and particle picking was done on-the-fly using Warp205. 
Automated picking in retrained BoxNet implemented in Warp205 yielded a total of 1,354,997 
particles from 8,993 micrographs, which were further subjected to 2D classification in 
CryoSPARC206. After 2D cleaning, 950,000 particles were used for heterogeneous 
refinement in CryoSPARC. Three ab-initio classes obtained from the first 300,000 particles 
picked during data acquisition were used as an input for the refinement. The class showing 
clear core TFIIH features was further 3D classified into 6 classes using RELION-3207. 
Particles corresponding to the best 3D class were subjected to CTF refinement and Bayesian 
polishing. Particles were 3D refined and post-processed with automatic B-factor 
determination in RELION. Final map showed an overall resolution of 3.6 Å according to the 
gold-standard Fourier shell correlation (FSC) 0.143 criterion with an applied B-factor of -
110.02 Å-2. Due to flexibility of peripheral regions of core TFIIH, we improved the map 
quality for 5 different regions of the complex by focused 3D classification and refinement. 
The classifications were performed with particles contributing to the final map without 
image alignment to speed up the calculations. Masks encompassing the regions of interest 
were created with UCSF Chimera210 and RELION. 3D classification of the DNA duplex 
revealed two alternative DNA conformations within the complex. 
 
4.14.3 Model building  
 
The final cryo-EM map and focused classified maps were used for model building. The final 
map was denoised in Warp 1.0.6205. Structures of ATPase lobe 1 and 2 of XPB, XPD, p44 
vWA-like domain and p52 C-terminus (residues 383-458) from the TFIIH structure (PDB 
core 5OF4)182, as well as the crystal structure of p34 vWA-like domain bound to p44 RING 
domain (PDB code 5O85)189 were rigid-body fitted into our cryo-EM density in UCSF 
Chimera210 and manually adjusted in COOT304. Due to high quality of the EM density, the 
NTE domain and part of the DRD domain (residues 71-199 and 266-300), as well as the p52 
region that interacts with XPB (residues 290-382) were built de novo guided by secondary 
structure prediction in PSIPRED305 and bulky amino acid side chains as sequence registers. 
In case of XPD we did not observe EM density corresponding to residues 273-325, so we 
removed this part of the structure. We observed a very strong density for the iron-sulphur 
cluster indicating that the ligand was not damaged or dissociated during protein expression 
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and purification, as well as sample preparation for cryo-EM. The N-terminal region of p52 
(residues 18-289) and zinc-fingers belonging to subunits p34 and p44 were modelled with 
SWISS-Model306,307 based on the yeast p52 counterpart (PDB code 5OQJ)70 and manually 
adjusted in COOT. Interestingly, the p34 zinc finger region in human contains additional 
cysteine (C257) and histidine (H258) residues not present in the yeast counterpart which 
allows binding of an additional zinc ion. The smallest TFIIH subunit TTDA (p8) was 
generated in Modeller308 with the yeast TTDA structure as a reference (PDB code 5OQJ)70, 
rigid-body fitted in our density using UCSF Chimera and manually adjusted in COOT. The 
NMR structure of truncated human XPA (PDB code 1XPA)92 was also docked in our density 
as a rigid body and adjusted in COOT. We observed additional helical density that extends 
from the C-terminus of the docked structure towards the ATPase lobe 2 of XPB when the 
map is filtered to lower resolution. Secondary structure prediction with PSIPRED shows that 
the 22 residues that follow the docked XPA C-terminus form a helix, so we extended the C-
terminal helix in COOT guided by the cryo-EM density.  
DNA sequence was assigned based on the position of the DNA duplex-single strand 
junction, however protein binding to the junction could induce additional DNA melting so 
register shifts cannot be excluded. DNA duplex was built by docking ideal B-DNA into the 
density, followed by manual adjustments in COOT. Several rounds of real space refinement 
and geometry optimization with secondary structure restraints (including base pairing and 
base stacking restrains) were performed in PHENIX208. The DNA duplex-single strand 
junction and single-strand extensions were manually built in COOT. The EM density for the 
5’-3’ DNA single strand showed clear separation of sugar, phosphate and DNA bases for 
nucleotides A30-G36 and for C40-A41. The decreased quality of EM map for nucleotides 
G37-A39 and T42, presumably due to increased flexibility of DNA between XPD helicase 
lobes, allowed the trajectory of DNA to be determined, but the nucleotides were positioned 
manually in COOT guided by the structure of NS3 helicase in complex with DNA309 and 
real space refined in PHENIX. All core TFIIH subunits, XPA and DNA were first real-space 
refined in PHENIX separately in their corresponding focused classified maps. Then, all 
components were combined and real-space refined together in the global map. The final 
model was validated using Molprobity310 (Supplemental Table 5) and showed a score of 2.24. 
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5. SUPPLEMENTARY MATERIALS 
The first four Supplementary Tables contain the crosslinking data. Only the inter-subunit 
crosslinking sites with the score above three are provided and the complete list of sites is 
available upon request. Also, if a crosslinking site was detected more than once, the highest 
score for the site is provided in the table. P1, protein1; P2, protein 2; R1, residue in protein 
1; R2, residue in protein 2, S, score.  
 
Supplemental Table 1 | Core TFIIH-XPA-XPC-Rad23b crosslinking data. 
P1 P2 R1 R2 S P1 P2 R1 R2 S 
XPD p44 751 190 6,94 Rad23 XPC 51 469 11,17 
XPD p62 634 293 3,87 Rad23 XPC 14 469 14,29 
XPD p62 96 365 5,1 p62 p34 378 125 5,74 
XPD p62 370 38 8,45 p62 p34 365 125 7,52 
XPD p62 113 293 8,84 p62 p34 370 125 10,59 
XPD p62 128 38 10,23 p62 p34 353 125 13,75 
XPD p62 603 293 13,31 p62 p44 378 40 5,18 
XPD XPA 370 63 6,38 p62 p44 252 126 5,48 
XPD XPB 181 145 5,57 p62 p44 370 190 5,88 
XPD XPC 634 913 5 p62 p44 365 190 6,65 
XPC p52 917 77 7,83 p62 p44 38 190 7,37 
XPC p62 72 38 5,44 p62 p44 504 126 11,68 
XPC p62 77 38 7,11 p62 p44 489 126 13,28 
XPC p62 113 38 7,66 p62 p52 547 552 4,28 
XPC p62 108 38 11,98 p62 XPC 38 72 5,44 
XPC Rad23 477 51 4,42 p62 XPC 114 113 6,1 
XPC Rad23 469 14 14,29 p62 XPD 275 128 6,58 
XPC XPA 853 236 9,79 p62 XPD 293 113 8,84 
XPC XPB 913 529 6,89 p62 XPD 38 128 10,23 
XPC XPD 913 634 5 p62 XPD 353 113 15,13 
XPB p44 549 77 8,37 p52 p62 452 547 4,28 
XPB p44 601 77 10,36 p52 XPA 140 224 7,32 
XPB p52 16 140 9,73 p52 XPB 150 16 4,37 
XPB p52 706 438 11,53 p52 XPB 140 16 9,73 
XPB TTDA 767 31 5,1 p52 XPB 438 706 11,53 
XPB TTDA 526 71 9,25 p52 XPC 77 917 7,83 
XPB XPA 399 157 6,45 p52 XPC 81 917 14,59 
XPB XPA 569 224 7,59 p44 p34 190 198 7,63 
XPB XPC 529 913 6,89 p44 p34 126 149 8,79 
XPB XPD 145 181 5,57 p44 p34 193 298 9,36 
XPA p52 224 140 7,32 p44 p34 388 125 14,61 
XPA XPB 157 399 6,45 p44 p62 40 378 5,18 
XPA XPB 224 569 7,59 p44 p62 23 305 5,3 
XPA XPC 236 853 9,79 p44 p62 126 252 5,48 
                                                                       SUPPLEMENTARY MATERIALS                                              
 
 108 
XPA XPD 86 370 6,06 p44 p62 190 38 7,37 
XPA XPD 63 370 6,38 p44 XPB 77 549 8,37 
TTDA p52 1 453 4,8 p44 XPD 190 751 6,94 
TTDA p52 2 453 9,8 p34 p44 298 190 7,63 
TTDA XPB 31 767 5,1 p34 p44 149 126 8,79 
TTDA XPB 71 526 9,25 p34 p44 125 388 14,61 
Rad23 XPC 36 469 5,26 p34 p62 125 353 13,75 
Rad23 XPC 63 469 8,13 Rad23 XPC 34 469 8,37 
 
Supplemental Table 2 | Core TFIIH-XPA-XPG crosslinking data. 
P1 P 2 R1 R2 S P1 P 2 R1 R2 S 
XPG XPD 1120 268 3,42 XPD p62 128 38 6,69 
XPG XPD 1011 128 3,47 XPD p62 181 296 7,74 
XPG XPD 154 603 3,71 XPD p62 113 305 9,64 
XPG XPD 1011 268 3,77 XPD p44 751 193 4,84 
XPG XPD 433 370 3,78 XPD p44 751 40 7,15 
XPG XPD 64 370 3,93 XPD p44 751 190 9,05 
XPG XPD 274 634 4,02 XPD p44 751 23 11,78 
XPG XPD 498 370 4,25 XPB XPG 715 1011 3,19 
XPG XPD 120 268 4,28 XPB XPG 549 1011 3,39 
XPG XPD 274 268 4,64 XPB XPG 688 1011 3,73 
XPG XPD 163 113 4,72 XPB XPG 569 1011 4,16 
XPG XPD 1071 370 4,72 XPB XPG 52 1071 4,20 
XPG XPD 438 268 5,06 XPB XPG 142 1120 4,97 
XPG XPD 120 113 5,30 XPB XPG 52 1120 6,21 
XPG XPD 433 268 5,33 XPB XPG 142 1071 6,53 
XPG XPD 392 370 5,44 XPB XPG 44 1071 6,92 
XPG XPD 913 128 5,56 XPB XPG 688 1004 8,04 
XPG XPD 293 370 5,78 XPB XPG 549 1004 8,41 
XPG XPD 154 128 5,81 XPB XPG 476 274 8,61 
XPG XPD 274 128 5,88 XPB XPG 222 1071 10,08 
XPG XPD 172 341 6,13 XPB XPG 526 1071 11,02 
XPG XPD 126 341 6,13 XPB XPG 688 1071 18,48 
XPG XPD 126 370 6,15 XPB XPD 44 89 3,10 
XPG XPD 120 341 6,82 XPB XPD 569 82 4,83 
XPG XPD 120 370 6,99 XPB XPD 601 507 8,06 
XPG XPD 172 128 7,08 XPB XPD 311 113 12,49 
XPG XPD 163 128 7,29 XPB XPA 715 224 3,04 
XPG XPD 95 181 7,46 XPB XPA 222 67 3,34 
XPG XPD 433 274 7,69 XPB XPA 569 236 3,75 
XPG XPD 104 128 7,97 XPB XPA 217 188 5,14 
XPG XPD 213 128 8,09 XPB XPA 569 224 6,06 
XPG XPD 120 181 8,51 XPB XPA 526 236 7,78 
                                                                       SUPPLEMENTARY MATERIALS                                              
 
 109 
XPG XPD 154 268 9,57 XPB XPA 399 157 9,96 
XPG XPD 126 128 9,61 XPB TTDA 44 71 3,01 
XPG XPD 172 268 9,97 XPB TTDA 526 31 3,15 
XPG XPD 1004 128 10,14 XPB TTDA 526 71 12,42 
XPG XPD 293 341 10,57 XPB TTDA 476 71 13,40 
XPG XPD 498 268 10,66 XPB p52 16 140 4,73 
XPG XPD 95 341 11,67 XPB p52 706 438 4,97 
XPG XPD 120 128 12,57 XPB p52 16 150 5,93 
XPG XPD 274 341 13,02 XPB p52 526 438 8,06 
XPG XPD 95 268 13,53 XPB p44 142 23 7,03 
XPG XPD 104 341 16,01 XPB p44 476 306 10,74 
XPG XPD 126 268 17,74 XPB p44 601 77 12,53 
XPG XPB 1011 715 3,19 XPB p44 577 77 12,86 
XPG XPB 1011 549 3,39 XPB p44 549 77 16,85 
XPG XPB 1011 688 3,73 XPA XPG 236 1011 3,34 
XPG XPB 1011 569 4,16 XPA XPG 236 1004 7,63 
XPG XPB 1071 52 4,20 XPA XPD 86 692 3,92 
XPG XPB 1120 142 4,97 XPA XPD 67 370 4,37 
XPG XPB 1120 52 6,21 XPA XPD 86 370 5,25 
XPG XPB 1071 142 6,53 XPA XPD 89 370 6,02 
XPG XPB 1071 44 6,92 XPA XPD 63 370 6,17 
XPG XPB 1004 688 8,04 XPA XPD 167 634 6,94 
XPG XPB 1004 549 8,41 XPA XPB 224 715 3,04 
XPG XPB 274 476 8,61 XPA XPB 67 222 3,34 
XPG XPB 1071 222 10,08 XPA XPB 236 569 3,75 
XPG XPB 1071 526 11,02 XPA XPB 188 217 5,14 
XPG XPB 1071 688 18,48 XPA XPB 224 569 6,06 
XPG XPA 1011 236 3,34 XPA XPB 236 526 7,78 
XPG XPA 1004 236 7,63 XPA XPB 157 399 9,96 
XPG TTDA 1071 31 4,76 XPA p52 224 140 4,59 
XPG p62 1011 535 3,17 XPA p52 236 438 6,89 
XPG p62 120 504 3,83 XPA p52 259 438 25,74 
XPG p62 1004 114 4,02 TTDA XPG 31 1071 4,76 
XPG p62 952 504 4,58 TTDA XPB 71 44 3,01 
XPG p62 498 38 5,70 TTDA XPB 31 526 3,15 
XPG p62 938 38 5,76 TTDA XPB 71 526 12,42 
XPG p62 754 38 7,49 TTDA XPB 71 476 13,40 
XPG p62 95 38 9,74 TTDA p52 6 456 3,94 
XPG p52 1011 81 3,11 TTDA p52 2 456 7,41 
XPG p52 1071 459 3,22 p62 XPG 535 1011 3,17 
XPG p52 392 459 4,10 p62 XPG 504 120 3,83 
XPG p52 1120 127 4,66 p62 XPG 114 1004 4,02 
XPG p52 1011 438 4,93 p62 XPG 504 952 4,58 
XPG p52 1120 140 5,10 p62 XPG 38 498 5,70 
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XPG p52 1071 127 6,27 p62 XPG 38 938 5,76 
XPG p52 952 77 6,74 p62 XPG 38 754 7,49 
XPG p52 1134 127 7,18 p62 XPG 38 95 9,74 
XPG p52 1123 127 8,84 p62 XPD 305 181 4,10 
XPG p52 1004 81 8,87 p62 XPD 240 128 6,47 
XPG p52 1004 77 9,71 p62 XPD 38 128 6,69 
XPG p52 1004 438 9,92 p62 XPD 296 181 7,74 
XPG p52 1134 140 12,87 p62 XPD 305 113 9,64 
XPG p52 1071 77 14,39 p62 p52 38 77 12,85 
XPG p44 95 110 4,24 p62 p44 353 190 3,35 
XPG p44 1011 126 4,27 p62 p44 38 190 7,16 
XPG p44 1004 110 6,68 p62 p34 365 125 4,66 
XPG p44 1004 126 8,01 p62 p34 370 125 7,44 
XPG p34 1011 125 3,44 p62 p34 353 125 17,68 
XPG p34 1120 125 5,24 p52 XPG 81 1011 3,11 
XPG p34 1120 74 5,60 p52 XPG 459 1071 3,22 
XPG p34 1071 125 6,21 p52 XPG 459 392 4,10 
XPG p34 1123 125 9,59 p52 XPG 127 1120 4,66 
XPD XPG 268 1120 3,42 p52 XPG 438 1011 4,93 
XPD XPG 128 1011 3,47 p52 XPG 140 1120 5,10 
XPD XPG 603 154 3,71 p52 XPG 127 1071 6,27 
XPD XPG 268 1011 3,77 p52 XPG 77 952 6,74 
XPD XPG 370 433 3,78 p52 XPG 127 1134 7,18 
XPD XPG 370 64 3,93 p52 XPG 127 1123 8,84 
XPD XPG 634 274 4,02 p52 XPG 81 1004 8,87 
XPD XPG 370 498 4,25 p52 XPG 77 1004 9,71 
XPD XPG 268 120 4,28 p52 XPG 438 1004 9,92 
XPD XPG 268 274 4,64 p52 XPG 140 1134 12,87 
XPD XPG 113 163 4,72 p52 XPG 77 1071 14,39 
XPD XPG 370 1071 4,72 p52 XPB 140 16 4,73 
XPD XPG 268 438 5,06 p52 XPB 438 706 4,97 
XPD XPG 113 120 5,30 p52 XPB 150 16 5,93 
XPD XPG 268 433 5,33 p52 XPB 438 526 8,06 
XPD XPG 370 392 5,44 p52 XPA 140 224 4,59 
XPD XPG 128 913 5,56 p52 XPA 438 236 6,89 
XPD XPG 370 293 5,78 p52 XPA 438 259 25,74 
XPD XPG 128 154 5,81 p52 TTDA 456 6 3,94 
XPD XPG 128 274 5,88 p52 TTDA 456 2 7,41 
XPD XPG 341 172 6,13 p52 p62 77 38 12,85 
XPD XPG 341 126 6,13 p52 p34 140 100 3,04 
XPD XPG 370 126 6,15 p52 p34 127 100 6,56 
XPD XPG 341 120 6,82 p52 p34 140 97 8,67 
XPD XPG 370 120 6,99 p52 p34 127 97 22,96 
XPD XPG 128 172 7,08 p44 XPG 110 95 4,24 
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XPD XPG 128 163 7,29 p44 XPG 126 1011 4,27 
XPD XPG 181 95 7,46 p44 XPG 110 1004 6,68 
XPD XPG 274 433 7,69 p44 XPG 126 1004 8,01 
XPD XPG 128 104 7,97 p44 XPD 193 751 4,84 
XPD XPG 128 213 8,09 p44 XPD 40 751 7,15 
XPD XPG 181 120 8,51 p44 XPD 190 751 9,05 
XPD XPG 268 154 9,57 p44 XPD 23 751 11,78 
XPD XPG 128 126 9,61 p44 XPB 23 142 7,03 
XPD XPG 268 172 9,97 p44 XPB 306 476 10,74 
XPD XPG 128 1004 10,14 p44 XPB 77 601 12,53 
XPD XPG 341 293 10,57 p44 XPB 77 577 12,86 
XPD XPG 268 498 10,66 p44 XPB 77 549 16,85 
XPD XPG 341 95 11,67 p44 p62 190 353 3,35 
XPD XPG 128 120 12,57 p44 p62 190 295 4,47 
XPD XPG 341 274 13,02 p44 p62 190 38 7,16 
XPD XPG 268 95 13,53 p44 p62 388 122 14,92 
XPD XPG 341 104 16,01 p34 XPG 125 1011 3,44 
XPD XPG 268 126 17,74 p34 XPG 125 1120 5,24 
XPD XPB 89 44 3,10 p34 XPG 74 1120 5,60 
XPD XPB 82 569 4,83 p34 XPG 125 1071 6,21 
XPD XPB 507 601 8,06 p34 XPG 125 1123 9,59 
XPD XPB 113 311 12,49 p34 p62 125 365 4,66 
XPD XPA 692 86 3,92 p34 p62 125 370 7,44 
XPD XPA 370 67 4,37 p34 p62 125 353 17,68 
XPD XPA 370 86 5,25 p34 p52 100 140 3,04 
XPD XPA 370 89 6,02 p34 p52 100 127 6,56 
XPD XPA 370 63 6,17 p34 p52 97 140 8,67 
XPD XPA 634 167 6,94 p34 p52 97 127 22,96 
XPD p62 181 305 4,10 p34 p44 298 190 4,47 




Supplemental Table 3 | RNAP-CsB-CsA-DDB1-UVSSA crosslinking data. 
P1 P2 R1 R2 S P1 P2 R1 R2 S 
CsA CsB 85 1327 9,19 Rpb10 Rpb3 37 171 7,10 
CsA CsB 167 650 10,54 Rpb10 Rpb3 47 225 9,94 
CsA CsB 167 804 9,05 Rpb10 Rpb3 110 2 6,94 
CsA CsB 167 1216 6,38 Rpb10 Rpb3 110 81 10,61 
CsA CsB 167 1363 7,07 Rpb10 Rpb3 112 20 5,64 
CsA CsB 167 1487 12,71 Rpb10 UVSSA 1 652 1,62 
CsA CsB 174 1392 14,80 Rpb2 CsB 326 324 7,95 
CsA CsB 212 131 11,49 Rpb2 CsB 409 131 11,19 
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CsA CsB 212 462 14,01 Rpb2 CsB 417 181 9,55 
CsA CsB 212 783 14,00 Rpb2 CsB 437 170 10,70 
CsA CsB 212 804 7,22 Rpb2 CsB 504 324 6,27 
CsA CsB 212 1156 9,57 Rpb2 Rpb1 288 796 6,25 
CsA CsB 212 1360 8,37 Rpb2 Rpb1 288 1133 4,15 
CsA CsB 212 1363 17,46 Rpb2 Rpb1 288 1135 4,31 
CsA CsB 212 1489 5,49 Rpb2 Rpb1 326 1219 10,64 
CsA CsB 233 131 4,59 Rpb2 Rpb1 341 149 11,20 
CsA CsB 233 170 12,12 Rpb2 Rpb1 341 213 11,98 
CsA CsB 233 462 6,86 Rpb2 Rpb1 341 1008 4,61 
CsA CsB 233 804 5,04 Rpb2 Rpb1 409 550 5,62 
CsA DDB1 233 191 14,18 Rpb2 Rpb1 498 285 11,91 
CsA DDB1 233 204 4,92 Rpb2 Rpb1 535 331 9,81 
CsA UVSSA 34 129 15,85 Rpb2 Rpb1 535 337 14,53 
CsA UVSSA 34 130 7,01 Rpb2 Rpb1 571 149 13,99 
CsA UVSSA 85 129 7,52 Rpb2 Rpb1 571 346 10,94 
CsA UVSSA 167 339 11,71 Rpb2 Rpb1 571 796 10,10 
CsA UVSSA 167 491 9,88 Rpb2 Rpb1 571 853 7,97 
CsA UVSSA 212 334 10,08 Rpb2 Rpb1 571 1125 17,50 
CsA UVSSA 212 362 13,99 Rpb2 Rpb1 571 1132 10,66 
CsA UVSSA 212 379 9,39 Rpb2 Rpb1 571 1133 13,41 
CsA UVSSA 212 491 15,47 Rpb2 Rpb1 571 1135 11,24 
CsA UVSSA 212 523 6,55 Rpb2 Rpb1 574 1135 4,87 
CsA UVSSA 212 616 6,18 Rpb2 Rpb1 892 213 7,69 
CsA UVSSA 233 491 4,86 Rpb2 Rpb1 892 346 8,23 
CsA UVSSA 292 143 14,79 Rpb2 Rpb1 898 213 7,53 
CsA UVSSA 335 143 20,44 Rpb2 Rpb1 898 279 5,18 
CsB CsA 131 212 11,49 Rpb2 Rpb1 898 285 11,59 
CsB CsA 131 233 4,59 Rpb2 Rpb1 898 331 12,98 
CsB CsA 170 233 12,12 Rpb2 Rpb1 898 337 6,14 
CsB CsA 462 212 14,01 Rpb2 Rpb1 898 346 5,99 
CsB CsA 462 233 6,86 Rpb2 Rpb1 1019 853 10,36 
CsB CsA 650 167 10,54 Rpb2 Rpb1 1220 1 10,21 
CsB CsA 783 212 14,00 Rpb2 Rpb1 1220 32 12,19 
CsB CsA 804 167 9,05 Rpb2 Rpb1 1220 279 6,99 
CsB CsA 804 212 7,22 Rpb2 Rpb1 1220 285 8,66 
CsB CsA 804 233 5,04 Rpb2 Rpb1 1220 417 11,79 
CsB CsA 1156 212 9,57 Rpb2 Rpb1 1220 445 4,73 
CsB CsA 1216 167 6,38 Rpb2 Rpb3 966 166 3,92 
CsB CsA 1327 85 9,19 Rpb2 Rpb3 1019 199 1,51 
CsB CsA 1360 212 8,37 Rpb2 Rpb4 287 137 8,21 
CsB CsA 1363 167 7,07 Rpb2 Rpb4 291 137 17,23 
CsB CsA 1363 212 17,46 Rpb2 Rpb4 535 75 4,47 
CsB CsA 1392 174 14,80 Rpb2 Rpb7 1220 153 9,74 
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CsB CsA 1487 167 12,71 Rpb2 Rpb7 1220 163 7,97 
CsB CsA 1489 212 5,49 Rpb2 Rpb9 707 92 10,99 
CsB DDB1 1360 1060 3,57 Rpb2 UVSSA 288 679 11,00 
CsB DDB1 1363 150 3,20 Rpb2 UVSSA 291 679 12,07 
CsB DDB1 1363 1060 3,26 Rpb2 UVSSA 325 662 4,62 
CsB Rpb1 311 139 4,26 Rpb2 UVSSA 326 647 6,98 
CsB Rpb1 448 212 6,56 Rpb2 UVSSA 326 662 15,37 
CsB Rpb1 470 1132 0,87 Rpb2 UVSSA 326 679 11,21 
CsB Rpb11 609 62 4,41 Rpb2 UVSSA 966 616 6,69 
CsB Rpb2 131 409 11,19 Rpb3 CsB 155 292 4,49 
CsB Rpb2 170 437 10,70 Rpb3 CsB 155 316 6,83 
CsB Rpb2 181 417 9,55 Rpb3 Rpb10 155 67 14,09 
CsB Rpb2 324 326 7,95 Rpb3 Rpb11 2 110 6,94 
CsB Rpb2 324 504 6,27 Rpb3 Rpb11 20 112 5,64 
CsB Rpb3 292 155 4,49 Rpb3 Rpb11 81 110 10,61 
CsB Rpb3 316 155 6,83 Rpb3 Rpb11 167 37 5,28 
CsB UVSSA 333 647 4,96 Rpb3 Rpb11 171 37 7,10 
CsB UVSSA 337 647 6,94 Rpb3 Rpb11 225 47 9,94 
CsB UVSSA 448 362 10,58 Rpb3 Rpb2 166 966 3,92 
CsB UVSSA 448 616 7,24 Rpb3 Rpb2 199 1019 1,51 
CsB UVSSA 448 647 6,10 Rpb3 Rpb8 199 20 11,63 
CsB UVSSA 650 334 5,62 Rpb4 DDB1 137 570 6,56 
CsB UVSSA 650 491 6,34 Rpb4 Rpb1 91 1132 5,07 
CsB UVSSA 783 362 5,83 Rpb4 Rpb2 75 535 4,47 
CsB UVSSA 783 491 6,69 Rpb4 Rpb2 137 287 8,21 
CsB UVSSA 804 377 16,58 Rpb4 Rpb2 137 291 17,23 
CsB UVSSA 804 379 16,57 Rpb4 Rpb7 94 155 11,23 
CsB UVSSA 804 491 4,93 Rpb4 UVSSA 75 142 3,32 
CsB UVSSA 804 523 4,83 Rpb5 Rpb1 12 125 3,83 
CsB UVSSA 804 616 5,79 Rpb5 Rpb1 41 1350 10,33 
CsB UVSSA 988 362 8,95 Rpb5 UVSSA 47 584 9,25 
CsB UVSSA 991 362 7,12 Rpb5 UVSSA 47 590 8,92 
CsB UVSSA 1216 362 6,62 Rpb5 UVSSA 47 616 8,87 
CsB UVSSA 1216 491 8,07 Rpb5 UVSSA 85 647 7,77 
CsB UVSSA 1328 129 4,64 Rpb7 Rpb2 153 1220 9,74 
DDB1 CsA 194 233 14,18 Rpb7 Rpb2 163 1220 7,97 
DDB1 CsA 207 233 4,92 Rpb7 Rpb4 155 94 11,23 
DDB1 CsB 153 1363 3,20 Rpb8 Rpb1 21 758 8,09 
DDB1 CsB 1063 1360 3,57 Rpb8 Rpb1 146 32 6,23 
DDB1 CsB 1063 1363 3,26 Rpb8 Rpb1 146 581 16,29 
DDB1 Rpb1 726 213 7,92 Rpb8 Rpb3 20 199 11,63 
DDB1 Rpb4 573 137 6,56 Rpb9 Rpb2 92 707 10,99 
DDB1 UVSSA 63 414 1,46 Rpb9 UVSSA 92 491 6,16 
Rpb1 CsB 139 311 4,26 UVSSA CsA 129 34 15,85 
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Rpb1 CsB 212 448 6,56 UVSSA CsA 129 85 7,52 
Rpb1 CsB 1132 470 0,87 UVSSA CsA 130 34 7,01 
Rpb1 DDB1 213 723 7,92 UVSSA CsA 143 292 14,79 
Rpb1 Rpb10 279 1220 6,99 UVSSA CsA 143 335 20,44 
Rpb1 Rpb11 285 498 11,91 UVSSA CsA 334 212 10,08 
Rpb1 Rpb12 285 898 11,59 UVSSA CsA 339 167 11,71 
Rpb1 Rpb13 285 1220 8,66 UVSSA CsA 362 212 13,99 
Rpb1 Rpb14 331 535 9,81 UVSSA CsA 379 212 9,39 
Rpb1 Rpb15 331 898 12,98 UVSSA CsA 491 167 9,88 
Rpb1 Rpb16 337 535 14,53 UVSSA CsA 491 212 15,47 
Rpb1 Rpb17 337 898 6,14 UVSSA CsA 491 233 4,86 
Rpb1 Rpb18 346 571 10,94 UVSSA CsA 523 212 6,55 
Rpb1 Rpb19 346 892 8,23 UVSSA CsA 616 212 6,18 
Rpb1 Rpb2 1 1220 10,21 UVSSA CsB 129 1328 4,64 
Rpb1 Rpb20 346 898 5,99 UVSSA CsB 334 650 5,62 
Rpb1 Rpb21 417 1220 11,79 UVSSA CsB 362 448 10,58 
Rpb1 Rpb22 445 1220 4,73 UVSSA CsB 362 783 5,83 
Rpb1 Rpb23 550 409 5,62 UVSSA CsB 362 988 8,95 
Rpb1 Rpb24 796 288 6,25 UVSSA CsB 362 991 7,12 
Rpb1 Rpb25 796 571 10,10 UVSSA CsB 362 1216 6,62 
Rpb1 Rpb26 853 571 7,97 UVSSA CsB 377 804 16,58 
Rpb1 Rpb27 853 1019 10,36 UVSSA CsB 379 804 16,57 
Rpb1 Rpb28 1008 341 4,61 UVSSA CsB 491 650 6,34 
Rpb1 Rpb29 1125 571 17,50 UVSSA CsB 491 783 6,69 
Rpb1 Rpb3 32 1220 12,19 UVSSA CsB 491 804 4,93 
Rpb1 Rpb30 1132 571 10,66 UVSSA CsB 491 1216 8,07 
Rpb1 Rpb31 1133 288 4,15 UVSSA CsB 523 804 4,83 
Rpb1 Rpb32 1133 571 13,41 UVSSA CsB 616 448 7,24 
Rpb1 Rpb33 1135 288 4,31 UVSSA CsB 616 804 5,79 
Rpb1 Rpb34 1135 571 11,24 UVSSA CsB 647 333 4,96 
Rpb1 Rpb35 1135 574 4,87 UVSSA CsB 647 337 6,94 
Rpb1 Rpb36 1219 326 10,64 UVSSA CsB 647 448 6,10 
Rpb1 Rpb4 149 341 11,20 UVSSA DDB1 414 60 1,46 
Rpb1 Rpb4 1132 91 5,07 UVSSA Rpb1 523 619 12,87 
Rpb1 Rpb5 149 571 13,99 UVSSA Rpb1 523 976 7,53 
Rpb1 Rpb5 125 12 3,83 UVSSA Rpb1 584 212 6,75 
Rpb1 Rpb5 1350 41 10,33 UVSSA Rpb1 616 212 11,26 
Rpb1 Rpb6 213 341 11,98 UVSSA Rpb1 695 1219 7,42 
Rpb1 Rpb7 213 892 7,69 UVSSA Rpb12 652 1 1,62 
Rpb1 Rpb8 213 898 7,53 UVSSA Rpb2 616 966 6,69 
Rpb1 Rpb8 32 146 6,23 UVSSA Rpb2 647 326 6,98 
Rpb1 Rpb8 581 146 16,29 UVSSA Rpb2 662 325 4,62 
Rpb1 Rpb8 758 21 8,09 UVSSA Rpb2 662 326 15,37 
Rpb1 Rpb9 279 898 5,18 UVSSA Rpb2 679 288 11,00 
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Rpb1 UVSSA 212 584 6,75 UVSSA Rpb2 679 291 12,07 
Rpb1 UVSSA 212 616 11,26 UVSSA Rpb2 679 326 11,21 
Rpb1 UVSSA 619 523 12,87 UVSSA Rpb4 142 75 3,32 
Rpb1 UVSSA 976 523 7,53 UVSSA Rpb5 584 47 9,25 
Rpb1 UVSSA 1219 695 7,42 UVSSA Rpb5 590 47 8,92 
Rpb10 CsB 62 609 4,41 UVSSA Rpb5 616 47 8,87 
Rpb10 Rpb3 67 155 14,09 UVSSA Rpb5 647 85 7,77 
Rpb10 Rpb3 37 167 5,28 UVSSA Rpb9 491 92 6,16 
 
 
Supplemental Table 4 | RNAP-core TFIIH-XPA-XPG crosslinking data. 
P1 P2 R1 R2 S P1 P2 R1 R2 S 
p34 p44 149 126 8,71 Rpb9 Rpb2 27 242 13,43 
p34 p52 97 127 16,41 Rpb9 Rpb2 30 242 4,42 
p34 p52 97 140 8,12 Rpb9 XPB 30 418 6,85 
p34 p62 125 353 10,78 TTDA p52 2 456 10,05 
p34 p62 125 378 4,39 TTDA p52 6 456 3,84 
p34 XPG 74 1120 6,67 TTDA XPA 2 259 13,08 
p34 XPG 125 95 5,58 TTDA XPA 71 224 8,30 
p34 XPG 152 913 6,61 TTDA XPB 17 282 3,77 
p44 p34 126 149 8,71 TTDA XPB 71 59 3,74 
p44 p62 31 504 6,98 TTDA XPB 71 476 20,57 
p44 p62 110 504 7,05 TTDA XPB 71 526 15,73 
p44 p62 126 38 6,52 TTDA XPB 71 609 5,31 
p44 p62 190 38 7,18 TTDA XPB 71 767 7,44 
p44 XPB 23 142 4,19 XPA p52 151 438 8,73 
p44 XPB 77 549 18,61 XPA p52 224 140 6,37 
p44 XPB 77 577 7,30 XPA p52 224 438 7,07 
p44 XPG 126 95 14,25 XPA p52 236 438 5,07 
p44 XPG 126 1004 9,66 XPA p52 259 438 30,91 
p44 XPG 126 1011 5,23 XPA Rpb1 217 132 4,99 
p44 XPG 190 913 10,43 XPA Rpb5 135 85 3,92 
p52 p34 127 97 16,41 XPA TTDA 224 71 8,30 
p52 p34 140 97 8,12 XPA TTDA 259 2 13,08 
p52 p62 452 547 4,57 XPA XPB 157 399 10,97 
p52 TTDA 456 2 10,05 XPA XPB 224 52 4,50 
p52 TTDA 456 6 3,84 XPA XPB 224 569 6,76 
p52 XPA 140 224 6,37 XPA XPB 224 715 4,94 
p52 XPA 438 151 8,73 XPA XPB 236 526 9,07 
p52 XPA 438 224 7,07 XPA XPD 63 370 6,08 
p52 XPA 438 236 5,07 XPA XPD 137 370 4,87 
p52 XPA 438 259 30,91 XPA XPD 167 634 7,88 
p52 XPB 438 706 9,76 XPA XPG 213 213 3,24 
p52 XPD 81 101 13,74 XPA XPG 236 1004 6,38 
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p52 XPG 77 438 9,66 XPA XPG 236 1011 6,25 
p52 XPG 77 754 12,07 XPB p44 142 23 4,19 
p52 XPG 77 904 5,53 XPB p44 549 77 18,61 
p52 XPG 77 952 5,80 XPB p44 577 77 7,30 
p52 XPG 77 1004 9,04 XPB p52 706 438 9,76 
p52 XPG 77 1011 6,00 XPB p62 311 255 5,09 
p52 XPG 77 1071 9,05 XPB Rpb1 52 127 5,64 
p52 XPG 77 1123 4,73 XPB Rpb2 282 242 3,39 
p52 XPG 127 1123 5,31 XPB Rpb2 311 144 8,71 
p52 XPG 140 1120 7,80 XPB Rpb2 528 824 6,85 
p52 XPG 140 1123 9,02 XPB Rpb5 311 186 3,39 
p52 XPG 140 1134 16,24 XPB Rpb9 418 30 6,85 
p52 XPG 459 392 6,20 XPB TTDA 59 71 3,74 
p62 p34 353 125 10,78 XPB TTDA 282 17 3,77 
p62 p34 378 125 4,39 XPB TTDA 476 71 20,57 
p62 p44 38 126 6,52 XPB TTDA 526 71 15,73 
p62 p44 38 190 7,18 XPB TTDA 609 71 5,31 
p62 p44 504 31 6,98 XPB TTDA 767 71 7,44 
p62 p44 504 110 7,05 XPB XPA 52 224 4,50 
p62 p52 547 452 4,57 XPB XPA 399 157 10,97 
p62 Rpb1 492 1008 5,20 XPB XPA 526 236 9,07 
p62 Rpb2 252 824 4,55 XPB XPA 569 224 6,76 
p62 Rpb6 114 98 3,71 XPB XPA 715 224 4,94 
p62 Rpb7 365 1 5,84 XPB XPG 44 1120 3,68 
p62 XPB 255 311 5,09 XPB XPG 52 1071 6,75 
p62 XPD 38 128 9,65 XPB XPG 52 1120 8,90 
p62 XPD 305 128 4,88 XPB XPG 52 1123 12,15 
p62 XPG 38 95 10,41 XPB XPG 52 1134 5,09 
p62 XPG 38 498 6,01 XPB XPG 52 1171 5,50 
p62 XPG 38 754 8,99 XPB XPG 142 95 5,37 
p62 XPG 114 95 5,24 XPB XPG 142 913 6,89 
p62 XPG 114 120 5,55 XPB XPG 142 1004 11,89 
p62 XPG 114 754 9,90 XPB XPG 142 1008 18,55 
p62 XPG 240 95 4,27 XPB XPG 142 1011 5,37 
Rpb1 p62 1008 492 5,20 XPB XPG 142 1050 11,16 
Rpb1 Rpb2 1 1136 19,61 XPB XPG 142 1071 13,26 
Rpb1 Rpb2 139 333 7,94 XPB XPG 142 1123 4,71 
Rpb1 Rpb2 213 257 10,66 XPB XPG 142 1134 6,52 
Rpb1 Rpb2 331 450 4,06 XPB XPG 167 1004 12,05 
Rpb1 Rpb2 331 451 14,29 XPB XPG 222 64 7,67 
Rpb1 Rpb2 331 813 5,26 XPB XPG 222 95 9,16 
Rpb1 Rpb2 331 814 12,29 XPB XPG 222 1004 10,78 
Rpb1 Rpb2 337 451 10,41 XPB XPG 311 913 5,61 
Rpb1 Rpb2 344 487 7,47 XPB XPG 326 1004 9,35 
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Rpb1 Rpb2 346 487 11,61 XPB XPG 326 1011 5,41 
Rpb1 Rpb2 346 808 5,45 XPD p52 101 81 13,74 
Rpb1 Rpb2 346 814 7,31 XPD p62 128 38 9,65 
Rpb1 Rpb2 417 1136 7,33 XPD p62 128 305 4,88 
Rpb1 Rpb2 550 325 5,89 XPD Rpb1 89 707 5,54 
Rpb1 Rpb2 796 204 4,06 XPD Rpb1 89 708 7,67 
Rpb1 Rpb2 796 487 14,31 XPD Rpb2 689 320 5,02 
Rpb1 Rpb2 796 490 4,83 XPD Rpb2 689 330 3,22 
Rpb1 Rpb2 803 242 10,09 XPD XPA 370 63 6,08 
Rpb1 Rpb2 853 487 7,90 XPD XPA 370 137 4,87 
Rpb1 Rpb2 853 935 9,13 XPD XPA 634 167 7,88 
Rpb1 Rpb2 1125 487 17,41 XPD XPG 35 402 4,86 
Rpb1 Rpb2 1132 487 4,11 XPD XPG 113 163 14,33 
Rpb1 Rpb2 1133 487 10,94 XPD XPG 128 95 13,91 
Rpb1 Rpb2 1133 490 4,35 XPD XPG 128 104 12,30 
Rpb1 Rpb2 1135 204 4,50 XPD XPG 128 108 8,80 
Rpb1 Rpb2 1135 487 13,82 XPD XPG 128 120 12,47 
Rpb1 Rpb2 1219 242 11,19 XPD XPG 128 163 13,51 
Rpb1 Rpb2 1234 242 9,46 XPD XPG 128 172 10,89 
Rpb1 Rpb3 581 225 9,69 XPD XPG 128 213 9,84 
Rpb1 Rpb3 697 199 7,69 XPD XPG 128 754 8,64 
Rpb1 Rpb4 1132 91 6,68 XPD XPG 128 913 10,21 
Rpb1 Rpb4 1133 91 4,86 XPD XPG 128 1004 10,84 
Rpb1 Rpb5 125 186 8,04 XPD XPG 128 1011 5,46 
Rpb1 Rpb5 127 186 5,37 XPD XPG 133 163 8,97 
Rpb1 Rpb5 132 186 10,45 XPD XPG 181 172 6,98 
Rpb1 Rpb5 134 186 11,30 XPD XPG 268 64 20,66 
Rpb1 Rpb5 1350 12 4,17 XPD XPG 268 95 23,69 
Rpb1 Rpb5 1350 15 9,38 XPD XPG 268 120 4,64 
Rpb1 Rpb5 1350 41 6,97 XPD XPG 268 172 8,07 
Rpb1 Rpb6 1376 59 4,57 XPD XPG 268 274 6,86 
Rpb1 Rpb6 1479 101 9,22 XPD XPG 268 293 15,25 
Rpb1 Rpb7 1 111 16,95 XPD XPG 268 333 6,04 
Rpb1 Rpb7 1 236 3,05 XPD XPG 268 1071 20,74 
Rpb1 Rpb8 32 146 3,53 XPD XPG 274 95 12,02 
Rpb1 Rpb8 581 146 11,50 XPD XPG 274 293 5,95 
Rpb1 Rpb8 758 21 10,53 XPD XPG 274 433 9,23 
Rpb1 Rpb8 767 21 6,91 XPD XPG 274 913 7,12 
Rpb1 XPA 132 217 4,99 XPD XPG 274 1011 5,57 
Rpb1 XPB 127 52 5,64 XPD XPG 274 1071 7,91 
Rpb1 XPD 707 89 5,54 XPD XPG 341 95 13,69 
Rpb1 XPD 708 89 7,67 XPD XPG 341 104 12,37 
Rpb1 XPG 19 938 3,85 XPD XPG 341 120 6,47 
Rpb10 Rpb2 1 808 9,24 XPD XPG 341 172 7,54 
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Rpb10 Rpb2 2 204 6,89 XPD XPG 341 274 14,22 
Rpb10 Rpb2 58 749 17,24 XPD XPG 341 1011 6,32 
Rpb10 Rpb3 1 152 19,43 XPD XPG 370 95 7,79 
Rpb10 Rpb3 67 155 13,60 XPD XPG 370 120 7,86 
Rpb11 Rpb3 37 166 4,60 XPD XPG 370 293 5,09 
Rpb11 Rpb3 37 171 6,37 XPD XPG 370 392 6,99 
Rpb11 Rpb3 37 225 4,02 XPD XPG 370 433 6,04 
Rpb11 Rpb3 47 225 15,55 XPD XPG 370 913 6,16 
Rpb11 Rpb3 52 225 15,57 XPD XPG 370 1004 4,59 
Rpb11 Rpb3 110 81 7,57 XPD XPG 370 1008 3,99 
Rpb11 Rpb3 112 20 8,61 XPD XPG 370 1011 4,27 
Rpb12 XPG 2 1079 3,26 XPD XPG 370 1120 5,24 
Rpb2 p62 824 252 4,55 XPD XPG 634 274 8,44 
Rpb2 Rpb1 204 796 4,06 XPD XPG 634 293 5,27 
Rpb2 Rpb1 204 1135 4,50 XPD XPG 634 913 9,36 
Rpb2 Rpb1 242 803 10,09 XPG p34 95 125 5,58 
Rpb2 Rpb1 242 1219 11,19 XPG p34 913 152 6,61 
Rpb2 Rpb1 242 1234 9,46 XPG p34 1120 74 6,67 
Rpb2 Rpb1 257 213 10,66 XPG p44 95 126 14,25 
Rpb2 Rpb1 325 550 5,89 XPG p44 913 190 10,43 
Rpb2 Rpb1 333 139 7,94 XPG p44 1004 126 9,66 
Rpb2 Rpb1 450 331 4,06 XPG p44 1011 126 5,23 
Rpb2 Rpb1 451 331 14,29 XPG p52 392 459 6,20 
Rpb2 Rpb1 451 337 10,41 XPG p52 438 77 9,66 
Rpb2 Rpb1 487 344 7,47 XPG p52 754 77 12,07 
Rpb2 Rpb1 487 346 11,61 XPG p52 904 77 5,53 
Rpb2 Rpb1 487 796 14,31 XPG p52 952 77 5,80 
Rpb2 Rpb1 487 853 7,90 XPG p52 1004 77 9,04 
Rpb2 Rpb1 487 1125 17,41 XPG p52 1011 77 6,00 
Rpb2 Rpb1 487 1132 4,11 XPG p52 1071 77 9,05 
Rpb2 Rpb1 487 1133 10,94 XPG p52 1120 140 7,80 
Rpb2 Rpb1 487 1135 13,82 XPG p52 1123 77 4,73 
Rpb2 Rpb1 490 796 4,83 XPG p52 1123 127 5,31 
Rpb2 Rpb1 490 1133 4,35 XPG p52 1123 140 9,02 
Rpb2 Rpb1 808 346 5,45 XPG p52 1134 140 16,24 
Rpb2 Rpb1 813 331 5,26 XPG p62 95 38 10,41 
Rpb2 Rpb1 814 331 12,29 XPG p62 95 114 5,24 
Rpb2 Rpb1 814 346 7,31 XPG p62 95 240 4,27 
Rpb2 Rpb1 935 853 9,13 XPG p62 120 114 5,55 
Rpb2 Rpb1 1136 1 19,61 XPG p62 498 38 6,01 
Rpb2 Rpb1 1136 417 7,33 XPG p62 754 38 8,99 
Rpb2 Rpb10 204 2 6,89 XPG p62 754 114 9,90 
Rpb2 Rpb10 749 58 17,24 XPG Rpb1 938 19 3,85 
Rpb2 Rpb10 808 1 9,24 XPG Rpb12 1079 2 3,26 
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Rpb2 Rpb3 203 137 12,47 XPG Rpb2 1004 487 4,50 
Rpb2 Rpb3 207 137 23,61 XPG Rpb2 1175 623 6,98 
Rpb2 Rpb3 257 137 19,61 XPG XPA 213 213 3,24 
Rpb2 Rpb3 402 75 3,67 XPG XPA 1004 236 6,38 
Rpb2 Rpb3 808 155 11,02 XPG XPA 1011 236 6,25 
Rpb2 Rpb3 814 155 9,67 XPG XPB 64 222 7,67 
Rpb2 Rpb3 935 171 7,93 XPG XPB 95 142 5,37 
Rpb2 Rpb5 204 15 4,31 XPG XPB 95 222 9,16 
Rpb2 Rpb7 1136 123 10,09 XPG XPB 913 142 6,89 
Rpb2 Rpb7 1136 163 19,48 XPG XPB 913 311 5,61 
Rpb2 Rpb7 1136 236 8,30 XPG XPB 1004 142 11,89 
Rpb2 Rpb8 1136 24 10,97 XPG XPB 1004 167 12,05 
Rpb2 Rpb9 242 27 13,43 XPG XPB 1004 222 10,78 
Rpb2 Rpb9 242 30 4,42 XPG XPB 1004 326 9,35 
Rpb2 XPB 144 311 8,71 XPG XPB 1008 142 18,55 
Rpb2 XPB 242 282 3,39 XPG XPB 1011 142 5,37 
Rpb2 XPB 824 528 6,85 XPG XPB 1011 326 5,41 
Rpb2 XPD 320 689 5,02 XPG XPB 1050 142 11,16 
Rpb2 XPD 330 689 3,22 XPG XPB 1071 52 6,75 
Rpb2 XPG 487 1004 4,50 XPG XPB 1071 142 13,26 
Rpb2 XPG 623 1175 6,98 XPG XPB 1120 44 3,68 
Rpb3 Rpb1 199 697 7,69 XPG XPB 1120 52 8,90 
Rpb3 Rpb1 225 581 9,69 XPG XPB 1123 52 12,15 
Rpb3 Rpb10 152 1 19,43 XPG XPB 1123 142 4,71 
Rpb3 Rpb10 155 67 13,60 XPG XPB 1134 52 5,09 
Rpb3 Rpb11 20 112 8,61 XPG XPB 1134 142 6,52 
Rpb3 Rpb11 81 110 7,57 XPG XPB 1171 52 5,50 
Rpb3 Rpb11 166 37 4,60 XPG XPD 64 268 20,66 
Rpb3 Rpb11 171 37 6,37 XPG XPD 95 128 13,91 
Rpb3 Rpb11 225 37 4,02 XPG XPD 95 268 23,69 
Rpb3 Rpb11 225 47 15,55 XPG XPD 95 274 12,02 
Rpb3 Rpb11 225 52 15,57 XPG XPD 95 341 13,69 
Rpb3 Rpb2 155 808 11,02 XPG XPD 95 370 7,79 
Rpb3 Rpb2 155 814 9,67 XPG XPD 104 128 12,30 
Rpb3 Rpb2 171 935 7,93 XPG XPD 104 341 12,37 
Rpb3 Rpb6 166 50 5,82 XPG XPD 108 128 8,80 
Rpb3 Rpb8 199 20 12,83 XPG XPD 120 128 12,47 
Rpb4 Rpb1 91 1132 6,68 XPG XPD 120 268 4,64 
Rpb4 Rpb1 91 1133 4,86 XPG XPD 120 341 6,47 
Rpb4 Rpb2 24 1136 10,97 XPG XPD 120 370 7,86 
Rpb4 Rpb2 75 402 3,67 XPG XPD 163 113 14,33 
Rpb4 Rpb2 137 203 12,47 XPG XPD 163 128 13,51 
Rpb4 Rpb2 137 207 23,61 XPG XPD 163 133 8,97 
Rpb4 Rpb2 137 257 19,61 XPG XPD 172 128 10,89 
                                                                       SUPPLEMENTARY MATERIALS                                              
 
 120 
Rpb4 Rpb7 24 153 5,83 XPG XPD 172 181 6,98 
Rpb4 Rpb7 94 155 20,01 XPG XPD 172 268 8,07 
Rpb5 Rpb1 12 1350 4,17 XPG XPD 172 341 7,54 
Rpb5 Rpb1 15 1350 9,38 XPG XPD 213 128 9,84 
Rpb5 Rpb1 41 1350 6,97 XPG XPD 274 268 6,86 
Rpb5 Rpb1 186 125 8,04 XPG XPD 274 341 14,22 
Rpb5 Rpb1 186 127 5,37 XPG XPD 274 634 8,44 
Rpb5 Rpb1 186 132 10,45 XPG XPD 293 268 15,25 
Rpb5 Rpb1 186 134 11,30 XPG XPD 293 274 5,95 
Rpb5 Rpb2 15 204 4,31 XPG XPD 293 370 5,09 
Rpb5 Rpb6 164 50 6,38 XPG XPD 293 634 5,27 
Rpb5 XPA 85 135 3,92 XPG XPD 333 268 6,04 
Rpb5 XPB 186 311 3,39 XPG XPD 392 370 6,99 
Rpb6 p62 98 114 3,71 XPG XPD 402 35 4,86 
Rpb6 Rpb1 59 1376 4,57 XPG XPD 433 274 9,23 
Rpb6 Rpb1 101 1479 9,22 XPG XPD 433 370 6,04 
Rpb6 Rpb3 50 166 5,82 XPG XPD 754 128 8,64 
Rpb6 Rpb5 50 164 6,38 XPG XPD 913 128 10,21 
Rpb7 p62 1 365 5,84 XPG XPD 913 274 7,12 
Rpb7 Rpb1 111 1 16,95 XPG XPD 913 370 6,16 
Rpb7 Rpb1 236 1 3,05 XPG XPD 913 634 9,36 
Rpb7 Rpb2 123 1136 10,09 XPG XPD 1004 128 10,84 
Rpb7 Rpb2 163 1136 19,48 XPG XPD 1004 370 4,59 
Rpb7 Rpb2 236 1136 8,30 XPG XPD 1008 370 3,99 
Rpb7 Rpb4 153 24 5,83 XPG XPD 1011 128 5,46 
Rpb7 Rpb4 155 94 20,01 XPG XPD 1011 274 5,57 
Rpb8 Rpb1 21 758 10,53 XPG XPD 1011 341 6,32 
Rpb8 Rpb1 21 767 6,91 XPG XPD 1011 370 4,27 
Rpb8 Rpb1 146 32 3,53 XPG XPD 1071 268 20,74 
Rpb8 Rpb1 146 581 11,50 XPG XPD 1071 274 7,91 




















Supplemental Table 5 | Cryo-EM data collection, refinement and validation statistics. 
 TFIIH-XPA-DNA 
Data collection and processing  
Magnification 130 000 
Voltage (kV) 300 
Electron exposure (e–/Å2) 41 
Defocus range (μm) 0.6-4.3 
Pixel size (Å/pix) 1.05 
Symmetry imposed C1 
Initial particle images (no.) 1354997 
Final particle images (no.) 227776 
Map resolution (Å) 3.6 
FSC threshold 0.143 
Map resolution range (Å) 3.1-7.7 
Refinement  
Initial model used (PDB code) Ab-initio in CryoSPARC 
Model resolution (Å) 3.4 
FSC threshold 0.5 
Map sharpening B factor (Å2) denoised map with flattened amplitude 
spectrum 
Model composition  
Non-hydrogen atoms 19804 
Protein residues 2349 
Ligands SF4, 6xZn 
B factors (Å2)  
Protein 96.81 
Ligand 202.97 
R.m.s. deviations  
Bond lengths (Å) 0.017 
Bond angles (°) 1.722 
Validation  
MolProbity score 2.23 
Clashscore 11.94 
Poor rotamers (%) 1.5 
Ramachandran plot  
Favored (%) 91.95 
Allowed (%) 7.93 
Disallowed (%) 0.12 
 
 





1 Lindahl, T. & Barnes, D. E. Repair of endogenous DNA damage. Cold Spring 
Harbor symposia on quantitative biology 65, 127-133, (2000). 
2 Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K. & Linn, S. Molecular 
Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints. 
Annual review of biochemistry 73, 39-85, (2004). 
3 Wood, R. D. Fifty years since DNA repair was linked to cancer. Nature 557, 648-
649, (2018). 
4 Jeggo, P. A., Pearl, L. H. & Carr, A. M. DNA repair, genome stability and cancer: a 
historical perspective. Nature Reviews Cancer 16, 35, (2015). 
5 Torgovnick, A. & Schumacher, B. DNA repair mechanisms in cancer development 
and therapy. Frontiers in genetics 6, 157-157, (2015). 
6 Yi, C. & He, C. DNA repair by reversal of DNA damage. Cold Spring Harbor 
perspectives in biology 5, a012575-a012575. 
7 Liu, Z., Wang, L. & Zhong, D. Dynamics and mechanisms of DNA repair by 
photolyase. Physical chemistry chemical physics : PCCP 17, 11933-11949, (2015). 
8 Warren, J. J., Forsberg, L. J. & Beese, L. S. The structural basis for the mutagenicity 
of O6-methyl-guanine lesions. Proceedings of the National Academy of Sciences 
103, 19701, (2006). 
9 Lindahl, T., Sedgwick, B., Sekiguchi, M. & Nakabeppu, Y. Regulation and 
expression of the adaptive response to alkylating agents. Annual review of 
biochemistry 57, 133-157, (1988). 
10 Kunkel, T. A. & Erie, D. A. DNA MISMATCH REPAIR. Annual review of 
biochemistry 74, 681-710, (2005). 
11 Li, G.-M. Mechanisms and functions of DNA mismatch repair. Cell Research 18, 
85, (2007). 
12 Wion, D. & Casadesus, J. N6-methyl-adenine: an epigenetic signal for DNA-protein 
interactions. Nature reviews. Microbiology 4, 183-192, (2006). 
13 Obmolova, G., Ban, C., Hsieh, P. & Yang, W. Crystal structures of mismatch repair 
protein MutS and its complex with a substrate DNA. Nature 407, 703-710, (2000). 
14 Ban, C. & Yang, W. Crystal structure and ATPase activity of MutL: implications for 
DNA repair and mutagenesis. Cell 95, 541-552, (1998). 
15 Junop, M. S., Obmolova, G., Rausch, K., Hsieh, P. & Yang, W. Composite active 
site of an ABC ATPase: MutS uses ATP to verify mismatch recognition and 
authorize DNA repair. Molecular cell 7, 1-12, (2001). 
16 Krokan, H. E. & Bjørås, M. Base excision repair. Cold Spring Harbor perspectives 
in biology 5, a012583-a012583. 
17 Jacobs, A. L. & Schar, P. DNA glycosylases: in DNA repair and beyond. 
Chromosoma 121, 1-20, (2012). 
18 Kavli, B., Otterlei, M., Slupphaug, G. & Krokan, H. E. Uracil in DNA--general 
mutagen, but normal intermediate in acquired immunity. DNA Repair (Amst) 6, 505-
516, (2007). 
19 Schärer, O. D. Nucleotide excision repair in eukaryotes. Cold Spring Harbor 
perspectives in biology 5, a012609-a012609. 
20 Marteijn, J. A., Lans, H., Vermeulen, W. & Hoeijmakers, J. H. J. Understanding 
nucleotide excision repair and its roles in cancer and ageing. Nature Reviews 
Molecular Cell Biology 15, 465, (2014). 
                                                                       REFERENCES                                              
 
 123 
21 Geacintov, N. E. et al. Thermodynamic and structural factors in the removal of bulky 
DNA adducts by the nucleotide excision repair machinery. Biopolymers 65, 202-210, 
(2002). 
22 Huang, J. C. & Sancar, A. Determination of minimum substrate size for human 
excinuclease. The Journal of biological chemistry 269, 19034-19040, (1994). 
23 Dip, R., Camenisch, U. & Naegeli, H. Mechanisms of DNA damage recognition and 
strand discrimination in human nucleotide excision repair. DNA Repair (Amst) 3, 
1409-1423, (2004). 
24 Sugasawa, K. et al. A multistep damage recognition mechanism for global genomic 
nucleotide excision repair. Genes & development 15, 507-521, (2001). 
25 Mocquet, V. et al. The human DNA repair factor XPC-HR23B distinguishes 
stereoisomeric benzo[a]pyrenyl-DNA lesions. The EMBO journal 26, 2923-2932, 
(2007). 
26 Min, J. H. & Pavletich, N. P. Recognition of DNA damage by the Rad4 nucleotide 
excision repair protein. Nature 449, 570-575, (2007). 
27 Kisker, C., Kuper, J. & Van Houten, B. Prokaryotic nucleotide excision repair. Cold 
Spring Harbor perspectives in biology 5, a012591-a012591, (2013). 
28 Chapman, J. R., Taylor, Martin R. G. & Boulton, Simon J. Playing the End Game: 
DNA Double-Strand Break Repair Pathway Choice. Molecular cell 47, 497-510, 
(2012). 
29 Li, J. & Xu, X. DNA double-strand break repair: a tale of pathway choices. Acta 
biochimica et biophysica Sinica 48, 641-646, (2016). 
30 Wyman, C. & Kanaar, R. DNA Double-Strand Break Repair: All's Well that Ends 
Well. Annual Review of Genetics 40, 363-383, (2006). 
31 Lieber, M. R. The mechanism of double-strand DNA break repair by the 
nonhomologous DNA end-joining pathway. Annual review of biochemistry 79, 181-
211, (2010). 
32 Chang, H. H. Y., Pannunzio, N. R., Adachi, N. & Lieber, M. R. Non-homologous 
DNA end joining and alternative pathways to double-strand break repair. Nature 
reviews. Molecular cell biology 18, 495-506, (2017). 
33 Ranjha, L., Howard, S. M. & Cejka, P. Main steps in DNA double-strand break 
repair: an introduction to homologous recombination and related processes. 
Chromosoma 127, 187-214, (2018). 
34 Jasin, M. & Rothstein, R. Repair of strand breaks by homologous recombination. 
Cold Spring Harbor perspectives in biology 5, a012740-a012740. 
35 Boyce, R. P. & Howard-Flanders, P. RELEASE OF ULTRAVIOLET LIGHT-
INDUCED THYMINE DIMERS FROM DNA IN E. COLI K-12. Proceedings of 
the National Academy of Sciences of the United States of America 51, 293-300, 
(1964). 
36 Pettijohn, D. & Hanawalt, P. EVIDENCE FOR REPAIR-REPLICATION OF 
ULTRAVIOLET DAMAGED DNA IN BACTERIA. Journal of molecular biology 
9, 395-410, (1964). 
37 Rasmussen, R. E. & Painter, R. B. EVIDENCE FOR REPAIR OF ULTRA-VIOLET 
DAMAGED DEOXYRIBONUCLEIC ACID IN CULTURED MAMMALIAN 
CELLS. Nature 203, 1360-1362, (1964). 
38 Setlow, R. B. & Carrier, W. L. THE DISAPPEARANCE OF THYMINE DIMERS 
FROM DNA: AN ERROR-CORRECTING MECHANISM. Proceedings of the 
National Academy of Sciences of the United States of America 51, 226-231, (1964). 
39 Cleaver, J. E. Defective repair replication of DNA in xeroderma pigmentosum. 
Nature 218, 652-656, (1968). 
                                                                       REFERENCES                                              
 
 124 
40 DiGiovanna, J. J. & Kraemer, K. H. Shining a light on xeroderma pigmentosum. The 
Journal of investigative dermatology 132, 785-796, (2012). 
41 De Weerd-Kastelein, E. A., Keijzer, W. & Bootsma, D. Genetic heterogeneity of 
xeroderma pigmentosum demonstrated by somatic cell hybridization. Nature: New 
biology 238, 80-83, (1972). 
42 Thompson, L. H. Chinese hamster cells meet DNA repair: an entirely acceptable 
affair. BioEssays : news and reviews in molecular, cellular and developmental 
biology 20, 589-597, (1998). 
43 Araújo, S. J. et al. Nucleotide excision repair of DNA with recombinant human 
proteins: definition of the minimal set of factors, active forms of TFIIH, and 
modulation by CAK. Genes & development 14, 349-359, (2000). 
44 Aboussekhra, A. et al. Mammalian DNA nucleotide excision repair reconstituted 
with purified protein components. Cell 80, 859-868, (1995). 
45 Mu, D. et al. Reconstitution of human DNA repair excision nuclease in a highly 
defined system. The Journal of biological chemistry 270, 2415-2418, (1995). 
46 Sugasawa, K. et al. Xeroderma pigmentosum group C protein complex is the initiator 
of global genome nucleotide excision repair. Molecular cell 2, 223-232, (1998). 
47 Chen, X. et al. Kinetic gating mechanism of DNA damage recognition by Rad4/XPC. 
Nature communications 6, 5849-5849, (2015). 
48 Trego, K. S. & Turchi, J. J. Pre-steady-state binding of damaged DNA by XPC-
hHR23B reveals a kinetic mechanism for damage discrimination. Biochemistry 45, 
1961-1969, (2006). 
49 Donahue, B. A., Yin, S., Taylor, J. S., Reines, D. & Hanawalt, P. C. Transcript 
cleavage by RNA polymerase II arrested by a cyclobutane pyrimidine dimer in the 
DNA template. Proceedings of the National Academy of Sciences of the United 
States of America 91, 8502-8506, (1994). 
50 Selby, C. P. & Sancar, A. Human transcription-repair coupling factor CSB/ERCC6 
is a DNA-stimulated ATPase but is not a helicase and does not disrupt the ternary 
transcription complex of stalled RNA polymerase II. The Journal of biological 
chemistry 272, 1885-1890, (1997). 
51 Brueckner, F., Hennecke, U., Carell, T. & Cramer, P. CPD damage recognition by 
transcribing RNA polymerase II. Science (New York, N.Y.) 315, 859-862, (2007). 
52 Buschta-Hedayat, N., Buterin, T., Hess, M. T., Missura, M. & Naegeli, H. 
Recognition of nonhybridizing base pairs during nucleotide excision repair of DNA. 
Proceedings of the National Academy of Sciences 96, 6090, (1999). 
53 Hess, M. T., Schwitter, U., Petretta, M., Giese, B. & Naegeli, H. Bipartite substrate 
discrimination by human nucleotide excision repair. Proceedings of the National 
Academy of Sciences of the United States of America 94, 6664-6669, (1997). 
54 Masutani, C. et al. Purification and cloning of a nucleotide excision repair complex 
involving the xeroderma pigmentosum group C protein and a human homologue of 
yeast RAD23. The EMBO journal 13, 1831-1843, (1994). 
55 Nishi, R. et al. Centrin 2 stimulates nucleotide excision repair by interacting with 
xeroderma pigmentosum group C protein. Mol Cell Biol 25, 5664-5674, (2005). 
56 Sugasawa, K., Akagi, J., Nishi, R., Iwai, S. & Hanaoka, F. Two-step recognition of 
DNA damage for mammalian nucleotide excision repair: Directional binding of the 
XPC complex and DNA strand scanning. Molecular cell 36, 642-653, (2009). 
57 Chu, G. & Chang, E. Xeroderma pigmentosum group E cells lack a nuclear factor 
that binds to damaged DNA. Science (New York, N.Y.) 242, 564-567, (1988). 
58 Reardon, J. T. & Sancar, A. Recognition and repair of the cyclobutane thymine 
dimer, a major cause of skin cancers, by the human excision nuclease. Genes & 
development 17, 2539-2551, (2003). 
                                                                       REFERENCES                                              
 
 125 
59 Wakasugi, M. et al. DDB accumulates at DNA damage sites immediately after UV 
irradiation and directly stimulates nucleotide excision repair. The Journal of 
biological chemistry 277, 1637-1640, (2002). 
60 Scrima, A. et al. Structural basis of UV DNA-damage recognition by the DDB1-
DDB2 complex. Cell 135, 1213-1223, (2008). 
61 Volker, M. et al. Sequential assembly of the nucleotide excision repair factors in 
vivo. Molecular cell 8, 213-224, (2001). 
62 Yokoi, M. et al. The xeroderma pigmentosum group C protein complex XPC-HR23B 
plays an important role in the recruitment of transcription factor IIH to damaged 
DNA. The Journal of biological chemistry 275, 9870-9875, (2000). 
63 Riedl, T., Hanaoka, F. & Egly, J. M. The comings and goings of nucleotide excision 
repair factors on damaged DNA. The EMBO journal 22, 5293-5303, (2003). 
64 Compe, E. & Egly, J. M. Nucleotide Excision Repair and Transcriptional Regulation: 
TFIIH and Beyond. Annual review of biochemistry 85, 265-290, (2016). 
65 Evans, E., Moggs, J. G., Hwang, J. R., Egly, J. M. & Wood, R. D. Mechanism of 
open complex and dual incision formation by human nucleotide excision repair 
factors. The EMBO journal 16, 6559-6573, (1997). 
66 Fuss, J. O. & Tainer, J. A. XPB and XPD helicases in TFIIH orchestrate DNA duplex 
opening and damage verification to coordinate repair with transcription and cell 
cycle via CAK kinase. DNA repair 10, 697-713, (2011). 
67 Fan, L. et al. Conserved XPB core structure and motifs for DNA unwinding: 
implications for pathway selection of transcription or excision repair. Molecular cell 
22, 27-37, (2006). 
68 Coin, F., Oksenych, V. & Egly, J. M. Distinct roles for the XPB/p52 and XPD/p44 
subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair. 
Molecular cell 26, 245-256, (2007). 
69 Fishburn, J., Tomko, E., Galburt, E. & Hahn, S. Double-stranded DNA translocase 
activity of transcription factor TFIIH and the mechanism of RNA polymerase II open 
complex formation. Proceedings of the National Academy of Sciences of the United 
States of America 112, 3961-3966, (2015). 
70 Schilbach, S. et al. Structures of transcription pre-initiation complex with TFIIH and 
Mediator. Nature 551, 204, (2017). 
71 Kuper, J., Wolski, S. C., Michels, G. & Kisker, C. Functional and structural studies 
of the nucleotide excision repair helicase XPD suggest a polarity for DNA 
translocation. The EMBO journal 31, 494-502, (2012). 
72 Abdulrahman, W. et al. ARCH domain of XPD, an anchoring platform for CAK that 
conditions TFIIH DNA repair and transcription activities. Proceedings of the 
National Academy of Sciences of the United States of America 110, E633-642, 
(2013). 
73 Li, C. L. et al. Tripartite DNA Lesion Recognition and Verification by XPC, TFIIH, 
and XPA in Nucleotide Excision Repair. Molecular cell 59, 1025-1034, (2015). 
74 Sontz, P. A., Mui, T. P., Fuss, J. O., Tainer, J. A. & Barton, J. K. DNA charge 
transport as a first step in coordinating the detection of lesions by repair proteins. 
Proceedings of the National Academy of Sciences of the United States of America 
109, 1856-1861, (2012). 
75 Mathieu, N., Kaczmarek, N. & Naegeli, H. Strand- and site-specific DNA lesion 
demarcation by the xeroderma pigmentosum group D helicase. Proceedings of the 
National Academy of Sciences of the United States of America 107, 17545-17550, 
(2010). 
76 Fan, L. et al. XPD helicase structures and activities: insights into the cancer and 
aging phenotypes from XPD mutations. Cell 133, 789-800, (2008). 
                                                                       REFERENCES                                              
 
 126 
77 Lehmann, A. R. XPD structure reveals its secrets. DNA Repair (Amst) 7, 1912-1915, 
(2008). 
78 Liu, H. et al. Structure of the DNA repair helicase XPD. Cell 133, 801-812, (2008). 
79 Lukianova, O. A. & David, S. S. A role for iron-sulfur clusters in DNA repair. 
Current opinion in chemical biology 9, 145-151, (2005). 
80 Gregersen, L. H. & Svejstrup, J. Q. The Cellular Response to Transcription-Blocking 
DNA Damage. Trends in biochemical sciences 43, 327-341, (2018). 
81 Camenisch, U., Dip, R., Schumacher, S. B., Schuler, B. & Naegeli, H. Recognition 
of helical kinks by xeroderma pigmentosum group A protein triggers DNA excision 
repair. Nature structural & molecular biology 13, 278-284, (2006). 
82 Yang, Z. et al. Specific and efficient binding of xeroderma pigmentosum 
complementation group A to double-strand/single-strand DNA junctions with 3'- 
and/or 5'-ssDNA branches. Biochemistry 45, 15921-15930, (2006). 
83 Sugitani, N., Sivley, R. M., Perry, K. E., Capra, J. A. & Chazin, W. J. XPA: A key 
scaffold for human nucleotide excision repair. DNA repair 44, 123-135, (2016). 
84 Coin, F. et al. Nucleotide Excision Repair Driven by the Dissociation of CAK from 
TFIIH. Molecular cell 31, 9-20, (2008). 
85 Bunick, C. G., Miller, M. R., Fuller, B. E., Fanning, E. & Chazin, W. J. Biochemical 
and structural domain analysis of xeroderma pigmentosum complementation group 
C protein. Biochemistry 45, 14965-14979, (2006). 
86 Giglia-Mari, G. et al. Dynamic interaction of TTDA with TFIIH is stabilized by 
nucleotide excision repair in living cells. PLoS biology 4, e156, (2006). 
87 Ziani, S. et al. Sequential and ordered assembly of a large DNA repair complex on 
undamaged chromatin. J Cell Biol 206, 589-598, (2014). 
88 Buchko, G. W. et al. Interactions of human nucleotide excision repair protein XPA 
with DNA and RPA70 Delta C327: chemical shift mapping and 15N NMR relaxation 
studies. Biochemistry 38, 15116-15128, (1999). 
89 Mer, G. et al. Structural basis for the recognition of DNA repair proteins UNG2, 
XPA, and RAD52 by replication factor RPA. Cell 103, 449-456, (2000). 
90 Lee, S. H., Kim, D. K. & Drissi, R. Human xeroderma pigmentosum group A protein 
interacts with human replication protein A and inhibits DNA replication. The Journal 
of biological chemistry 270, 21800-21805, (1995). 
91 Daughdrill, G. W. et al. Chemical shift changes provide evidence for overlapping 
single-stranded DNA- and XPA-binding sites on the 70 kDa subunit of human 
replication protein A. Nucleic acids research 31, 4176-4183, (2003). 
92 Ikegami, T. et al. Solution structure of the DNA- and RPA-binding domain of the 
human repair factor XPA. Nature structural biology 5, 701-706, (1998). 
93 Li, L., Lu, X., Peterson, C. A. & Legerski, R. J. An interaction between the DNA 
repair factor XPA and replication protein A appears essential for nucleotide excision 
repair. Mol Cell Biol 15, 5396-5402, (1995). 
94 Saijo, M., Takedachi, A. & Tanaka, K. Nucleotide excision repair by mutant 
xeroderma pigmentosum group A (XPA) proteins with deficiency in interaction with 
RPA. The Journal of biological chemistry 286, 5476-5483, (2011). 
95 Li, L., Elledge, S. J., Peterson, C. A., Bales, E. S. & Legerski, R. J. Specific 
association between the human DNA repair proteins XPA and ERCC1. Proceedings 
of the National Academy of Sciences of the United States of America 91, 5012-5016, 
(1994). 
96 Tsodikov, O. V. et al. Structural basis for the recruitment of ERCC1-XPF to 
nucleotide excision repair complexes by XPA. The EMBO journal 26, 4768-4776, 
(2007). 
                                                                       REFERENCES                                              
 
 127 
97 Wakasugi, M. et al. Physical and functional interaction between DDB and XPA in 
nucleotide excision repair. Nucleic acids research 37, 516-525, (2009). 
98 Gilljam, K. M., Muller, R., Liabakk, N. B. & Otterlei, M. Nucleotide excision repair 
is associated with the replisome and its efficiency depends on a direct interaction 
between XPA and PCNA. PloS one 7, e49199, (2012). 
99 Krasikova, Y. S., Rechkunova, N. I., Maltseva, E. A., Petruseva, I. O. & Lavrik, O. 
I. Localization of xeroderma pigmentosum group A protein and replication protein 
A on damaged DNA in nucleotide excision repair. Nucleic acids research 38, 8083-
8094, (2010). 
100 Koch, S. C. et al. Structural insights into the recognition of cisplatin and AAF-dG 
lesion by Rad14 (XPA). Proceedings of the National Academy of Sciences of the 
United States of America 112, 8272-8277, (2015). 
101 Krasikova, Y. S. et al. Interaction of nucleotide excision repair factors XPC-HR23B, 
XPA, and RPA with damaged DNA. Biochemistry. Biokhimiia 73, 886-896, (2008). 
102 Liu, Y. et al. Cooperative interaction of human XPA stabilizes and enhances specific 
binding of XPA to DNA damage. Biochemistry 44, 7361-7368, (2005). 
103 Chen, R. & Wold, M. S. Replication protein A: single-stranded DNA's first 
responder: dynamic DNA-interactions allow replication protein A to direct single-
strand DNA intermediates into different pathways for synthesis or repair. BioEssays 
: news and reviews in molecular, cellular and developmental biology 36, 1156-1161, 
(2014). 
104 Kim, C., Paulus, B. F. & Wold, M. S. Interactions of human replication protein A 
with oligonucleotides. Biochemistry 33, 14197-14206, (1994). 
105 de Laat, W. L. et al. DNA-binding polarity of human replication protein A positions 
nucleases in nucleotide excision repair. Genes & development 12, 2598-2609, 
(1998). 
106 Spivak, G. Nucleotide excision repair in humans. DNA Repair (Amst) 36, 13-18, 
(2015). 
107 Hohl, M., Thorel, F., Clarkson, S. G. & Scharer, O. D. Structural determinants for 
substrate binding and catalysis by the structure-specific endonuclease XPG. The 
Journal of biological chemistry 278, 19500-19508, (2003). 
108 Schärer, O. D. XPG: its products and biological roles. Advances in experimental 
medicine and biology 637, 83-92, (2008). 
109 Enzlin, J. H. & Schärer, O. D. The active site of the DNA repair endonuclease XPF-
ERCC1 forms a highly conserved nuclease motif. The EMBO journal 21, 2045-2053, 
(2002). 
110 de Laat, W. L., Appeldoorn, E., Jaspers, N. G. & Hoeijmakers, J. H. DNA structural 
elements required for ERCC1-XPF endonuclease activity. The Journal of biological 
chemistry 273, 7835-7842, (1998). 
111 O'Donovan, A., Davies, A. A., Moggs, J. G., West, S. C. & Wood, R. D. XPG 
endonuclease makes the 3' incision in human DNA nucleotide excision repair. 
Nature 371, 432-435, (1994). 
112 Ito, S. et al. XPG Stabilizes TFIIH, Allowing Transactivation of Nuclear Receptors: 
Implications for Cockayne Syndrome in XP-G/CS Patients. Molecular cell 26, 231-
243, (2007). 
113 Mu, D., Wakasugi, M., Hsu, D. S. & Sancar, A. Characterization of reaction 
intermediates of human excision repair nuclease. The Journal of biological chemistry 
272, 28971-28979, (1997). 
114 Staresincic, L. et al. Coordination of dual incision and repair synthesis in human 
nucleotide excision repair. The EMBO journal 28, 1111-1120, (2009). 
                                                                       REFERENCES                                              
 
 128 
115 Mocquet, V. et al. Sequential recruitment of the repair factors during NER: the role 
of XPG in initiating the resynthesis step. The EMBO journal 27, 155-167, (2008). 
116 Ogi, T. et al. Three DNA polymerases, recruited by different mechanisms, carry out 
NER repair synthesis in human cells. Molecular cell 37, 714-727, (2010). 
117 Moser, J. et al. Sealing of chromosomal DNA nicks during nucleotide excision repair 
requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Molecular 
cell 27, 311-323, (2007). 
118 Nudler, E. RNA polymerase active center: the molecular engine of transcription. 
Annual review of biochemistry 78, 335-361, (2009). 
119 Archambault, J. & Friesen, J. D. Genetics of eukaryotic RNA polymerases I, II, and 
III. Microbiological reviews 57, 703-724, (1993). 
120 Vermeulen, W. & Fousteri, M. Mammalian transcription-coupled excision repair. 
Cold Spring Harb Perspect Biol 5, a012625, (2013). 
121 Svejstrup, J. Q. The RNA polymerase II transcription cycle: cycling through 
chromatin. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 
1677, 64-73, (2004). 
122 Hantsche, M. & Cramer, P. The Structural Basis of Transcription: 10 Years After the 
Nobel Prize in Chemistry. Angewandte Chemie (International ed. in English) 55, 
15972-15981, (2016). 
123 Bernecky, C., Herzog, F., Baumeister, W., Plitzko, J. M. & Cramer, P. Structure of 
transcribing mammalian RNA polymerase II. Nature 529, 551-554, (2016). 
124 Mellon, I., Spivak, G. & Hanawalt, P. C. Selective removal of transcription-blocking 
DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 51, 
241-249, (1987). 
125 Bohr, V. A., Smith, C. A., Okumoto, D. S. & Hanawalt, P. C. DNA repair in an active 
gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more 
efficient than in the genome overall. Cell 40, 359-369, (1985). 
126 Sweder, K. S. & Hanawalt, P. C. Preferential repair of cyclobutane pyrimidine 
dimers in the transcribed strand of a gene in yeast chromosomes and plasmids is 
dependent on transcription. Proceedings of the National Academy of Sciences 89, 
10696, (1992). 
127 Troelstra, C. et al. ERCC6, a member of a subfamily of putative helicases, is 
involved in Cockayne's syndrome and preferential repair of active genes. Cell 71, 
939-953, (1992). 
128 van den Boom, V. et al. DNA damage stabilizes interaction of CSB with the 
transcription elongation machinery. J Cell Biol 166, 27-36, (2004). 
129 Henning, K. A. et al. The Cockayne syndrome group A gene encodes a WD repeat 
protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. 
Cell 82, 555-564, (1995). 
130 Zhang, X. et al. Mutations in UVSSA cause UV-sensitive syndrome and destabilize 
ERCC6 in transcription-coupled DNA repair. Nature genetics 44, 593-597, (2012). 
131 Nakazawa, Y. et al. Mutations in UVSSA cause UV-sensitive syndrome and impair 
RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair. 
Nature genetics 44, 586-592, (2012). 
132 Schwertman, P. et al. UV-sensitive syndrome protein UVSSA recruits USP7 to 
regulate transcription-coupled repair. Nature genetics 44, 598-602, (2012). 
133 Fairman-Williams, M. E., Guenther, U.-P. & Jankowsky, E. SF1 and SF2 helicases: 
family matters. Current opinion in structural biology 20, 313-324, (2010). 
134 Lake, R. J. & Fan, H.-Y. Structure, function and regulation of CSB: a multi-talented 
gymnast. Mechanisms of ageing and development 134, 202-211, (2013). 
                                                                       REFERENCES                                              
 
 129 
135 Wang, L. et al. Regulation of the Rhp26ERCC6/CSB chromatin remodeler by a 
novel conserved leucine latch motif. Proceedings of the National Academy of 
Sciences of the United States of America 111, 18566-18571, (2014). 
136 Anindya, R. et al. A ubiquitin-binding domain in Cockayne syndrome B required for 
transcription-coupled nucleotide excision repair. Molecular cell 38, 637-648, (2010). 
137 Selby, C. P. & Sancar, A. Cockayne syndrome group B protein enhances elongation 
by RNA polymerase II. Proceedings of the National Academy of Sciences of the 
United States of America 94, 11205-11209, (1997). 
138 Xu, J. et al. Structural basis for the initiation of eukaryotic transcription-coupled 
DNA repair. Nature 551, 653-657, (2017). 
139 Fousteri, M., Vermeulen, W., van Zeeland, A. A. & Mullenders, L. H. F. Cockayne 
Syndrome A and B Proteins Differentially Regulate Recruitment of Chromatin 
Remodeling and Repair Factors to Stalled RNA Polymerase II In Vivo. Molecular 
cell 23, 471-482, (2006). 
140 Citterio, E. et al. ATP-dependent chromatin remodeling by the Cockayne syndrome 
B DNA repair-transcription-coupling factor. Mol Cell Biol 20, 7643-7653, (2000). 
141 Cho, I., Tsai, P.-F., Lake, R. J., Basheer, A. & Fan, H.-Y. ATP-dependent chromatin 
remodeling by Cockayne syndrome protein B and NAP1-like histone chaperones is 
required for efficient transcription-coupled DNA repair. PLoS genetics 9, e1003407-
e1003407, (2013). 
142 Velez-Cruz, R., Zadorin, A. S., Coin, F. & Egly, J. M. Sirt1 suppresses RNA 
synthesis after UV irradiation in combined xeroderma pigmentosum group 
D/Cockayne syndrome (XP-D/CS) cells. Proceedings of the National Academy of 
Sciences of the United States of America 110, E212-220, (2013). 
143 Nicolai, S. et al. Identification of Novel Proteins Co-Purifying with Cockayne 
Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and 
Chromatin Dynamics. PloS one 10, e0128558, (2015). 
144 Spivak, G. The many faces of Cockayne syndrome. Proceedings of the National 
Academy of Sciences of the United States of America 101, 15273-15274, (2004). 
145 Fischer, Eric S. et al. The Molecular Basis of CRL4DDB2/CSA Ubiquitin Ligase 
Architecture, Targeting, and Activation. Cell 147, 1024-1039, (2011). 
146 Saijo, M. The role of Cockayne syndrome group A (CSA) protein in transcription-
coupled nucleotide excision repair. Mech Ageing Dev 134, 196-201, (2013). 
147 Groisman, R. et al. CSA-dependent degradation of CSB by the ubiquitin-proteasome 
pathway establishes a link between complementation factors of the Cockayne 
syndrome. Genes & development 20, 1429-1434, (2006). 
148 Anindya, R., Aygün, O. & Svejstrup, J. Q. Damage-Induced Ubiquitylation of 
Human RNA Polymerase II by the Ubiquitin Ligase Nedd4, but Not Cockayne 
Syndrome Proteins or BRCA1. Molecular cell 28, 386-397, (2007). 
149 Schwertman, P., Vermeulen, W. & Marteijn, J. A. UVSSA and USP7, a new couple 
in transcription-coupled DNA repair. Chromosoma 122, 275-284, (2013). 
150 Okuda, M., Nakazawa, Y., Guo, C., Ogi, T. & Nishimura, Y. Common TFIIH 
recruitment mechanism in global genome and transcription-coupled repair 
subpathways. Nucleic acids research 45, 13043-13055, (2017). 
151 Okuda, M., Kinoshita, M., Kakumu, E., Sugasawa, K. & Nishimura, Y. Structural 
Insight into the Mechanism of TFIIH Recognition by the Acidic String of the 
Nucleotide Excision Repair Factor XPC. Structure (London, England : 1993) 23, 
1827-1837, (2015). 
152 Svejstrup, J. Q. Mechanisms of transcription-coupled DNA repair. Nature Reviews 
Molecular Cell Biology 3, 21, (2002). 
                                                                       REFERENCES                                              
 
 130 
153 Hanawalt, P. C. & Spivak, G. Transcription-coupled DNA repair: two decades of 
progress and surprises. Nature Reviews Molecular Cell Biology 9, 958, (2008). 
154 Kamarthapu, V. & Nudler, E. Rethinking transcription coupled DNA repair. Current 
opinion in microbiology 24, 15-20, (2015). 
155 Cheung, A. C. & Cramer, P. Structural basis of RNA polymerase II backtracking, 
arrest and reactivation. Nature 471, 249-253, (2011). 
156 Reines, D. Elongation factor-dependent transcript shortening by template-engaged 
RNA polymerase II. The Journal of biological chemistry 267, 3795-3800, (1992). 
157 Izban, M. G. & Luse, D. S. The increment of SII-facilitated transcript cleavage varies 
dramatically between elongation competent and incompetent RNA polymerase II 
ternary complexes. The Journal of biological chemistry 268, 12874-12885, (1993). 
158 Wang, D. & Hawley, D. K. Identification of a 3'-->5' exonuclease activity associated 
with human RNA polymerase II. Proceedings of the National Academy of Sciences 
of the United States of America 90, 843-847, (1993). 
159 Jeon, C., Yoon, H. & Agarwal, K. The transcription factor TFIIS zinc ribbon 
dipeptide Asp-Glu is critical for stimulation of elongation and RNA cleavage by 
RNA polymerase II. Proceedings of the National Academy of Sciences of the United 
States of America 91, 9106-9110, (1994). 
160 Wilson, M. D., Harreman, M. & Svejstrup, J. Q. Ubiquitylation and degradation of 
elongating RNA polymerase II: the last resort. Biochim Biophys Acta 1829, 151-157, 
(2013). 
161 Steurer, B. & Marteijn, J. A. Traveling Rocky Roads: The Consequences of 
Transcription-Blocking DNA Lesions on RNA Polymerase II. Journal of molecular 
biology 429, 3146-3155, (2017). 
162 Huibregtse, J. M., Yang, J. C. & Beaudenon, S. L. The large subunit of RNA 
polymerase II is a substrate of the Rsp5 ubiquitin-protein ligase. Proceedings of the 
National Academy of Sciences of the United States of America 94, 3656-3661, 
(1997). 
163 Harreman, M. et al. Distinct ubiquitin ligases act sequentially for RNA polymerase 
II polyubiquitylation. Proceedings of the National Academy of Sciences of the United 
States of America 106, 20705-20710, (2009). 
164 Ganesan, A., Spivak, G. & Hanawalt, P. C. in Progress in Molecular Biology and 
Translational Science Vol. 110  (ed Paul W. Doetsch)  25-40 (Academic Press, 
2012). 
165 Epshtein, V. et al. UvrD facilitates DNA repair by pulling RNA polymerase 
backwards. Nature 505, 372-377, (2014). 
166 Gerard, M. et al. Purification and interaction properties of the human RNA 
polymerase B(II) general transcription factor BTF2. The Journal of biological 
chemistry 266, 20940-20945, (1991). 
167 Takagi, Y. et al. Ubiquitin ligase activity of TFIIH and the transcriptional response 
to DNA damage. Molecular cell 18, 237-243, (2005). 
168 Graham, J. M., Jr. et al. Cerebro-oculo-facio-skeletal syndrome with a nucleotide 
excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet 
pregnancy. American journal of human genetics 69, 291-300, (2001). 
169 Scharer, O. D. Hot topics in DNA repair: the molecular basis for different disease 
states caused by mutations in TFIIH and XPG. DNA Repair (Amst) 7, 339-344, 
(2008). 
170 Fisher, R. P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. 
Journal of cell science 118, 5171-5180, (2005). 
171 Ito, S. et al. MMXD, a TFIIH-independent XPD-MMS19 protein complex involved 
in chromosome segregation. Molecular cell 39, 632-640, (2010). 
                                                                       REFERENCES                                              
 
 131 
172 Sainsbury, S., Bernecky, C. & Cramer, P. Structural basis of transcription initiation 
by RNA polymerase II. Nature Reviews Molecular Cell Biology 16, 129, (2015). 
173 Douziech, M. et al. Mechanism of promoter melting by the xeroderma pigmentosum 
complementation group B helicase of transcription factor IIH revealed by protein-
DNA photo-cross-linking. Mol Cell Biol 20, 8168-8177, (2000). 
174 Kim, T. K., Ebright, R. H. & Reinberg, D. Mechanism of ATP-dependent promoter 
melting by transcription factor IIH. Science (New York, N.Y.) 288, 1418-1422, 
(2000). 
175 Lin, Y. C., Choi, W. S. & Gralla, J. D. TFIIH XPB mutants suggest a unified 
bacterial-like mechanism for promoter opening but not escape. Nature structural & 
molecular biology 12, 603-607, (2005). 
176 Lu, H., Zawel, L., Fisher, L., Egly, J. M. & Reinberg, D. Human general transcription 
factor IIH phosphorylates the C-terminal domain of RNA polymerase II. Nature 358, 
641-645, (1992). 
177 Phatnani, H. P. & Greenleaf, A. L. Phosphorylation and functions of the RNA 
polymerase II CTD. Genes & development 20, 2922-2936, (2006). 
178 Glover-Cutter, K. et al. TFIIH-associated Cdk7 kinase functions in phosphorylation 
of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by 
RNA polymerase II. Mol Cell Biol 29, 5455-5464, (2009). 
179 Cho, E. J., Takagi, T., Moore, C. R. & Buratowski, S. mRNA capping enzyme is 
recruited to the transcription complex by phosphorylation of the RNA polymerase II 
carboxy-terminal domain. Genes & development 11, 3319-3326, (1997). 
180 Egloff, S. et al. Serine-7 of the RNA polymerase II CTD is specifically required for 
snRNA gene expression. Science (New York, N.Y.) 318, 1777-1779, (2007). 
181 Winkler, G. S. et al. TFIIH with inactive XPD helicase functions in transcription 
initiation but is defective in DNA repair. The Journal of biological chemistry 275, 
4258-4266, (2000). 
182 Greber, B. J. et al. The cryo-electron microscopy structure of human transcription 
factor IIH. Nature 549, 414-417, (2017). 
183 Schultz, P. et al. Molecular Structure of Human TFIIH. Cell 102, 599-607, (2000). 
184 Gibbons, B. J. et al. Subunit architecture of general transcription factor TFIIH. 
Proceedings of the National Academy of Sciences of the United States of America 
109, 1949-1954, (2012). 
185 Chang, W.-H. & Kornberg, R. D. Electron Crystal Structure of the Transcription 
Factor and DNA Repair Complex, Core TFIIH. Cell 102, 609-613, (2000). 
186 Luo, J. et al. Architecture of the Human and Yeast General Transcription and DNA 
Repair Factor TFIIH. Molecular cell 59, 794-806, (2015). 
187 Kainov, D. E. et al. Structure determination of the minimal complex between Tfb5 
and Tfb2, two subunits of the yeast transcription/DNA-repair factor TFIIH: a 
retrospective study. Acta crystallographica. Section D, Biological crystallography 
66, 745-755, (2010). 
188 Gervais, V. et al. TFIIH contains a PH domain involved in DNA nucleotide excision 
repair. Nature Structural &Amp; Molecular Biology 11, 616, (2004). 
189 Radu, L. et al. The intricate network between the p34 and p44 subunits is central to 
the activity of the transcription/DNA repair factor TFIIH. Nucleic acids research 45, 
10872-10883, (2017). 
190 Gradia, S. D. et al. MacroBac: New Technologies for Robust and Efficient Large-
Scale Production of Recombinant Multiprotein Complexes. Methods in enzymology 
592, 1-26, (2017). 
                                                                       REFERENCES                                              
 
 132 
191 Araki, M. et al. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma 
pigmentosum group C complex that initiates global genome nucleotide excision 
repair. The Journal of biological chemistry 276, 18665-18672, (2001). 
192 Sugasawa, K. et al. HHR23B, a human Rad23 homolog, stimulates XPC protein in 
nucleotide excision repair in vitro. Molecular and cellular biology 16, 4852-4861, 
(1996). 
193 Bernardes de Jesus, B. M., Bjoras, M., Coin, F. & Egly, J. M. Dissection of the 
molecular defects caused by pathogenic mutations in the DNA repair factor XPC. 
Mol Cell Biol 28, 7225-7235, (2008). 
194 Lafrance-Vanasse, J., Arseneault, G., Cappadocia, L., Legault, P. & Omichinski, J. 
G. Structural and functional evidence that Rad4 competes with Rad2 for binding to 
the Tfb1 subunit of TFIIH in NER. Nucleic acids research 41, 2736-2745, (2013). 
195 Hey, T., Lipps, G. & Krauss, G. Binding of XPA and RPA to damaged DNA 
investigated by fluorescence anisotropy. Biochemistry 40, 2901-2910, (2001). 
196 Sugitani, N., Shell, S. M., Soss, S. E. & Chazin, W. J. Redefining the DNA-binding 
domain of human XPA. Journal of the American Chemical Society 136, 10830-
10833, (2014). 
197 Kastner, B. et al. GraFix: sample preparation for single-particle electron 
cryomicroscopy. Nature methods 5, 53-55, (2008). 
198 He, Y. et al. Near-atomic resolution visualization of human transcription promoter 
opening. Nature 533, 359-365, (2016). 
199 Mu, H., Geacintov, N. E., Broyde, S., Yeo, J.-E. & Schärer, O. D. Molecular basis 
for damage recognition and verification by XPC-RAD23B and TFIIH in nucleotide 
excision repair. DNA Repair 71, 33-42, (2018). 
200 Titov, D. V. et al. XPB, a subunit of TFIIH, is a target of the natural product 
triptolide. Nature Chemical Biology 7, 182, (2011). 
201 He, Q. L. et al. Covalent modification of a cysteine residue in the XPB subunit of 
the general transcription factor TFIIH through single epoxide cleavage of the 
transcription inhibitor triptolide. Angewandte Chemie (International ed. in English) 
54, 1859-1863, (2015). 
202 Kiianitsa, K., Solinger, J. A. & Heyer, W. D. NADH-coupled microplate photometric 
assay for kinetic studies of ATP-hydrolyzing enzymes with low and high specific 
activities. Analytical biochemistry 321, 266-271, (2003). 
203 Firman, K. & Szczelkun, M. D. Measuring motion on DNA by the type I restriction 
endonuclease EcoR124I using triplex displacement. The EMBO journal 19, 2094-
2102, (2000). 
204 Kumaran, S., Kozlov, A. G. & Lohman, T. M. Saccharomyces cerevisiae replication 
protein A binds to single-stranded DNA in multiple salt-dependent modes. 
Biochemistry 45, 11958-11973, (2006). 
205 Tegunov, D. & Cramer, P. Real-time cryo-EM data pre-processing with Warp. 
bioRxiv, (2018). 
206 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms 
for rapid unsupervised cryo-EM structure determination. Nature methods 14, 290-
296, (2017). 
207 Zivanov, J. et al. RELION-3: new tools for automated high-resolution cryo-EM 
structure determination. bioRxiv, (2018). 
208 Adams, P. D. et al. PHENIX: a comprehensive Python-based system for 
macromolecular structure solution. Acta crystallographica. Section D, Biological 
crystallography 66, 213-221, (2010). 
209 Ziani, S. et al. Sequential and ordered assembly of a large DNA repair complex on 
undamaged chromatin. The Journal of cell biology 206, 589-598, (2014). 
                                                                       REFERENCES                                              
 
 133 
210 Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research 
and analysis. Journal of computational chemistry 25, 1605-1612, (2004). 
211 Tomko, E. J., Fishburn, J., Hahn, S. & Galburt, E. A. TFIIH generates a six-base-
pair open complex during RNAP II transcription initiation and start-site scanning. 
Nature structural & molecular biology 24, 1139-1145, (2017). 
212 Kawaoka, J., Jankowsky, E. & Pyle, A. M. Backbone tracking by the SF2 helicase 
NPH-II. Nature structural & molecular biology 11, 526-530, (2004). 
213 Pyle, A. M. Translocation and unwinding mechanisms of RNA and DNA helicases. 
Annual review of biophysics 37, 317-336, (2008). 
214 Lehmann, A. R. The xeroderma pigmentosum group D (XPD) gene: one gene, two 
functions, three diseases. Genes & development 15, 15-23, (2001). 
215 Mathieu, N., Kaczmarek, N., Ruthemann, P., Luch, A. & Naegeli, H. DNA quality 
control by a lesion sensor pocket of the xeroderma pigmentosum group D helicase 
subunit of TFIIH. Current biology : CB 23, 204-212, (2013). 
216 Fuss, J. O., Tsai, C.-L., Ishida, J. P. & Tainer, J. A. Emerging critical roles of Fe–S 
clusters in DNA replication and repair. Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research 1853, 1253-1271, (2015). 
217 Paul, V. D. & Lill, R. Biogenesis of cytosolic and nuclear iron–sulfur proteins and 
their role in genome stability. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research 1853, 1528-1539, (2015). 
218 Brooks, S. C., Adhikary, S., Rubinson, E. H. & Eichman, B. F. Recent advances in 
the structural mechanisms of DNA glycosylases. Biochimica et biophysica acta 
1834, 247-271, (2013). 
219 Leclerc, V., Raisin, S. & Léopold, P. Dominant-negative mutants reveal a role for 
the Cdk7 kinase at the mid-blastula transition in Drosophila embryos. The EMBO 
journal 19, 1567-1575, (2000). 
220 Feaver, W. J., Gileadi, O., Li, Y. & Kornberg, R. D. CTD kinase associated with 
yeast RNA polymerase II initiation factor b. Cell 67, 1223-1230, (1991). 
221 Svejstrup, J. Q., Feaver, W. J., LaPointe, J. & Kornberg, R. D. RNA polymerase 
transcription factor IIH holoenzyme from yeast. The Journal of biological chemistry 
269, 28044-28048, (1994). 
222 Kosinski, J. et al. Xlink Analyzer: software for analysis and visualization of cross-
linking data in the context of three-dimensional structures. Journal of structural 
biology 189, 177-183, (2015). 
223 Constantinescu-Aruxandei, D., Petrovic-Stojanovska, B., Penedo, J. C., White, M. 
F. & Naismith, J. H. Mechanism of DNA loading by the DNA repair helicase XPD. 
Nucleic acids research 44, 2806-2815, (2016). 
224 Evans, E., Fellows, J., Coffer, A. & Wood, R. D. Open complex formation around a 
lesion during nucleotide excision repair provides a structure for cleavage by human 
XPG protein. The EMBO journal 16, 625-638, (1997). 
225 Sinha, R. P. & Hader, D. P. UV-induced DNA damage and repair: a review. 
Photochemical & photobiological sciences : Official journal of the European 
Photochemistry Association and the European Society for Photobiology 1, 225-236, 
(2002). 
226 de Lima-Bessa, K. M. et al. CPDs and 6-4PPs play different roles in UV-induced 
cell death in normal and NER-deficient human cells. DNA Repair (Amst) 7, 303-312, 
(2008). 
227 You, Y. H., Szabo, P. E. & Pfeifer, G. P. Cyclobutane pyrimidine dimers form 
preferentially at the major p53 mutational hotspot in UVB-induced mouse skin 
tumors. Carcinogenesis 21, 2113-2117, (2000). 
                                                                       REFERENCES                                              
 
 134 
228 Cadet, J., Sage, E. & Douki, T. Ultraviolet radiation-mediated damage to cellular 
DNA. Mutation research 571, 3-17, (2005). 
229 Ravanat, J. L., Douki, T. & Cadet, J. Direct and indirect effects of UV radiation on 
DNA and its components. Journal of photochemistry and photobiology. B, Biology 
63, 88-102, (2001). 
230 Mouret, S. et al. Cyclobutane pyrimidine dimers are predominant DNA lesions in 
whole human skin exposed to UVA radiation. Proceedings of the National Academy 
of Sciences 103, 13765, (2006). 
231 Blackburn, G. M. & Davies, R. J. H. The structure of DNA-derived thymine dimer. 
Biochemical and Biophysical Research Communications 22, 704-706, (1966). 
232 Kneuttinger, A. C. et al. Formation and Direct Repair of UV-induced Dimeric DNA 
Pyrimidine Lesions. Photochemistry and photobiology 90, 1-14, (2014). 
233 Selby, C. P., Drapkin, R., Reinberg, D. & Sancar, A. RNA polymerase II stalled at a 
thymine dimer: footprint and effect on excision repair. Nucleic acids research 25, 
787-793, (1997). 
234 Tornaletti, S., Reines, D. & Hanawalt, P. C. Structural characterization of RNA 
polymerase II complexes arrested by a cyclobutane pyrimidine dimer in the 
transcribed strand of template DNA. The Journal of biological chemistry 274, 24124-
24130, (1999). 
235 Shaevitz, J. W., Abbondanzieri, E. A., Landick, R. & Block, S. M. Backtracking by 
single RNA polymerase molecules observed at near-base-pair resolution. Nature 
426, 684-687, (2003). 
236 Galburt, E. A. et al. Backtracking determines the force sensitivity of RNAP II in a 
factor-dependent manner. Nature 446, 820-823, (2007). 
237 Fei, J. & Chen, J. KIAA1530 protein is recruited by Cockayne syndrome 
complementation group protein A (CSA) to participate in transcription-coupled 
repair (TCR). The Journal of biological chemistry 287, 35118-35126, (2012). 
238 Groisman, R. et al. CSA-dependent degradation of CSB by the ubiquitin-proteasome 
pathway establishes a link between complementation factors of the Cockayne 
syndrome. Genes & development 20, 1429-1434, (2006). 
239 Wang, L. et al. Regulation of the Rhp26/ERCC6/CSB chromatin remodeler by a 
novel conserved leucine latch motif. Proceedings of the National Academy of 
Sciences 111, 18566, (2014). 
240 Kettenberger, H., Armache, K.-J. & Cramer, P. Architecture of the RNA Polymerase 
II-TFIIS Complex and Implications for mRNA Cleavage. Cell 114, 347-357, (2003). 
241 Conaway, R. C., Kong, S. E. & Conaway, J. W. TFIIS and GreB: Two Like-Minded 
Transcription Elongation Factors with Sticky Fingers. Cell 114, 272-274, (2003). 
242 Harper, J. W. & Elledge, S. J. The DNA damage response: ten years after. Molecular 
cell 28, 739-745, (2007). 
243 Jiang, G. & Sancar, A. Recruitment of DNA damage checkpoint proteins to damage 
in transcribed and nontranscribed sequences. Mol Cell Biol 26, 39-49, (2006). 
244 Ljungman, M. & Zhang, F. Blockage of RNA polymerase as a possible trigger for 
u.v. light-induced apoptosis. Oncogene 13, 823-831, (1996). 
245 Ljungman, M. Activation of DNA damage signaling. Mutation research 577, 203-
216, (2005). 
246 Shin, J. H., Xu, L. & Wang, D. Mechanism of transcription-coupled DNA 
modification recognition. Cell & bioscience 7, 9-9, (2017). 
247 Hawryluk, P. J., Ujvári, A. & Luse, D. S. Characterization of a novel RNA 
polymerase II arrest site which lacks a weak 3' RNA-DNA hybrid. Nucleic acids 
research 32, 1904-1916, (2004). 
                                                                       REFERENCES                                              
 
 135 
248 Sidorenkov, I., Komissarova, N. & Kashlev, M. Crucial Role of the RNA:DNA 
Hybrid in the Processivity of Transcription. Molecular cell 2, 55-64, (1998). 
249 Nudler, E., Mustaev, A., Goldfarb, A. & Lukhtanov, E. The RNA–DNA Hybrid 
Maintains the Register of Transcription by Preventing Backtracking of RNA 
Polymerase. Cell 89, 33-41, (1997). 
250 Theil, A. F., Hoeijmakers, J. H. & Vermeulen, W. TTDA: big impact of a small 
protein. Experimental cell research 329, 61-68, (2014). 
251 Theil, A. F. et al. Disruption of TTDA results in complete nucleotide excision repair 
deficiency and embryonic lethality. PLoS genetics 9, e1003431, (2013). 
252 Coin, F. et al. p8/TTD-A as a Repair-Specific TFIIH Subunit. Molecular cell 21, 
215-226, (2006). 
253 Naegeli, H., Bardwell, L. & Friedberg, E. C. The DNA helicase and adenosine 
triphosphatase activities of yeast Rad3 protein are inhibited by DNA damage. A 
potential mechanism for damage-specific recognition. The Journal of biological 
chemistry 267, 392-398, (1992). 
254 Naegeli, H., Bardwell, L. & Friedberg, E. C. Inhibition of Rad3 DNA helicase 
activity by DNA adducts and abasic sites: implications for the role of a DNA helicase 
in damage-specific incision of DNA. Biochemistry 32, 613-621, (1993). 
255 Mathieu, N., Kaczmarek, N. & Naegeli, H. Strand- and site-specific DNA lesion 
demarcation by the xeroderma pigmentosum group D helicase. Proceedings of the 
National Academy of Sciences 107, 17545, (2010). 
256 Dubaele, S. et al. Basal transcription defect discriminates between xeroderma 
pigmentosum and trichothiodystrophy in XPD patients. Molecular cell 11, 1635-
1646, (2003). 
257 Cleaver, J. E., Thompson, L. H., Richardson, A. S. & States, J. C. A summary of 
mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne 
syndrome, and trichothiodystrophy. Human mutation 14, 9-22, (1999). 
258 Kralund, H. H. et al. Xeroderma Pigmentosum-Trichothiodystrophy overlap patient 
with novel XPD/ERCC2 mutation. Rare diseases (Austin, Tex.) 1, e24932-e24932, 
(2013). 
259 Coin, F. et al. Mutations in the XPD helicase gene result in XP and TTD phenotypes, 
preventing interaction between XPD and the p44 subunit of TFIIH. Nature genetics 
20, 184-188, (1998). 
260 Seroz, T., Perez, C., Bergmann, E., Bradsher, J. & Egly, J. M. p44/SSL1, the 
regulatory subunit of the XPD/RAD3 helicase, plays a crucial role in the 
transcriptional activity of TFIIH. The Journal of biological chemistry 275, 33260-
33266, (2000). 
261 Botta, E. et al. Analysis of Mutations in the XPD Gene in Italian Patients with 
Trichothiodystrophy: Site of Mutation Correlates with Repair Deficiency, but Gene 
Dosage Appears to Determine Clinical Severity. The American Journal of Human 
Genetics 63, 1036-1048, (1998). 
262 Rudolf, J., Makrantoni, V., Ingledew, W. J., Stark, M. J. R. & White, M. F. The DNA 
Repair Helicases XPD and FancJ Have Essential Iron-Sulfur Domains. Molecular 
cell 23, 801-808, (2006). 
263 Wakasugi, M. & Sancar, A. Order of assembly of human DNA repair excision 
nuclease. The Journal of biological chemistry 274, 18759-18768, (1999). 
264 Jones, C. J. & Wood, R. D. Preferential binding of the xeroderma pigmentosum 
group A complementing protein to damaged DNA. Biochemistry 32, 12096-12104, 
(1993). 
265 Asahina, H. et al. The XPA protein is a zinc metalloprotein with an ability to 
recognize various kinds of DNA damage. Mutation research 315, 229-237, (1994). 
                                                                       REFERENCES                                              
 
 136 
266 Robins, P., Jones, C. J., Biggerstaff, M., Lindahl, T. & Wood, R. D. 
Complementation of DNA repair in xeroderma pigmentosum group A cell extracts 
by a protein with affinity for damaged DNA. The EMBO journal 10, 3913-3921, 
(1991). 
267 He, Z., Henricksen, L. A., Wold, M. S. & Ingles, C. J. RPA involvement in the 
damage-recognition and incision steps of nucleotide excision repair. Nature 374, 
566-569, (1995). 
268 Batty, D., Rapic'-Otrin, V., Levine, A. S. & Wood, R. D. Stable binding of human 
XPC complex to irradiated DNA confers strong discrimination for damaged sites. 
Journal of molecular biology 300, 275-290, (2000). 
269 Dienemann, C., Schwalb, B., Schilbach, S. & Cramer, P. Promoter Distortion and 
Opening in the RNA Polymerase II Cleft. Molecular cell 73, 97-106.e104, (2019). 
270 Lisica, A. et al. Mechanisms of backtrack recovery by RNA polymerases I and II. 
Proceedings of the National Academy of Sciences of the United States of America 
113, 2946-2951, (2016). 
271 Schutz, P. et al. Crystal structure of the yeast eIF4A-eIF4G complex: an RNA-
helicase controlled by protein-protein interactions. Proceedings of the National 
Academy of Sciences of the United States of America 105, 9564-9569, (2008). 
272 Montpetit, B. et al. A conserved mechanism of DEAD-box ATPase activation by 
nucleoporins and InsP6 in mRNA export. Nature 472, 238-242, (2011). 
273 Selby, C. P. & Sancar, A. Structure and function of transcription-repair coupling 
factor. II. Catalytic properties. The Journal of biological chemistry 270, 4890-4895, 
(1995). 
274 Selby, C. P. & Sancar, A. Structure and function of transcription-repair coupling 
factor. I. Structural domains and binding properties. The Journal of biological 
chemistry 270, 4882-4889, (1995). 
275 Adebali, O., Chiou, Y.-Y., Hu, J., Sancar, A. & Selby, C. P. Genome-wide 
transcription-coupled repair in Escherichia coli is mediated by the Mfd translocase. 
Proceedings of the National Academy of Sciences, 201700230, (2017). 
276 Grishkevich, V. & Yanai, I. Gene length and expression level shape genomic 
novelties. Genome research 24, 1497-1503, (2014). 
277 Lee, S.-K., Yu, S.-L., Prakash, L. & Prakash, S. Requirement of Yeast RAD2, a 
Homolog of Human XPG Gene, for Efficient RNA Polymerase II Transcription: 
Implications for Cockayne Syndrome. Cell 109, 823-834, (2002). 
278 Sarker, A. H. et al. Recognition of RNA polymerase II and transcription bubbles by 
XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne 
Syndrome. Molecular cell 20, 187-198, (2005). 
279 Bakshi, S., Choi, H. & Weisshaar, J. C. The spatial biology of transcription and 
translation in rapidly growing Escherichia coli. Frontiers in microbiology 6, 636, 
(2015). 
280 Kohler, R., Mooney, R. A., Mills, D. J., Landick, R. & Cramer, P. Architecture of a 
transcribing-translating expressome. Science (New York, N.Y.) 356, 194-197, (2017). 
281 Tennyson, C. N., Klamut, H. J. & Worton, R. G. The human dystrophin gene requires 
16 hours to be transcribed and is cotranscriptionally spliced. Nature genetics 9, 184-
190, (1995). 
282 Murata, K. & Wolf, M. Cryo-electron microscopy for structural analysis of dynamic 
biological macromolecules. Biochimica et Biophysica Acta (BBA) - General Subjects 
1862, 324-334, (2018). 
283 Yang, M. Q. et al. The emerging genomics and systems biology research lead to 
systems genomics studies. BMC genomics 15 Suppl 11, I1-I1, (2014). 
                                                                       REFERENCES                                              
 
 137 
284 Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms 
of action. European journal of pharmacology 740, 364-378, (2014). 
285 Fennell, D. A. et al. Cisplatin in the modern era: The backbone of first-line 
chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews 44, 42-50, 
(2016). 
286 Szymkowski, D. E., Yamada, M., Moggs, J. G., Karran, P. & Wood, R. D. 
Differential Human Nucleotide Excision Repair of Paired and Mispaired Cisplatin-
DNA Adducts. Nucleic acids research 25, 480-490, (1997). 
287 Rosell, R. et al. Nucleotide excision repair pathways involved in Cisplatin resistance 
in non-small-cell lung cancer. Cancer control : journal of the Moffitt Cancer Center 
10, 297-305, (2003). 
288 Gentile, F., Tuszynski, J. A. & Barakat, K. H. New design of nucleotide excision 
repair (NER) inhibitors for combination cancer therapy. Journal of molecular 
graphics & modelling 65, 71-82, (2016). 
289 Burgers, P. M. J. & Kunkel, T. A. Eukaryotic DNA Replication Fork. Annual review 
of biochemistry 86, 417-438, (2017). 
290 Bernecky, C., Plitzko, J. M. & Cramer, P. Structure of a transcribing RNA 
polymerase II-DSIF complex reveals a multidentate DNA-RNA clamp. Nature 
structural & molecular biology 24, 809-815, (2017). 
291 Brosey, C. A., Chagot, M.-E. & Chazin, W. J. Preparation of the modular multi-
domain protein RPA for study by NMR spectroscopy. Methods in molecular biology 
(Clifton, N.J.) 831, 181-195, (2012). 
292 Berger, I., Fitzgerald, D. J. & Richmond, T. J. Baculovirus expression system for 
heterologous multiprotein complexes. Nature Biotechnology 22, 1583, (2004). 
293 Vos, S. M. et al. Architecture and RNA binding of the human negative elongation 
factor. eLife 5, e14981, (2016). 
294 Vos, S. M., Stewart, N. K., Oakley, M. G. & Berger, J. M. Structural basis for the 
MukB-topoisomerase IV interaction and its functional implications in vivo. The 
EMBO journal 32, 2950-2962, (2013). 
295 Vos, S. M. et al. Structure of activated transcription complex Pol II–DSIF–PAF–
SPT6. Nature 560, 607-612, (2018). 
296 Sydow, J. F. et al. Structural basis of transcription: mismatch-specific fidelity 
mechanisms and paused RNA polymerase II with frayed RNA. Molecular cell 34, 
710-721, (2009). 
297 Boehning, M. et al. RNA polymerase II clustering through carboxy-terminal domain 
phase separation. Nature structural & molecular biology 25, 833-840, (2018). 
298 Butenandt, J. P. M. E., André Carell, Thomas. Synthesis, Crystal Structure, and 
Enzymatic Evaluation of a DNA-Photolesion Isostere. Vol. 4 642-654 (1998). 
299 Combe, C. W., Fischer, L. & Rappsilber, J. xiNET: cross-link network maps with 
residue resolution. Molecular & cellular proteomics : MCP 14, 1137-1147, (2015). 
300 Yang, B. et al. Identification of cross-linked peptides from complex samples. Nature 
methods 9, 904-906, (2012). 
301 Tang, G. et al. EMAN2: an extensible image processing suite for electron 
microscopy. Journal of structural biology 157, 38-46, (2007). 
302 Scheres, S. H. W. RELION: implementation of a Bayesian approach to cryo-EM 
structure determination. Journal of structural biology 180, 519-530, (2012). 
303 Kimanius, D., Forsberg, B. O., Scheres, S. H. W. & Lindahl, E. Accelerated cryo-
EM structure determination with parallelisation using GPUs in RELION-2. eLife 5, 
e18722, (2016). 
                                                                       REFERENCES                                              
 
 138 
304 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of 
Coot. Acta crystallographica. Section D, Biological crystallography 66, 486-501, 
(2010). 
305 Buchan, D. W. A., Minneci, F., Nugent, T. C. O., Bryson, K. & Jones, D. T. Scalable 
web services for the PSIPRED Protein Analysis Workbench. Nucleic acids research 
41, W349-W357, (2013). 
306 Biasini, M. et al. SWISS-MODEL: modelling protein tertiary and quaternary 
structure using evolutionary information. Nucleic acids research 42, W252-258, 
(2014). 
307 Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL 
workspace. Nature protocols 4, 1-13, (2009). 
308 Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. 
Current protocols in protein science 86, 2.9.1-2.9.37, (2016). 
309 Kim, J. L. et al. Hepatitis C virus NS3 RNA helicase domain with a bound 
oligonucleotide: the crystal structure provides insights into the mode of unwinding. 
Structure (London, England : 1993) 6, 89-100, (1998). 
310 Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular 
crystallography. Acta crystallographica. Section D, Biological crystallography 66, 
12-21, (2010). 




I am thankful to Patrick Cramer for providing me with an opportunity to do my PhD research in 
his lab. It is uncommon to be given such a freedom and amazing resources I have enjoyed during 
my PhD work. I am thankful for his mentorship and fruitful scientific discussions. I am also 
thankful to members of my thesis committee: Prof. Holger Stark for finding the time to advise 
me even outside of my TAC meetings and for allowing me to use the ProteoPlex pipeline his lab 
developed, Prof. Claudia Höbartner for providing advice on DNA chemistry and allowing me to 
use her lab equipment whenever I needed to, and finally Dr. Vladimir Pena for nice discussions 
and supportive words. I am also thankful to Steffen Burkhard and Kerstin Grüniger for providing 
such an amazing support to students in my graduate program and for helping me out on many 
occasions. 
 
I was lucky to be surrounded with amazing colleagues, many of which became dear friends. I 
am in dept to Seychelle Vos for all of her help in the beginning of my PhD project, she was 
always happy to advise and share protocols. Thanks to Franz Fischer for teaching me about the 
insect cell culture and always keeping it cool. I am thankful to Carrie Bernecky for teaching me 
a lot about EM and also for many discussions and a lot of support when thing in the lab just did 
not work (and let me just say, there were quite some of those days), and for laughing at my silly 
puns. Huge thanks to Svetlana Dodonova, for many scientific discussions, for feeding me 
chocolate and for all the fun chats and coffee breaks. Dimitry Tegunov, you Netflix junky, thanks 
for all the help with the science stuff and for making sure I wouldn’t starve during the late nights 
in the lab! Thanks to Christian for teaching me a lot about EM and model building. Marco, I 
have nothing to thank you for. I want to thank Haibo, Simon, Hauke, Felix (the best flatmate!), 
Sara, Paulina, Ying, Anna, Kristina, Katharina and Saskia for scientific discussion, fun chats and 
support. Servus to Kerstin, you are the best, thank you for proofreading my thesis! Thanks to 
Manuela and Geli for good chats about life and gardens and cats – it was a welcomed distraction 
when I needed a little break.  
 
I am thankful for great scientific collaborations throughout my PhD. Biggest thanks goes to 
Aleksandar Chernev from the lab of Prof. Henning Urlaub, who did countless mass-spectrometry 
experiments for me and who always went along with my crazy ideas. I am thankful to Jan 
Seikowski, Dr. Vladimir Belov and Prof. Claudia Höbartner for synthesizing the CPD-
containing oligo I used for TCR reconstitutions. I also briefly collaborated with Jana Schmitzova 
from the lab of Dr. Vladimir Pena. Her love for science is truly inspiring.  
 
Maybe the most important acknowledgements go to the people who unconditionally supported 
me through my PhD journey, my mum, my dad and my amazing sister. Veliko hvala na ogromnoj 
potpori tijekom mog doktorata, ne bih to mogao odgurati bez vas! Thanks to Petra Jug for always 
making me laugh. Also, I am grateful to have formed a family of my own in Göttingen, where I 
have met some amazing people. Siv, I loved our walks and long hours spent Geocaching, thanks 
for being there for me when I needed support. Irena, thanks for the tough love, P10 forever! 
Shiru, I will never forget those delicious green tea egg rolls from Taiwan. Silvia, thanks for all 
the cozy blanket moments and for all the joy and laughter you are always bringing. Barratt, thank 
you for cooking amazing vegan food and for your support. Tahere, thanks for listening when I 
needed to talk. 
                                                                                       LIST OF ABBREVIATIONS                                             
 
 140 
List of abbreviations 
ATP adenosine triphosphate 
APS ammonium peroxodisulfate 
CTD C-terminal domain of RNA-polymerase II 
EM electron microscopy 
FRET fluorescence resonance energy transfer 
GTF general transcription factor 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid  
His histidine 
IPTG isopropyl-β-D-1-thiogalactopyranoside  
NTP nucleotide triphosphate 
PAGE polyacrylamide gel electrophoresis  
RNAP RNA-polymerase II 
s.d. standard deviation 
TEMED N,N,Nʹ,Nʹ-Tetramethylethylendiamine  
UV ultra violet 
v/v volume/volume 
w/v weight/volume 
                                                                                       LIST OF FIGURES                                             
 
 141 
List of figures 
Figure 1 | The main steps of nucleotide excision DNA repair (NER). .................................. 4 
Figure 2 | Schematic representation of human global-genome nucleotide excision repair 
(GGR). ................................................................................................................................... 8 
Figure 3 | The fate of lesion arrested RNAP. ....................................................................... 12 
Figure 4 | Cryo-EM structure of human TFIIH. .................................................................. 15 
Figure 5 | Cryo-EM structure of Rad26 bound to RNA-polymerase II. .............................. 16 
Figure 6 | Purification of the human TFIIH core. ................................................................ 18 
Figure 7 | In vitro reconstitution of the TFIIH complex. ..................................................... 19 
Figure 8 | Binding of XPC-Rad23b to DNA as measured by fluorescence anisotropy. ...... 20 
Figure 9 | Reconstitution and the crosslinking mass-spectrometry network of the core 
TFIIH-XPA-XPC-Rad23b-DNA complex. ......................................................................... 21 
Figure 10 | Negative stain reconstruction of the core TFIH–XPA–XPC-Rad23b–DNA 
complex. .............................................................................................................................. 22 
Figure 11 | Biochemical characterization of the core TFIIH ATPases. ............................... 23 
Figure 12 | Regulation of ATPases in core TFIIH. .............................................................. 25 
Figure 13 | Cryo-EM data processing. ................................................................................. 27 
Figure 14 | Structure of human TFIIH-XPA-DNA complex. .............................................. 29 
Figure 15 | Cryo-EM map quality. ....................................................................................... 30 
Figure 16 | Detailed analysis of XPB and XPD bound to the DNA. ................................... 31 
Figure 17 | Large-scale structural changes in TFIIH upon activation for repair. ................ 32 
Figure 18 | XPA-DNA interactions. .................................................................................... 34 
Figure 19 | XPD-DNA interactions. .................................................................................... 36 
Figure 20 | XPD regulation by the kinase module. .............................................................. 37 
Figure 21 | Structural basis for XPD inhibition by the kinase module. ............................... 38 
Figure 22 | Structural basis for XPD activation by XPA. .................................................... 39 
Figure 23 | Crosslinking mass-spectrometry network of the core TFIIH-XPA-XPG-DNA 
complex. .............................................................................................................................. 40 
Figure 24 | Organic synthesis of a chemical CPD analogue. ............................................... 43 
Figure 25 | Testing the CPD-containing DNA scaffold. ...................................................... 44 
Figure 26 | Complex formation between the RNAP and TCR–specific factors. ................. 45 
Figure 27 | The effect of CsB and UVSSA on transcription in vitro. .................................. 46 
Figure 28 | TCR-specific factors do not stimulate transcription past the CPD lesion nor the 
dissociation of the lesion-arrested RNAP from the DNA template. .................................... 48 
Figure 29 | Core TFIIH inhibits transcription in the presence of XPG and XPA. ............... 50 
Figure 30 | Core TFIIH induces RNAP backtracking in the presence of XPG and XPA. .. 51 
Figure 31 | XPB translocase pushes RNAP backwards. ...................................................... 52 
Figure 32 | Active RNAP backtracking by XPB exposes CPD lesions to repair. ............... 53 
Figure 33 | Crosslinking mass-spectrometry network of the RNAP-core TFIIH–XPA–XPG 
complex and the effect of DNA lesions on XPB translocase activity. ................................ 54 
Figure 34 | NER model which incorporates novel insights obtained in this study. ............. 57 
Figure 35 | Extension of the previous model for the human TFIIH core. ........................... 58 
Figure 36 | Different conformations of the TFIIH core in transcription and DNA repair. .. 59 
Figure 37 | DNA-bound TFIIH core at 3.6Å reveals structural etiology of Xeroderma 
Pigmentosum (XP) and Trichothiodystrophy (TTD). ......................................................... 61 
Figure 38 | Comparison between Rad14 bound to the damaged DNA duplex and XPA 
bound to the duplex-single strand junction. ......................................................................... 64 
Figure 39 | A possible role for XPB in DNA opening. ........................................................ 68 
Figure 40 | New insights into the mechanism of human TCR. ............................................ 72 




List of tables 
Table 1 | List of NER factors and their role in DNA repair .................................................. 6 
Table 2 | List of chemicals and consumables. ..................................................................... 75 
Table 3 | List of buffers. ...................................................................................................... 77 
Table 4 | List of growth media for E. coli and insect cells. ................................................. 77 
Table 5 | List of antibiotics and supplements for E. coli cultures. ....................................... 78 
Table 6 | Bacterial strains used in this study. ....................................................................... 78 
Table 7 | Insect cell strains used in this study. ..................................................................... 78 
Table 8 | Vectors produced for protein expression in this study. ........................................ 79 
Table 9 | Overhang sequences for the ligation-independent cloning. .................................. 82 
Table 10 | PCR program used for gene amplification. ........................................................ 82 
Table 11 | LIC reaction for purified inserts and target vectors. ........................................... 83 
Table 12 | List of DNA constructs used in this study. ......................................................... 93 




Supplemental Table 1 | Core TFIIH-XPA-XPC-Rad23b crosslinking data. ..................... 107 
Supplemental Table 2 | Core TFIIH-XPA-XPG crosslinking data. .................................. 108 
Supplemental Table 3 | RNAP-CsB-CsA-DDB1-UVSSA crosslinking data. .................. 111 
Supplemental Table 4 | RNAP-core TFIIH-XPA-XPG crosslinking data. ....................... 115 
Supplemental Table 5 | Cryo-EM data collection, refinement and validation statistics. ... 121 
 
 
 
